POSTER PRESENTATIONS
presented in San Diego
and available on the CTAD25 Digital
Platform and App

POSTER LIST

P001 Designing a Trial for LATE (Limbic-predominant Age-related TDP-43 Encephalopathy) with Donepezil: Double-blind Parallel vs Crossover Methodologies with Amyloid Stratification
Presenter: Leila Parand

Leila PARAND, Keith VOSSEL
UCLA, Los Angeles, United States

P002 Instructing Efficient Early Phase Preclinical Alzheimer's Disease Trials
Presenter: Paul R. Gaona Partida

Paul R. GAONA PARTIDA[1] , Tselmen ANUURAD [2], Ian SEQUEIRA [3], Em RAGAINE [4], Christopher TURNER [5], Joshua D. GRILL [6, 7, 8, 9], Daniel L. GILLEN [1, 8, 10]
[1] Department of Statistics, Donald Bren School of Information and Computer Sciences of University of California Irvine, Irvine, United States, [2] Department of Statistics & Data Science, University of California Los Angeles, Los Angeles, United States, [3] Department of Statistics and Applied Probability, University of California Santa Barbara, Santa Barbara, United States, [4] Department of Statistics, University of Georgia, Athens, United States, [5] Physics and Astronomy Department, Pomona College, Pomona, United States, [6] Institute for Memory Impairments and Neurological Disorders University of California Irvine, Irvine, United States, [7] Alzheimer's Disease Research Center University of California Irvine, Irvine, United States, [8] Department of Neurobiology and Behavior University of California Irvine, Irvine, United States, [9] Department of Psychiatry and Human Behavior University of California Irvine, Irvine, United States, [10] Department of Psychiatry and Human Behavior University of California Irvine, Irvine

P003 CSF cGMP Levels correlates with Alzheimer's Disease Severity in the POLARIS-AD Phase 3 Trial Screening Cohort
Presenter: Tianyang Xi

Sunmin JIN [1], Fred KIM [2], Vitella FOMENKO [2], James A ROCK [2], Jai Jun CHOUNG [3], Tianyang XI [2]
[1] AriBio Co., Ltd., Seoul, Republic of Korea, [2] AriBio Co., Ltd., San Diego, United States, [3] AriBio Co., Ltd., Seongnam-Si, Republic of Korea

P004 Learning from failure: investigating reasons for failure of effective treatments identified in a meta-analysis of Alzheimer's disease studies
Presenter: Samuel P. Dickson

Samuel P. DICKSON, Kent HENDRIX, Tyler DUKE, Maxwell J. DICKSON, Craig MALLINCKRODT, Suzanne B. HENDRIX
Pentara Corporation, Salt Lake City, United States

P005 Phase II clinical trial on the effect of urolithin A in Alzheimer's disease
Presenter: Kateřina Veverová

Kateřina VEVEROVÁ [1] , Jan LACZÓ [1], Shu-Qin CAO [2], Evandro FEI FANG-STAVEM [2], Martin VYHNÁLEK [3]
[1] Memory Clinic, Department of Neurology, Charles University, Second Faculty of Medicine and Motol University Hospital, Prague, Czech Republic, [2] Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Oslo, Norway, [3] Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Prague, Czech Republic

P006 Characterizing Enrollment Patterns in a Preclinical Alzheimer's Disease Trial
Presenter: Marina Ritchie

Marina RITCHIE [1] , Kedir HUSSEN [1], Oliver LANGFORD [1], Johanna JANSEN [2], Arnav BHATIA [3], Doris MOLINA-HENRY [1], Joshua GRILL [4], Paul AISEN [1], Reisa SPERLING [5], Shobha DHADDA [6], Michael IRIZARRY [6], Rema RAMAN [1]
[1] Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, [2] University of California, Santa Barbara, Santa Barbara, United States, [3] Santa Clara University, Santa Clara, United States, [4] University of California, Irvine, Irvine, United States, [5] Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Harvard Medical School, Boston, United States, [6] Eisai Inc., Nutley, United States

P007 Double 6/18-month Phase III study to reproduce symptomatic and potentially show disease-modifying efficacy of buntanetap in treating Alzheimer's disease
Presenter: Maria Maccecchini

Maria MACCECCHINI [1] , Cheng FANG [1], Melissa GAINES [1], Sarah MACALLUM [1], Daniel LASKOWITZ [2], Martin FARLOW [3]
[1] Annovis Bio, Malvern, United States, [2] Duke University, Durham, United States, [3] Indiana university, Indianapolis, United States

P008   Attitudes Toward the Study Partner Requirement in Alzheimer's Disease Preclinical Trials Among Racially and Ethnically Diverse Populations

Presenter: Yiren Xu

Yiren XU [1], Megan WITBRACHT [2], Crystal GLOVER [2, 3], Daniel GILLEN [1, 2], Joshua GRILL [2, 4, 5]

[1] Department of Statistics, University of California, Irvine, Irvine, United States, [2] Institute for Memory Impairments and Neurological Disorders UCI MIND, University of California, Irvine, Irvine, United States, [3] Department of Neurology, University of California, Irvine, Irvine, United States, [4] Department of Psychiatry & Human Behavior, University of California, Irvine, Irvine, United States, [5] Department of Neurobiology and Behavior, University of California, Irvine, Irvine, United States

P009   Alzheimer's Disease Pivotal Trial Design for Zervimesine Following an End of Phase 2 Meeting with FDA

Presenter: Anthony Caggiano

Jennifer IACI [1], Michael GRUNDMAN [2, 3], Nash HERNANDEZ [4], Anthony CAGGIANO [1]

[1] Cognition Therapeutics, Purchase, Ny, United States, [2] Global R&D Partners, San Diego, Ca, United States, [3] University of California, San Diego, La Jolla, Ca, United States, [4] GloboScience Inc., Boston, Ma, United States

P010   Pharmacoeconomic Evaluation of Lecanemab for Early Alzheimer's Disease in the Northeast Chinase Population

Presenter: Huayan Liu

Huayan LIU [1], Boru JIN [1], Xue DU [1], Zhuolin JI [1], Lianghao SI [2]

[1] First Hospital of China Medical University, Shenyang, China, [2] Medical Affairs Department, Eisai China Inc., Shenyang, China

P011   Metabotyping Reveals Distinct Gut–Brain Response Profiles to Postbiotic and multi-nutrient Intervention in Older Adults

Presenter: Amanda J Lloyd

Amanda J LLOYD [1], Courtney DAVIES [1], Alexander N W TAYLOR [1], Alina WARREN-WALKER [1], Charly MORGAN [1], Nigel HOLT [1], Denis KAY [2], Kevin STEPHENS [3], Hariom YADAV [4], Douglas LYNCH [5], Alison WATSON [1], Laura LYONS [1], Manfred BECKMANN [1]

[1] Aberystwyth University, Aberystwyth, United Kingdom, [2] Neurodyn Life Sciences Inc, Charlottetown, Canada, [3] Agroceutical Products Ltdc, Glasbury, United Kingdom, [4] University of South Florida, Tampa, United States, [5] Postbiotics Inc, Winston Salem, United States

P013   The Alzheimer's Disease Diagnosis and Plasma p-tau217 (ADAPT) randomised controlled trial: protocol

Presenter: Joanne Rodda

Ashvini KESHAVAN [1, 2], Joanne RODDA [3, 4], Katharine WILTSHIRE [1, 2], Jemma HAZAN [5], Tanjil NAWAZ [6], Charlotte KELHAM [6], Liz DEANE [6], Catherine HENDERSON [7], Raphael WITTENBERG [7], Melanie HART [8, 9], Amanda HESLEGRAVE [2], Henrik ZETTERBERG [2, 10, 11, 12], Nicholas FREEMANTLE [6], Robert HOWARD [5], Jonathan M. SCHOTT [1, 2]

[1] Dementia Research Centre, UCL Queen Square Institute of Neurology, London, United Kingdom, [2] UK Dementia Research Institute at University College London, London, United Kingdom, [3] Kent and Medway NHS Mental Health Trust, Maidstone, United Kingdom, [4] Kent and Medway Medical School, Canterbury, United Kingdom, [5] UCL Division of Psychiatry, London, United Kingdom, [6] Comprehensive Clinical Trials Unit at University College London, London, United Kingdom, [7] Care Policy and Evaluation Centre, London School of Economics and Political Science, London, United Kingdom, [8] Neuroimmunology and CSF Laboratory, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, London, United Kingdom, [9] Department of Neuroinflammation, UCL Queen Square Institute of Neurology, London, United Kingdom, [10] Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden, [11] Hong Kong Center for Neurodegenerative Diseases, Clear Water Bay, Hong Kong Special Administrative Region, China, [12] Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, United States

P014   Clinical research protocol of Lecanemab based on synaptic plasticity for the treatment of early Alzheimer's disease

Presenter: Cuibai Wei

Aidi SHAN [1], Qingyuan SUN [1], Xiaodong HAN [1], Chang XU [1], Qi YAO [2], Xin WANG [1], Cuibai WEI [1, 3]

[1] Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China, [2] College of Integrated Traditional Chinase and Western Medicine, Changchun University of Chinase Medicine, Changchun, China, [3] inan Hospital of Xuanwu Hospital, Shandong First Medical University, 250102, Jinan, China

P015   Open Science: Building an International Data and Specimen Sharing Infrastructure for Alzheimer's Disease Clinical Trials

Presenter: Gustavo Jimenez-Maggiora

Gustavo JIMENEZ-MAGGIORA [1], Aaron SCHULTZ [2, 3], Michael DONOHUE [1], Hongmei QIU [1], Richard GALLARDO [1], Sara ABDEL-LATIF [1], Robert RISSMAN [1], Reisa SPERLING [2, 3], Paul AISEN [1]

[1] University of Southern California, San Diego, United States, [2] Center for Alzheimer Research and Treatment, Brigham and Women's Hospital, Massachusetts General Hospital, Boston, United States, [3] Harvard Medical School, Boston, United States

P016   Tau-Predictive Functional Connectome Patterns Predict Clinical Progression and Solanezumab Response in Preclinical Alzheimer's Disease
Presenter: Hamid Abuwarda

Hamid ABUWARDA [1,2] , Wen-Xiang TSAI [1,3], Shengxian DING [4], Mohamed ELHASSAN [1], Xilin SHEN [5], Yize ZHAO [6], Todd CONSTABLE [2,7,8], Carolyn FREDERICKS [1,2]
[1] Department of Neurology, School of Medicine, Yale University, New Haven, United States, [2] Interdepartmental Neuroscience Program, School of Medicine, Yale University, New Haven, United States, [3] Institute of Brain Science, National Yang Ming Chiao Tung University, Taipei, Taïwan, République de China, [4] Department of Biostatistics, School of Public Health, Yale University, New Haven, United States, [5] Department of Radiology, School of Medicine, Yale University, New Haven, United States, [6] Department of Biostatistics, School of Public Health, Yale University, New Haven, United States, [7] Department of Radiology, School of Medicine, Yale University, United States, [8] Department of Biomedical Engineering, School of Medicine, Yale University,, New Haven, United States

P018   Improving insights on disease modification in Alzheimer's disease by including sequential GSTs in the analysis hierarchy
Presenter: Joshua Christensen

Joshua CHRISTENSEN, Daniel SMITH, Kent HENDRIX, Craig MALLINCKRODT, Suzanne HENDRIX, Samuel DICKSON
Pentara Corporation, Millcreek, United States

P019   ALTITUDE-AD: Recruitment strategies for a global phase 2 trial of sabirnetug in early Alzheimer's disease
Presenter: Robyn Moxon

Robyn MOXON [1] , Alyssa CARROLL [1], Todd FEASTER [1], Kathy MARCOZZI PIERCE [1], Maddelyn HYLAND [1], Siew TIN GAN [1], Dung TRINH [2], Eric SIEMERS [1]
[1] Acumen Pharmaceuticals, Inc, Newton, Massachusetts, United States, [2] Healthy Brain Research, Long Beach, California, United States

P020   Study Design of a Multiple Ascending Intravenous Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics of VY7523 in Participants with Early Alzheimer's Disease
Presenter: Monroe Butler

Monroe BUTLER [1] , Naomi MUSE [1], Sarah PIANTEDOSI [1], Thrusha CHAUHAN [1], Beth MELLEN [1], Charlotte CHUNG [1], Raj RAJAGOVINDAN [1], Vik ARORA [1], Albena PATRONEVA [2], Maury EMERY [2], Alfred SANDROCK [1], Toby FERGUSON [1], Elena RATTI [1]
[1] Voyager Therapeutics, Lexington, United States, [2] Voyager Therapeutics Contractor, Lexington, United States

P021   The PRImus-AD study: design of the phase 2 study treating patients with MCI or mild dementia due to Alzheimer's disease (AD) with the orally available PRI-002
Presenter: Dieter Willbold

Dieter WILLBOLD [1,2] , Dagmar JÜRGENS [1], Tischler GERHARD [3], Brener ALEXANDER [3], Bartsch TINA [3], Kauselmann GUNTHER [1], Adermann KNUT [1], Zeiger KATHRIN [3], Kindner KATJA [3], Gabelich JULIE-ANNE [3], Peters OLIVER [4]
[1] Priavoid GmbH, Düsseldorf, Germany, [2] Heinrich Heine University Düsseldorf, Institute of Physical Biology, Düsseldorf, Germany, [3] PRInnovation GmbH, Düsseldorf, Germany, [4] Charite, Berlin, Germany

P022   A Phase 3 Clinical Protocol: Placebo-Controlled, Double-Blind, Parallel-Group to Evaluate Safety and Efficacy of NA-831 as Monotherapy and in Combination with Donanemab in Subjects with Early Alzheimer's Disease
Presenter: Lloyd Tran

Lloyd TRAN, Fern VU, Zung TRAN
Biomed Industries, Inc., San Jose, United States

P023   VHB937, a TREM2 stabilizing and activating fully human monoclonal antibody: A Phase 2 study design in Alzheimer's disease and rationale
Presenter: Ana Graf

Ana GRAF [1] , Dominik FEUERBACH [1], Derya SHIMSHEK [1], Judit SOVAGO [1], Gisela PERAUS [1], Aileen ZHU [2], Catherine AGOROPOULOU [1], Alexandra BOBIRCA [1], Carmen SERBAN [1]
[1] Novartis Pharma AG, Basel, Switzerland, [2] Novartis, Shanghai, China

P025 Has Alzheimer's been defined as a white person's disease? How biomarker-based inclusion criteria may lead to differential access to clinical trials across racial and ethnic groups, an analysis of the Bio-Hermes study
Presenter: Joshua Christensen

Joshua CHRISTENSEN, Suzanne HENDRIX, Garrett DUNCAN, Kent HENDRIX, Samuel DICKSON
Pentara Corporation, Millcreek, United States

P026 Utility of high throughput blood-based p-Tau217, GFAP, NfL and APOE ?4 immunoassays for clinical trials of Alzheimer's disease
Presenter: David Escobar

David ESCOBAR, Elizabeth RAMIREZ, Virginia NYANCHAMA, Navid KOOCHEK, Mark BLIMLINE, Naveen DAKAPPAGARI
Navigate BioPharma Services, Carlsbad, United States

P027 Incorporating auxiliary information into a continuation decision once a group sequential boundary has crossed into an interim futility stopping set
Presenter: Christina Magana-Ramirez

Christina MAGANA-RAMIREZ, Daniel GILLEN
Department of Statistics, University of California, Irvine, Irvine, United States

P028 Impact of a Multimodal Lifestyle Intervention on Dementia Risk Factors and Attitude Related to Dementia Risk: A Logistical Pilot Study
Presenter: J. Nicholas Cochran

Meagan COCHRAN [1], Jada PUGH [1], Tanner COLEMAN [1], S. Quinn JOHNSTON [1], Jared TAYLOR [1], Scott NEWBERRY [1], Whitley KELLEY [1], Lee HOOD [2], Jennifer LOVEJOY [2], J. Nicholas COCHRAN [1]
[1] HudsonAlpha Institute for Biotechnology, Huntsville, United States, [2] Phenome Health, Seattle, United States

P029 Annual Site Coordinator Meetings as a Catalyst for Retention Strategy Development in Alzheimer's Disease Longitudinal Cohort Studies
Presenter: Andrew Mellor

Andrew MELLOR [1], Hannatu AMAZA [2], Joseph DI BENEDETTO [3], Taylor CLANTON [1], Doris MOLINA-HENRY [1], Ozioma OKONKWO [2], Mónica RIVERA MINDT [3, 4], Rema RAMAN [1]
[1] Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, [2] Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, United States, [3] Department of Psychology, Latin American and Latino Studies Institute, and African and African American Studies, Fordham University, New York, United States, [4] Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, United States

P030 A Single-Center, Retrospective, Rater-Blinded, Crossover Study to Evaluate the Clinical Utility of a Medical Image Analysis Software for Quantitative Analysis of Brain PET Images in Patients with Alzheimer's Disease
Presenter: Jung Yun Seo

Jung Yun SEO [1], Sun Min LEE [1], Kyung Hwa SUN [1], Yong Jin PARK [2], Su Jin LEE [2], Young Sil AN [2], So Young MOON [1]
[1] ?Department of Neurology, Ajou University School of Medicine,, ?suwon, Republic of Korea, [2] ?Department of Nuclear Medicine and Molecular Imaging, Ajou University School of Medicine,, ?suwon, Republic of Korea

P031 Many Exciting New Targets for AD… But Do More MOAs Mean More Duplicate Subjects?
Presenter: Thomas Shiovitz

Thomas SHIOVITZ [1, 2], Chelsea STEINMETZ [1], Brittany STEINMILLER [1], Levi TROUT [1]
[1] CenExel CTSdatabase, LLC, Sherman Oaks, United States, [2] CenExel California Neuroscience Research, Sherman Oaks, United States

P032 Advancing Alzheimer's Research Through Community-Based Neurology Trials: A Profound Research Model
Presenter: Gregory Sahagian

Gregory SAHAGIAN [1, 2], Lora PARAHOVNIK [2]
[1] The Neurology Center of Southern California, Carlsbad, United States, [2] Profound Research, Nashville, United States

P033 Lessons from Real-world Clinical Implementation of Anti-amyloid ? Antibodies: Bridging the Gap to Clinical Trials

Presenter: Ryoko Ihara

Ryoko IHARA, Masanori KURIHARA, Keiko HATANO, Taro BANNAI, Ryosuke SHIMASAKI, Akira HATAKEYAMA, Ko FURUTA, Fumio SUZUKI, Aya TOKUMARU, Kenji ISHII, Atsushi IWATA
Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

P034 Successful Strategies for Recruitment and Retention as a Foundation for ADRD-focused Clinical Trials in a Rural Cohort

Presenter: Lisa Wiese

Lisa WIESE [1], Christine WILLIAMS [1], Diane J COOK [2], Juyoung PARK [3], Jan HOLT [1], Diana MITSOVA [1], Sheryl MAGZAMEN [4], Lilah BESSER [5], Madeline TOURELLE [5], [5]
[1] Florida Atlantic University, Boca Raton, United States, [2] Washington State University, Pullman, United States, [3] Washington State University, Phoenix, United States, [4] Colorado State University, Fort Collins, United States, [5] University of Miami, Miami, United States

P035 Effect of consenting clinician degree on screen fail rate in Alzheimer's Disease clinical trials

Presenter: Ralph Lee

Yu-Jay HUOH, Razyya ABDULMUMIN, James LUAYON, Dana NGUYEN, Tara PARNITVITHIKUL, Elizabeth SOSA, Edward ZAMRINI, Ralph LEE
Irvine Clinical Research, Irvine, United States

P036 Click or Clinic? Comparing Referral-to-Pre-Screen Attendance Rates Between Digital Advertisements and HCP Referrals in Alzheimer's Clinical Trials

Presenter: Thibaud Belleface

Thibaud BELLEFACE, Jeffrey APTER
Global Medical Institutes, Princeton, United States

P037 Minimal clinically important differences are often misapplied and misinterpreted and should be used with caution

Presenter: Kent Hendrix

Patrick O'KEEFE, Mitchell WASSOM, Kent HENDRIX, Craig MALLINCKRODT, Suzanne HENDRIX, Samuel DICKSON
Pentara, Millcreek, United States

P038 Rethinking Interim Analyses: When and Why to Avoid Them

Presenter: Samuel Johnson

Samuel JOHNSON, Katelyn MILLER, Kent HENDRIX, Craig MALLINCKRODT, Suzanne HENDRIX, Samuel DICKSON
Pentara Corporation, Millcreek, United States

P039 Improving Study Power Through Continuous Modeling of a Global Treatment Effect Versus Composite Responder Analysis

Presenter: Abe Durrant

Abe DURRANT [1], Andrew MILLANE [2], Craig MALLINCKRODT [2], Kent HENDRIX [2], Suzanne HENDRIX [2], Samuel DICKSON [2]
[1] Author, Salt Lake City, United States, [2] Co-Author, Salt Lake City, United States

P040 Feasibility of Participants with Symptomatic Alzheimer's Disease to Self-Administer Remternetug Subcutaneously: Results from the TRAILRUNNER-ALZ 1 Phase 3 Trial

Presenter: Matthew Hufford

Matthew HUFFORD, Kevin BIGLAN, Chad STROUD, Anna Eames SEFFERNICK, Meilin JIANG, Mausumi LIDOGASTER, Matan DABORA
Eli Lilly and Company, Indianpolis, United States

P041 Breaking down the influences of placebo progression and percent slowing in the context of time saved in Alzheimer's Disease clinical trials for populations in different disease stages

Presenter: Caleb Dayley

Caleb DAYLEY, Suzanne HENDRIX, Samuel DICKSON, Kent HENDRIX, Jason COOK
Pentara Corporation, Millcreek, United States

P042 The effect of corticosteroid pre-treatment with modified titration of donanemab on amyloid reduction and safety: TRAILBLAZER-ALZ 6 addendum design
Presenter: Hong Wang

Emel Serap NERY [1], Hong WANG [1], Paul ARDAYFIO [1], Rashna KHANNA [1], Diana SVALDI [1], Sergey SHCHERBININ [1], Wen XU [1], Paula HAUCK [1], Jin-Tai YU [2], Jiong SHI [3], Dawn BROOKS [1], Emily COLLINS [1], Mark MINTUN [1], John SIMS [1]
[1] Eli Lilly and Company, Indianapolis, United States, [2] Huashan Hospital, Shanghai, China, [3] The First Affiliated Hospital of University of Science and Technology of China, Hefei, China

P043 Study Insight Analytics (SIA) Algorithms Validation for SMART Independent Review of the ADAS-Cog Scale
Presenter: Selam Negash

Selam NEGASH, Matt WELCH, B ECHEVARRIA, Chris RANDOLPH
Clario, Philadelphia, United States

P044 REACHED – a pilot study exploring electronic health records and digital assessments to identify potential participants from understudied populations for clinical studies in Alzheimer's disease
Presenter: Ruth Croney

Frank BOESS [1], Nicola MAIORANO [1], Janice SMITH [2], Alexandria WISE-BROWN [3], Kelly COULTES [4], Giuseppe FILOSA [1], Frank PERILLI [5], Erin BECK [5], Ira GOODMAN [5], Ruth CRONEY [2]
[1] F. Hoffmann-La Roche, AG, Basel, Switzerland, [2] Roche Products Ltd, Welwyn Garden City, United Kingdom, [3] Genentech, Inc., South San Francisco, United States, [4] F. Hoffmann-La Roche Ltd, Mississauga, Canada, [5] SiteRx, New York, United States

P045 Web-Based Prescreening Survey for Alzheimer's Disease Clinical Trials: Enhancing Efficiency and Diversity
Presenter: Elisabeth Burnett

Elisabeth BURNETT, Anna SLADKY, Jenny ECHEVARRIA MEDINA, Ijeoma MBA, Patricia LOWE, Karen COLOMBO, Terrence LAFRANCE, Mariah ALEXIS, Juris JANAVS, Lauren MARCONI, Joette GIOVINCO, Ram BISHNOI, Amanda SMITH, Wendy BELDEN
USF Health Byrd Alzheimer's Institute, Tampa, United States

P046 Trends on patients' recruitment and retention in Alzheimer's disease modification trials.
Presenter: Karla Kanis

Andreas LYSANDROPOULOS [1], Jessica GARINGER [2], Karla KANIS [2]
[1] Parexel, Wavre, Belgium, [2] Parexel, Newton, United States

02 ● CLINICAL TRIALS: RESULTS

P047 Transcranial Vibroacoustic Stimulation Enhances Cognitive Function and Neural Plasticity in Older Adults: A Double-Blind Randomized Trial
Presenter: Fred Kim

Chang-Ho SHIN [1, 2], Jang-Han BAE [3, 4], Jae-Young HA [1], Jai Jun CHOUNG [1], Min-Woo CHO [1], Byung-In OH [5], Kun Ho LEE [6, 7], Young Chul YOUN [8], Sangyun KIM [9], Dong-Keun SONG [1], Vitella FOMENKO [10], Tianyang XI [10], Fred KIM [10]

[1] AriBio Co., Ltd., Seongnam-Si, Republic of Korea, [2] Department of AI Convergence Biomedical Engineering, Dongguk University, Goyang-Si, Republic of Korea, [3] Digital Health Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea, [4] Aging Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea, [5] Jangsoo Industry Co., Ltd., Seoul, Republic of Korea, [6] Gwangju Alzheimer's Disease and Related Dementias GARD Cohort Research Center, Chosun University, Gwangju, Republic of Korea, [7] Department of Biomedical Science, Chosun University, Gwangju, Republic of Korea, [8] Department of Neurology, Chung-Ang University College of Medicine, Seoul, Republic of Korea, [9] Department of Neurology, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam-Si, Republic of Korea, [10] AriBio Co., Ltd., San Diego, United States

P049 Stability and Improvement in Early Alzheimer's Disease with Lecanemab: Sub-analysis from a United States Multicenter, Retrospective Real-World Study
Presenter: Curtis Schreiber

Curtis SCHREIBER [1], David WEISMAN [2], Marwan SABBAGH [3], Michael ROSENBLOOM [4, 5, 6], Jose SORIA-LOPEZ [7, 8], Gregory COOPER [9], Samuel GILES [10], Cara LEAHY [11], Paul SCHULZ [12], Christian CAMARGO [13], Brooke ALLEN [14], Feride FRECH [15], Courtney ADAMS [15], Daryl JONES [15]

[1] Missouri Memory Center, , Citizens Memorial Hospital, Bolivar, United States, [2] Department of Neurosciences and the Alzheimer's Disease Research Center, University of California, San Diego, United States, [3] Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, United States, [4] Memory and Brain Wellness Center, University of Washington, Seattle, United States, [5] Department of Neurology, University of Washington, Seattle, United States, [6] University of Washington Alzheimer's Disease Research Center, Seattle, United States, [7] The Neuron Clinic, Chula Vista, United States, [8] Department of Neurosciences, University of California San Diego, La Jolla, United States, [9] Norton Neuroscience Institute, Louisville, United States, [10] Memory Treatment Centers, Jacksonville Beach, United States, [11] Memorial Healthcare Institute for Neuroscience, Owosso, United States, [12] Neurocognitive Disorders Center, Department of Neurology, The McGovern Medical School of UTHealth-Houston, Houston, United States, [13] Department of Neurology and Evelyn F. McKnight Brain Institute, University of Miami Miller School of Medicine, Miami, United States, [14] Roaring Fork Neurology, Basalt, United States, [15] Eisai Inc., Nutley, United States

P050 A Phase 1b study of the safety and tolerability of ALX-001 (BMS-984923) in Alzheimer's disease with a pilot study of synaptic imaging
Presenter: Adam Mecca

Adam MECCA [1], Ryan O'DELL [1], Emma COOPER [1], Jesse STANHOPE [1], Natalie BAER [1], Audra CURTIN [1], Elaheh SALARDINI [1], Mika NAGANAWA [1], Juan YOUNG [1], Susan DESTEFANO [1], Patrick SIMMS [2], Richard CARSON [1], Timothy SIEGERT [2], Stephen STRITTMATTER [1], Christopher VAN DYCK [1]

[1] Yale School of Medicine, New Haven, United States, [2] Allyx Therapeutics, New Haven, United States

P051 POLARIS-AD: Record-Breaking Global Enrollment in the Largest Phase 3 Trial of an Oral Multi-Mechanistic PDE5 Inhibitor for Early AD Using Biomarker-Agnostic Modalities for Amyloid Confirmation
Presenter: Sharon J Sha

Niels PRINS [1], Alireza ATRI [2], Fernando MELGAR-SOMOZA [3], Marzena ZBOCH [4], Do Hoon KIM [5], Yi TANG [6], Jennifer LYNCH [7], Howard CHERTKOW [8], Sangyun KIM [9], David GREELEY [10], James A ROCK [11], Fred KIM [11], Tianyang XI [11], Jai Jun CHOUNG [11], Sharon J SHA [12]

[1] Brian Research Center, Amsterdam, Netherlands, [2] Banner Sun Health Research and Banner Alzheimer's Institutes,, Sun City, United States, [3] Melgar-Caro MedCenter and Community Research, Miami, United States, [4] Wroclawskie Centrum Alzheimerowski, Wroclaw, Pologne, [5] Department of Psychiatry, Chuncheon Sacred Heart Hospital, Chuncheon, Republic of Korea, [6] Xuanwu Hospital Capital Medical University, Beijing, China, [7] Glasgow NeuroClin, Excel House, Motherwell, United Kingdom, [8] Baycrest Centre for Geriatric Care, Ontario, Canada, [9] eoul National SUniversity College of Medicine & Seoul National University, Seoul, Republic of Korea, [10] Northwest Neurological, Spokane, United States, [11] AriBio Co., Ltd, San Diego, United States, [12] Stanford, Palo Alto, United States

P052 Long-Term Benefit of Lecanemab in Patients with Low Baseline Amyloid: Estimation of Time Saved
Presenter: Sam Dickson

Sam DICKSON [1], John WHETTEN [1], Suzanne HENDRIX [1], Katherine YOUMANS-KIDDER [2], Daryl JONES [2]

[1] Pentara Corporation, Millcreek, United States, [2] Eisai Inc., Nutley, United States

P053 Patient, Care Partner, and Health Care Professional Acceptability of the Autoinjector for the Subcutaneous Delivery of Lecanemab in Patients With Early Alzheimer's Disease in the US
Presenter: Courtney Adams

Courtney ADAMS [1], Leah ZULLIG [2], Raymond TURNER [3], Daryl JONES [1]
[1] Eisai Inc., Nutley, United States, [2] Department of Population Health Sciences, Duke University School of Medicine, Durham, United States, [3] Department of Neurology, Georgetown University, Washington, United States

P054 Effects of Oral Valiltramiprosate on Clinical Efficacy, Safety and Brain Volume Outcomes in APOE4/4 Homozygotes with Early AD: Topline Results of APOLLOE4 Randomized, Placebo-Controlled 78-Week Multi-Center Trial
Presenter: Susan Abushakra

Susan ABUSHAKRA [1], David WATSON [2], Aidan POWER [1], Anton PORSTEINSSON [3], Marwan SABBAGH [4], Sharon COHEN [5], Emer MACSWEENEY [6], Merce BOADA [7], Pierre Jean OUSSET [8], Earvin LIANG [1], Susan FLINT [1], Patrick KESSLAK [1], John HEY [1], Adem ALBAYRAK [1], Martin TOLAR [1]
[1] Alzheon, Inc, Framingham, United States, [2] Alzheimer's Research and Treatment Center, Wellington, United States, [3] University of Rochester School of Medicine and Dentistry, Rochester, United States, [4] Barrow Neurological Institute, Phoenix, United States, [5] Toronto Memory Program, Toronto, Canada, [6] Re:Cognition Health, London, United Kingdom, [7] Ace Alzheimer Center, Barcelona, International University of Catalunya, Barcelona, Spain, [8] University of Toulouse and Toulouse Gerontopole, Toulouse, France

P055 Baseline Characteristics and Preliminary Safety from a Multicenter, Safety Surveillance Study of Lecanemab Treatment for Alzheimer's Disease in Real-World Clinical Practice using Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) Registry
Presenter: Marwan Sabbagh

Marwan SABBAGH [1], Laura CORNELISSEN [2], Barry MICHEL [2], Ilona SURICK [2], Shobha DHADDA [2], Michio KANEKIYO [2], Steven HERSCH [2], Michael IRIZARRY [2]
[1] Barrow Neurological Institute, Phoenix, United States, [2] Eisai Inc., Nutley, United States

P056 Clinical Stabilization in APOE4 Carriers with MCI over 3 Years Correlates with Reduced Hippocampal Atrophy in a Phase 2 Long Term Extension Study with Oral Valiltramiprosate
Presenter: John Hey

John HEY [1], Susan ABUSHAKRA [1], Jakub HORT [2], Katerina SHEARDOVA [3], Jeremy YU [1], Pat KESSLAK [1], Jean SCHAEFER [1], Adem ALBAYRAK [1], Margaret BRAY [1], Luc BRACOUD [4], Chris CONKLIN [5], Joyce SUHY [5], Aidan POWER [1], Martin TOLAR [1]
[1] Alzheon, Inc., Framingham, United States, [2] Charles University, Prague, Czech Republic, [3] International Clinical Research Center, Brno, Czech Republic, [4] Clario, Lyon, France, [5] Clario, San Mateo, United States

P057 XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer's Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial
Presenter: Kim A. Staats

Kim A. STAATS [1], Judith JAEGER [2], Sarah BARNUM [2], Sharon COHEN [3], Malu GAMEZ TANSEY [4], Christopher J. BARNUM [1]
[1] INmune Bio, Inc., Boca Raton, United States, [2] CognitionMetrics., LLC, Hixon, United States, [3] Toronto Memory Program, Toronto, Canada, [4] Department of Neurology, Indiana University School of Medicine, Stark Neuroscience Research Institute, Indianapolis, United States

P058 Correlations of Valiltramiprosate Effects on Hippocampal Volume and Cortical Thickness with Clinical Outcomes in APOE4/4 Subjects with MCI: Prespecified Analysis of MCI Group in the 78-Week APOLLOE4 Phase 3 Trial
Presenter: Aidan Power

Aidan POWER [1], Dugyu TOSUN [2], Earvin LIANG [1], Susan ABUSHAKRA [1], David WATSON [3], Emer MACSWEENEY [4], Merce BOADA [5], Karim BENNYS [6], Jorge MATIAS-GUIU [7], John A. HEY [1], Susan FLINT [1], J. Patrick KESSLAK [1], Luc BRACOUD [8], Margaret BRAY [1], Martin TOLAR [1]
[1] Alzheon Inc., Framingham, United States, [2] University of California Scan Francisco, San Francisco, United States, [3] Alzheimer's Research and Treatment Center, Wellington, United States, [4] Re:Cognition Health, London, United Kingdom, [5] International University of Catalunya, Barcelona, Spain, [6] Hopital Gui de Chauliac - CHRU de Montpellier, Montepellier, France, [7] Hospital Clinico San Carlos, Madrid, Spain, [8] Clario Inc., Philadelphia, United States

P059 Baseline antihypertensive medication use is associated with lower frequency of amyloid-related imaging abnormalities-edema with donanemab treatment even after controlling for mean arterial blood pressure: Analysis from TRAILBLAZER-ALZ randomized clinical trials
Presenter: Paul Ardayfio

Paul ARDAYFIO, Chakib BATTIOUI, Rashna KHANNA, Steve LAUZON, Mariângela LUCHEZI, Alessio ERAMO, Jennifer Ann ZIMMER, Cynthia D. EVANS, Emel Serap Monkul NERY, Hong WANG, Dawn A. BROOKS, John R. SIMS
Eli Lilly & Company, Indianapolis, United States

P060 Effects of the Oral Anti-amyloid Agent Valiltramiprosate on Measures of Microstructural Integrity: Diffusion MRI Results of the Phase 3 APOLLOE4 Trial in APOE4/4 Homozygotes with Early AD
Presenter: Earvin Liang

Earvin LIANG [1], Dugyu TOSUN [2], Susan ABUSHAKRA [1], David WATSON [3], Sharon COHEN [4], Emer MACSWEENEY [5], Chris CONKLIN [6], Madhura INGALHALIKAR [6], John A HEY [6], J Patrick KESSLAK [1], Susan FLINT [1], Martin TOLAR [1]
[1] Alzheon Inc., Framingham, United States, [2] University of California San Francisco, San Francisco, United States, [3] Alzheimer's Research and Treatment Center, Wellington, United States, [4] Toronto Memory Program, Toronto, United States, [5] Re:Cognition Health, London, United States, [6] Clario Inc, Philadelphia, United States

P061 Effects of transcranial Photobiomodulation(tPBM) on Cognitive Function and Brain functional connectivity: A Preliminary Clinical Study
Presenter: Morihiro Tsujishita

Morihiro TSUJISHITA [1, 2], Nam Heon KIM [3], Jun-Yeop KIM [3], Seung Wan KANG [3, 4]
[1] Faculty of Health and Medical Sciences, Department of Rehabilitation, Nara, Japan, [2] Nara Gakuen University; Graduate School of Rehabilitation Studies, Nara Gakuen University, Nara, Japan, [3] iMediSync Inc, Seoul, Republic of Korea, [4] National Standard Reference Data Center for Korean EEG, Seoul National University College of Nursing, Seoul, Republic of Korea

P062 Safety Outcomes of Lecanemab in Korean Real-World Clinical Practice: A Multicenter Observational Study
Presenter: Heekyoung Kang

Heekyoung KANG [1], Hyemin JANG [2], Jehyun AHN [3], Jae-Hong LEE [4], Duk L NA [5], Byeong Chae KIM [6], Eun-Joo KIM [7], Min Young CHUN [8], Jihwan YUN [9], Si Eun KIM [10], Soo Hyun CHO [6], Jun Pyo KIM [11], Sang Won SEO [3], Jae-Sung LIM [2], Hee Jin KIM [1]
[1] Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea - Seoul Korea, Republic of, Seoul, Republic of Korea, [2] Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea - Seoul Korea, Republic of, Seoul, Republic of Korea, [3] Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, [4] Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, [5] Happymind Clinic, Seoul, Republic of Korea, Seoul, Republic of Korea, [6] Department of Neurology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea, Seoul, Republic of Korea, [7] Department of Neurology, Pusan National University Hospital, Busan, Republic of Korea, Seoul, Republic of Korea, [8] Department of Neurology, Yongin Severance Hospital, Yonsei University Health System, Yongin-si, Gyeonggi-do, Republic of Korea, Seoul, Republic of Korea, [9] Department of Neurology, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, [10] Department of Neurology, Inje University Haeundae Paik Hospital, Busan, Republic of Korea, Seoul, Republic of Korea, [11] Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea - Seoul Korea, Republic of - Seoul Korea, Republic of, Seoul, Republic of Korea

P063 Cognitive and electrophysiological effects of postbiotic dietary supplementation in older adults: results from a randomised double-blind, placebo-controlled trial
Presenter: Hariom Yadav

Alina WARREN-WALKER [1], Courtney DAVIES [1], Charly MORGAN [1], Nigel HOLT [1], Douglas LYNCH [2], Denis KAY [3], Kevin STEPHENS [4], Hariom YADAV [5], Alexander Nw TAYLOR [1], Amanda J LLOYD [1]
[1] Aberystwyth University, Aberystwyth, United Kingdom, [2] Postbiotics Inc, Winston Salem, United States, [3] Neurodyn Life Sciences Inc, Charlottetown, Canada, [4] Agroceutical Products Ltd, Glasbury, United Kingdom, [5] University of South Florida, Tampa, United States

P064 Valacyclovir treatment of mild cognitive impairment with herpes simplex seropositivity: the VALMCI trial
Presenter: Davangere Devanand

Davangere DEVANAND, Terry GOLDBERG, Min QIAN, Renjie WEI, Howard ANDREWS, Lola NEDIC, Deborah DELIYANNIDES, Lawrence MAAYAN, Francesca ZANDERIGO, Edward HUEY
Columbia University, New York, United States

P065 Results from a Phase 1b trial on anti-A? oligomer vaccine ALZ-101 in early Alzheimer's disease
Presenter: Anders Sandberg

Anders SANDBERG [1], Juha RINNE [2], Zsófia LOVRÓ [3], Mika SCHEININ [3], Stefan PIERROU [1], Henrik ZETTERBERG [4]
[1] Alzinova AB, Mölndal, Sweden, [2] University of Turku and Turku University Hospital, Turku, Finland, [3] CRST / Link Medical, Turku, Finland, [4] University of Gothenburg, Göteborg, Sweden

P067   Effects of PoZibio® and Cerbella® supplementation on brain function and wellbeing in older adults
Presenter: Amanda J Lloyd

Courtney DAVIES [1], Alina WARREN-WALKER [1], Charly MORGAN [1], Nigel HOLT [1], Douglas LYNCH [2], Denis KAY [3], Kevin STEPHENS [4], Hariom YADAV [5], Alexander Nw TAYLOR [1], Amanda J LLOYD [1]
[1] Aberystwyth University, Aberystwyth, United Kingdom, [2] Postbiotics Inc, Winston Salem, United States, [3] Neurodyn Life Sciences Inc, Charlottetown, Canada, [4] Agroceutical Products Ltd, Glasbury, United Kingdom, [5] University of South Florida, Tampa, United States

P069   Computerised cognitive training benefits cognition in older adults with cognitive impairment in Long Covid: Outcomes from the BEACON randomised controlled trial
Presenter: Anne Corbett

Anne CORBETT [1], Shanice TULLOCH [2], Abbie PALMER [2], Millie SANDER [2], Arit INOK [2], Dag AARSLAND [3], Nerina FRAMPTON [2], Adam HAMPSHIRE [3], Clive BALLARD [1]
[1] Exeter, Exeter, United Kingdom, [2] University of Exeter, Exeter, United Kingdom, [3] King's College London, London, United Kingdom

P070   Anti-Abeta treatment without ARIA-E using the oligomer disassembling compound PRI-002 in an ongoing Phase 2 trial
Presenter: Oliver Peters

Oliver PETERS [1,2], Dagmar JÜRGENS [2], Gerhard TISCHLER [3], Alexander BRENER [3], Tina BARTSCH [3], Gunther KAUSELMANN [2], Knut ADERMANN [2], Kathrin ZEIGER [3], Katja LINDNER [3], Julie-Anne GABELICH [3], Dieter WILLBOLD [2]
[1] Charité, Berlin, Germany, [2] Priavoid, Düsseldorf, Germany, [3] Prinnovation, Leipzig, Germany

P071   Neflamapimod Significantly Lowers Plasma GFAP and Correlates with Clinical Benefit in Dementia with Lewy Bodies: Results from the RewinD-LB Trial
Presenter: John J Alam

John J ALAM [1], Hui-May CHU [2], Amanda GARDNER [3], Blackburn KELLY [3], Charlotte E TEUNISSEN [4]
[1] CeroMed, Inc, Boston, United States, [2] Anoxis Corporation, Natick, United States, [3] CervoMed, Boston, United States, [4] Amsterdam Medical Center, Amsterdam, Netherlands

P072   Real-World Clinical, Safety and Patient-Reported Outcomes of Treatment with Lecanemab in a New England Alzheimer's Disease Center
Presenter: Salvatore Napoli

Salvatore NAPOLI, Rachel O' DONNELL, Lauren NASSR, Emily MAIZE
Alzheimer's Neurology and Infusion Centers of New England, Foxboro, United States

P073   Amyloid Co-Pathology and Cognitive Decline in Buntanetap Treated Parkinson's Disease Dementia Patients
Presenter: Cheng Fang

Cheng FANG [1], Hui LIU [1], David FENG [2], Melissa GAINES [1], Maria MACCECCHINI [1]
[1] Annovis Bio, Malvern, United States, [2] TCM, New Jersey, United States

P074   Comparing the Effects of a Multi-component Behavioral Intervention for People with Mild Cognitive Impairment by Care partner Type
Presenter: Zhigang Xie

Zhigang XIE [1], Gelan YING [1], Stephanie AGHAMOOSA [2], Dona LOCKE [3], Glenn SMITH [1], Anne SHANDERA-OCHSNER [4], Melanie CHANDLER [5]
[1] University of Florida, Gainesville, United States, [2] The Medical University of South Carolina, Charleston, United States, [3] Mayo Clinic, Phoenix, United States, [4] Mayo Clinic, La Crosse, United States, [5] Mayo Clinic, Jacksonville, United States

P075   JOY-ALZ: First Nationwide Real-World Data Registry for Alzheimer's Disease in Korea
Presenter: Geon Ha Kim

Geon Ha KIM [1], Sung Hoon KANG [2], Seong-Ho KOH [3], So Young MOON [4], Young Ho PARK [5], Yong Soo SHIM [6], Dong Won YANG [7], Young Chul YOUN [8], Jae-Sung LIM [9], Hanna CHO [10], Hojin CHOI [3], Jung-Min PYUN [5], Kee Hyung PARK [11], Seong Hye CHOI [12]
[1] Ewha Womans University Mokdong Hospital, Seoul, Republic of Korea, [2] Korea University Guro Hospital, College of Medicine Korea University, Seoul, Republic of Korea, [3] Hanyang University Guri Hospital, Guri, Republic of Korea, [4] Ajou University School of Medicine, Suwon, Republic of Korea, [5] Seoul National University Bundang Hospital, Seongnam, Republic of Korea, [6] The Catholic University of Korea, St. Vincent's Hospital, Suwon, Republic of Korea, [7] Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, [8] Chung-Ang University Hospital, Seoul, Republic of Korea, [9] Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, [10] Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, [11] Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea, [12] Inha University School of Medicine, Incheon, Republic of Korea

P076 Oral Blarcamesine Comparison to Normal Cognitive Aging: Demonstrating Alignment with Prodromal Cognitive Aging Trajectories in Precision Medicine Patient Population Phase IIb/III Trial–for Early Alzheimer's Disease Patients
Presenter: Audrey Gabelle

Audrey GABELLE [1] , Marwan SABBAGH [2], Timo GRIMMER [3], Juan Carlos LOPEZ-TALAVERA [4], David GOULD [4], Wolfgang LIEDTKE [4], William R CHEZEM [4], Jin KUN [4], Christopher U MISSLING [4]
[1] Montpellier University, Montpellier, France, [2] Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Arizona, Phoenix, United States, [3] Technical University of Munich, School of Medicine and Health, Klinikum rechts der Isar, Munich, Germany, [4] Anavex Life Sciences, New York, [10111], New York, United States

P077 A Phase 1 Clinical Trial of BDNF Gene Therapy for AD and MCI: Update
Presenter: Mark Tuszynski

Douglas SCHARRE [1], Gabriel LEGER [2], Russell.Lonser@Osumc.Edu LONSER [3], Krzysztopf BANKIEWICZ [3], Mark TUSZYNSKI [2]
[1] Ohio State University Medical Center, Columbus, United States, [2] UC San Diego, La Jolla, United States, [3] Ohio State University, Columbus, United States

P078 Randomised controlled trial of extended-release guanfacine in Alzheimer's disease dementia (NorAD)
Presenter: Paresh Malhotra

Paresh MALHOTRA [1] , Hilary WATT [1], Karen HOANG [2], Mara GOLEMME [1], Johanna BRANDT [3], Chara TRIANTAFYLLOU [1], Richard PERRY [1], Praveen SINGH [4], Craig RITCHIE [5], Danielle WILSON [1], James PICKETT [6], Chris FOX [7], Rachel BURTON [3], James CARPENTER [3], Robert HOWARD [3]
[1] Imperial College London, London, United Kingdom, [2] Queen Mary University of London, London, United Kingdom, [3] University College London, London, United Kingdom, [4] Central and North West London NHS Foundation Trust, London, United Kingdom, [5] Brain Sciences Scotland, London, United Kingdom, [6] Owkin, London, United Kingdom, [7] University of Exeter, London, United Kingdom

P079 Results of a «First-in-Human» Open Label, Phase 1 Clinical Study of Intracerebroventricular Injections of Ex Vivo Expanded, Autologous, Wnt Activated,Adipose-Derived Stem Cells in 6 Participants with Mild to Moderate Alzheimer's Disease (AD)
Presenter: Christopher Duma

Christopher DUMA [1] , Hans KEIRSTEAD [1], Gabriel NISTOR [1], Robert LYNN [1], Gus ALVA [2], Karlyssa CHUNG [1], Ashley HARRIS [1], Sawyer FARMER [1], Jessica BUXTON [1], Zoe HARENG [1]
[1] Regeneration Biomedical, Inc., Newport Beach, United States, [2] Hoag Memorial Hospital Presbyterian, Newport Beach, United States

P080 Results of a Phase II Randomized, Double-Blind, Placebo-Controlled Trial of S-Adenosyl Methionine in Participants with Mild Cognitive Impairment or Dementia Due to Alzheimer's Disease
Presenter: Sarah Holper

Sarah HOLPER [1, 2, 3] , Kevin J. BARNHAM [3], Leonid CHURILOV [1], Paul YATES [4, 5], Amy BRODTMANN [6], Sally JOHNS [7], Colin L. MASTERS [3, 8], Rosie WATSON [1, 2], Nawaf YASSI [1, 2, 3]
[1] Department of Medicine, Melbourne Brain Centre @ The Royal Melbourne Hospital, University of Melbourne, Parkville, Vic, Australia, [2] Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Vic, Australia, [3] The Florey Institute of Neuroscience and Mental Health, Parkville, Vic, Australia, [4] Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Vic, Australia, [5] Medical and Cognitive Research Unit, Department of Geriatric Medicine, Austin Health, Heidelberg, Vic, Australia, [6] Department of Neurology, Eastern Health, Monash University, Box Hill, Vic, Australia, [7] Department of Geriatric Medicine, Modbury Hospital, Northern Adelaide Local Health Network, South Australia, Australia, [8] University of Melbourn, Parkville, Vic, Australia

P081 ABvac40 Vaccine Is Associated with Reduced Cortical Perfusion Decline in Early-Stage Alzheimer's Disease: Results from the AB1601 Phase 2 Study
Presenter: María Pascual-Lucas

María PASCUAL-LUCAS [1] , Ana María LACOSTA [1], María MONTAÑÉS [1], Jesús CANUDAS [1], Jorge LOSCOS [1], Jose TERENCIO [1, 2], Elena PRIETO [3], Kathie HIRSCHMUELLER [3], Javier ARBIZU [3]
[1] Araclon Biotech-Grifols, Zaragoza, Spain, [2] Grifols, Barcelona, Spain, [3] Clínica Universidad de Navarra, Pamplona, Spain

P082 The ORCHID Study: Optimizing Rural Community Health through Interdisciplinary Detection and Care
Presenter: Lisa Wiese

Lisa WIESE [1] , Candy WILSON [1], Beth KING [1], Bianca TOLEA [2], Magdalena TOLEA [2]
[1] Florida Atlantic University, Boca Raton, United States, [2] University of Miami, Miami, United States

P083 VNA-318, a first-in-class small molecule with a unique dual mode of action, exhibits properties in the first-in-human trial ideal for becoming a novel combination partner in the treatment of patients with Alzheimer's Disease
Presenter: Klaus Dugi

Klaus DUGI [1], Marina KLEIN [2], Silke KERN [1], Tanes IMAMURA DE LIMA [1], Leila MIRMOHAMADSADEGHI [1], Penelope ANDREUX [1]
[1] Vandria Ltd, Epalinges, Switzerland, [2] Biotrial, Rennes, France

P084 Advancing Alzheimer's Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine
Presenter: Marwan Sabbagh

Marwan SABBAGH [1], Timo GRIMMER [2], Juan Carlos LOPEZ-TALAVERA [3], William CHEZEM [3], Kun JIN [3], Christopher MISSLING [3]
[1] Barrow Neurological Institute, Phoenix, United States, [2] Technical University of Munich, Munich, Germany, [3] Anavex, New York, United States

P085 Biomarker Positive APOE4 Carriers with MCI Show Stability on MMSE Over 208-weeks of Treatment with Oral Valiltramiprosate in a Phase 2 Multi-Center Single-Arm Trial
Presenter: Patrick Kesslak

Patrick KESSLAK [1], Susan ABUSHAKRA [1], John HEY [1], Katrina SHEARDOVA [2], Jakub HORT [3], Niels PRINS [4], Margaret BRAY [1], Adem ALBAYRAK [1], Aidan POWER [1], Martin TOLAR [1], [1]
[1] Alzheon, Inc, Framingham, United States, [2] International Clinical Research Centre at St. Anne's University Hospital, Brno, Czech Republic, [3] Memory Clinic, Department of Neurology, Charles University, Prague, Czech Republic, [4] Alzheimer Center Amsterdam, Vrije University Medical Center, Amsterdam, Netherlands

P086 The Safety, Toerlability and ARIA Effects of the Oral Anti-Amyloid Agent Valiltramiprosate from the Phase 3 APOLLOE4 Trial in APOE4/4 Homozygotes with Early AD
Presenter: David Watson

David WATSON [1], Susan ABUSHAKRA [2], Jerome BARAKOS [3], J. Patrick KESSLAK [2], Earvin LIANG [2], Anton PORSTEINSSON [4], Marwan SABBAGH [5], Emer MACSWEENEY [6], Sharon COHEN [7], Merce BOADA [8], Rosalind MCLAINE [2], Susan FLINT [2], Aidan POWER [2], John A. HEY [2], Martin TOLAR [2]
[1] Alzheimer's Research and Treatment Center, Wellington, Fl, United States, [2] Alzheon Inc., Framingham, Ma, United States, [3] Pacific Medical Center and Clario Inc, San Mateo, Ca, United States, [4] University of Rochester School of Medicine and Dentistry, Rochester, Ny, United States, [5] Barrow Neurological Institute, Phoenix, Az, United States, [6] Re:Cognition Health, London, United Kingdom, [7] Toronto Memory Program, Toronto, Canada, [8] Ace Alzheimer Center, Barcelona, Spain

P087 Cognitive Effects of Postbiotics in Aging and Cognition: Stroop Performance Benefits in a Double-Blind Study
Presenter: Yadav Hariom

Alina WARREN-WALKER [1, 2], Courtney DAVIES [1], Amanda LLOYD [1], Nigel HOLT [1], Denis KAY [3], Kevin STEPHENS [4], Ram BISHNOI [5], Shalini JAIN [6], Yadav HARIOM [5]
[1] Aberystwyth University, Wales, United Kingdom, [2] Postbiotics Inc, Winston Salem, United States, [3] Neurodyn Life Sciences Inc, Charlottetown, Prince Edward Island, Canada, [4] Agroceutical Products Ltd, Glasbury, United Kingdom, [5] University of South Florida, Tampa, United States, [6] MusB Research LLC, New Port Richey, United States

P088 VIVA-MIND: Pharmacokinetic, pharmacodynamic, and MRI effects in a Phase 2 study evaluating varoglutamstat (PQ912) in early Alzheimer's disease
Presenter: Howard H. Feldman

Andrew J. MACKELFRESH [1, 2], Karen MESSER [3, 4], January DURANT [1, 2], Jing ZHANG [3], Carolyn REVTA [1, 2], James BREWER [1, 2], Nicola LAMA [5], Tanja WASSMANN [6], Torsten HOFFMANN [6], Antje MEYER [6], Sylvia SCHELL-MADER [6], Christine WENZKOWSKI [6], Michael SCHAEFFER [6], Frank WEBER [6], Howard H. FELDMAN [1, 2]
[1] Department of Neurosciences, University of California San Diego, La Jolla, United States, [2] Alzheimer's Disease Cooperative Study, University of California San Diego, La Jolla, United States, [3] Moores Cancer Center, University of California San Diego, La Jolla, United States, [4] Division of Biostatistics and Bioinformatics, Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, United States, [5] Certara, Basel, Switzerland, [6] Vivoryon Therapeutics N.V., Halle, Germany

P089 Real-World Effectiveness and Safety of Lecanemab in Japanese Patients with Alzheimer's Disease: A Single-Center Study
Presenter: Ryosuke Shimaskai

Ryosuke SHIMASKAI [1], Masanori KURIHARA [1, 2], Taro BANNAI [1], Keiko HATANO [1], Fumio SUZUKI [3], Aya TOKUMARU [3], Kenji ISHII [4], Ko FURUTA [5], Ryoko IHARA [1, 2], Atsushi IWATA [1, 2]
[1] Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, [2] Integrated Research Initiative for Living Well with Dementia, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, [3] Department of Diagnostic Radiology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, [4] Research Team for Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, [5] Department of Psychiatry, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

P090 Real-world experience with Lecanemab therapy for Alzheimer's disease in the Intermountain West
Presenter: Nicholas Frost

Nicholas FROST [1], Bethany CURD [1], Camilla ZUBRICK [1], Christine CLIATT BROWN [1], Michelle SORWEID [2], Sarah DEHONEY [1], Yoshimi ANZAI [3], Satoshi MINOSHIMA [3], Anna PARKS [4]
[1] Department of Neurology, University of Utah, Salt Lake City, United States, [2] Division of Geriatrics, University of Utah, Salt Lake City, United States, [3] Department of Radiology and Imaging Sciences, University of Utah, Salt Lake City, United States, [4] Department of Internal Medicine, University of Utah, Salt Lake City, United States

P091 Semaglutide Concentration in Cerebrospinal Fluid from Patients with Early Alzheimer's Disease After 12 Weeks of Subcutaneous Treatment
Presenter: Peter Johannsen

Peter JOHANNSEN [1], Marie Aare BENTSEN [1], Dylan Mathew BELMONT-RAUSCH [1], Lisbeth CARSTENSEN [1], Rose JEPPESEN [1], Gabriel MARTINO [1], Martí Jiménez MAUSBACH [1], Anne BÖRJESSON-HANSON [2,3], Lotte Bjerre KNUDSEN [1]
[1] Novo Nordisk, Copenhagen, Denmark, [2] Department of Aging, Karolinska University Hospital, Stockholm, Sweden, [3] Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden

P092 Analytical and clinical validation of the APOE genotyping PCR test in patients from the Phase III Clarity AD trial.
Presenter: Kozue Matsuda

Kozue MATSUDA
Sysmex Corporation, Kobe, Japan

P093 Brexpiprazole Treatment for Agitation Associated with Dementia due to Alzheimer's Disease : Post Hoc Subgroup Analysis Based on Care Setting (Inpatient/Outpatient) in Brexpiprazole for Alzheimer's Disease Patients with Agitated Symptoms (BRIDGE) Study
Presenter: Shimizu Koichi

Shimizu KOICHI [1], Seiyama YUTA [2], Shibasaki YOSHIYUKI [1], Toda RIKIYA [1], Nakamichi NORIHIRO [1], Adachi JUN [3], Hirota NAOKI [4], Nakai MASAMI [4], Takahashi KANEYOSHI [1], Nakamura YU [5]
[1] Department of Medical Affairs, Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan, [2] Department of Medical Affairs, Otsuka Pharmaceutical Co., Ltd, Osaka, Japan, [3] Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd, Tokyo, Japan, [4] Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd, Osaka, Japan, [5] Faculty of Medicine/Graduate School of Medicine, Kagawa University, Kagawa, Japan

P094 Assessment of Orthostatic tolerance and Efficacy of Fimasartan in elderly Alzheimer's disease patients with Hypertension: A 16-Week Observational study
Presenter: Mee Y Park

Mee Y PARK [1], Hyeun J HAN [2], Jean S AN [3]
[1] Yeungnam Medical University Center, Daegu, Republic of Korea, [2] Ilsan Brain Neurology Clinic, Ilsan, Republic of Korea, [3] University of Illinois Chicago, Chicago, United States

P095 PrP-siRNA: Rationale and Design for a First-in-Human Evaluation of the Safety and Pharmacology of Intrathecally Administered Divalent Small Interfering RNA (di-siRNA) to Reduce Prion Protein (PrP) in Patients with Prion Diseases
Presenter: Steven Arnold

Steven ARNOLD [1], Aleksander VIDENOVIC [1], Merit CUDKOWICZ [1], Marianne CHASE [1], David KLEMENTS [1], Christopher COFFEY [2], Dixie ECKLUND [2], Lumy SAWAKI-ADAMS [3], Gabriel LEGER [4], Sonia VALLABH [5], Eric MINIKEL [5]
[1] MassGenneral Brigham, Boston, United States, [2] University of Iowa, Iowa City, United States, [3] NINDS, NIH, Bethesda, United States, [4] University of California San Diego, San Diego, United States, [5] Broad Institute, Cambridge, United States

P096 Comparison of Amyloid-related Imaging Abnormalities Risk for Lecanemab versus Donanemab and the Potential Implications
Presenter: Anna Burke

Marwan SABBAGH [1], Sharon COHEN [2], Ariel CHAO [3], Keith BETTS [3], Ashley HOLUB [3], Anna BURKE [1], Christopher VAN DYCK [4]
[1] Barrow Neurological Institute, Phoenix, AZ, USA, Phoenix, United States, [2] Toronto Memory Program, Toronto, ON, Canada, Toronto, Canada, [3] Analysis Group Inc., Boston, MA, USA, Boston, United States, [4] Yale Alzheimer's Disease Research Center, New Haven, CT, USA, New Haven, United States

P097 Outcomes from a Real-World Academic Anti-Amyloid Therapy Adjudication Board
Presenter: Michael Rosenbloom

Varun MEHTA, Andrea SCHNEE, Thomas GRABOWSKI, Michael ROSENBLOOM
University of Washington, Seattle, United States

P099 Multicenter Case Registry Study of Lecanemab in Early Alzheimer's Disease in Northwest China
Presenter: Peijie Liu

Peijie LIU, Simeng CUI, Jie LIU, Liangjun DANG, Qiumin QU, Jin WANG
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

P100 Repeated Theta Burst Stimulation to Brain Area 8AV Transiently Improves Memory Retention in Early-Stage Alzheimer's Disease
Presenter: Michael Rosenbloom

Michael ROSENBLOOM, John YI, Andrea STOCCO
University of Washington, Seattle, United States

P101 Real-world treatment with lecanemab: medically significant and insignificant ARIA, and pseudo-ARIA.
Presenter: Lawrence Honig

Lawrence HONIG
Columbia University, New York, United States

P102 Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study
Presenter: Brian Rash

Brian RASH [1], John REEVES [1], Chris CONKLIN [2], Madhura INGALHALIKAR [3], Nataliya AGAFONOVA [1], Joshua HARE [1]
[1] Longeveron INC, Miami, United States, [2] Clario, Philadelphia, United States, [3] Clario, Miami, United States

P103 A Delphi panel exploring the burden of ARIA management from the provider's perspective
Presenter: Marwan Sabbagh

Marwan SABBAGH [1], Feride FRECH [2], Chenyue ZHAO [2], Hideki TOYOSAKI [2], Richard PERRY [3], Medi STONE [3], Sophie POPE [3], Jerome BARAKOS [4], Raymond TURNER [5]
[1] Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, United States, [2] Eisai, Inc., Nutley, New Jersey, United States, [3] Adelphi Values PROVE, Bollington, Cheshire, United Kingdom, [4] Sutter Health California Pacific Medical Center, San Francisco, California, United States, [5] Department of Neurology, University of Georgetown, Washington, District Of Columbia, United States

P104 Clinical trials (phases 1 & 2) of transdermal ALC919 peptide to activate brain mitochondrial complex I
Presenter: Sam Gandy

Sam GANDY [1], Toshiharu SUZUKI [2], Yasuomi OUCHI [3], Hirotoshi ADACHI [4], Eugenii RABINER [5], Manfred WINDISCH [6], Mary SANO [1]
[1] Icahn School of Medicine at Mount Sinai, New York, United States, [2] Hokkaido University & Tokyo Metropolitan University, Sapporo & Tokyo, Japan, [3] Hamamatsu University School of Medicine, Hamamatsu, Japan, [4] PassPort Technologies, San Diego, United States, [5] Perceptive Discovery, London, United Kingdom, [6] NeuroScios, Graz, Autriche

P105 A Review of Patient Demographics, Clinical Characteristics, Eligibility, and Treatment Planning for lecanemab in an Academic Medical Center
Presenter: Nour Abi Chakra

Nour ABI CHAKRA, John DICKSON, Liliana RAMIREZ GOMEZ, Daniel SAUKKONEN, Michael ERKKINEN
Mass General Brigham, Boston, United States

P106 MTX46943, a Novel TREM2 Small Molecule Agonist For The Treatment of Early-Stage Alzheimer´s Disease ?
Presenter: Niels Plath

Manuela POLYDORO [1], Ivana GERIC [2], Jin ZHENG [1], Tina SOMMER BISGAARD [1], Ashley COMER [1], Laura SANS [1], Joachim VILSTRUP [1], Leen WOLFS [2], Arya NAIR [2], Morten S ANDERSEN [1], Ninna FREDERIKSEN [1], Peter FLAGSTAD [1], Maria DALBY [1], Rita BALICE-GORDON [1], Niels PLATH [1]
[1] Muna Therapeutics, Copenhagen, Denmark, [2] Muna Therapeutics, Leuven, Belgium

P107 International Registry for Alzheimer's Disease and Other Dementias (InRAD): design, data model, and interoperability
Presenter: Robert Perneczky

Casper DE BOER [1], Jean VONSY [2], Johan VAN BEEK [2], Robert HYDE [2], Chen WANG [3], Giovanni FRISONI [3], Wiesje VAN DER FLIER [4], Jung-Lung HSU [5], Frank JESSEN [6], Robert PERNECZKY [7, 8, 9]
[1] Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands; Amsterdam Neuroscience, Neurodegeneration,, Amsterdam, Netherlands,, [2] TW1 Healthcare Consulting Ltd, London, United Kingdom, [3] Memory Centre, Department of Rehabilitation and Geriatrics, Geneva University Hospitals; Laboratory of Neuroimaging of Aging LANVIE, University of Geneva, Geneva, Switzerland, [4] Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, Netherlands, [5] New Taipei Municipal TuCheng Hospital; President of the Taiwan Dementia Society, New Taipei City, Taïwan, République de China, [6] Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany; German Centre for Neurodegenerative Diseases DZNE Cologne; Chair, European Alzheimer's Disease Consortium EADC, Cologne, Germany, [7] Department of Psychiatry and Psychotherapy, LMU Hospital, Ludwig-Maximilians-Universität München, Munich, Germany; German Centre for Neurodegenerative Diseases DZNE Munich, Munich, Germany; Munich Cluster for Systems Neurology SyNergy, Munich, Germany, [8] Ageing Epidemiology Research Unit AGE, School of Public Health, Imperial College London, London, United Kingdom, [9] Division of Neuroscience, University of Sheffield, Sheffield, United Kingdom

P108 Safety, Pharmacokinetics and Cardiodynamics of CMS121, a Novel Small Molecule Fisetin Derivative with Neuroprotective Properties, in Phase 1 Healthy Adult Volunteers
Presenter: Pamela Maher

Pamela MAHER [1], Ronald CHRISTOPHER [2], Rebecca EVANS [2], William RASCHKE [2]
[1] Salk Institute, La Jolla, United States, [2] Virogenics, San Diego, United States

P109 Study Design in a Phase 2a Registration Trial for OAB-14 in the Treatment of Mild Cognitive Impairment (MCI) or Mild and Moderate Dementia due to Alzheimer's Disease
Presenter: Tang Yi

Tang YI [1], Zheng ZHONGHUI [2], Wang YIYUN [2]
[1] Xuanwu Hospital Capital Medical University, Beijing, China, [2] Shandong Xinhua Pharmaceutical Company Limited, Zibo, China

P110 THN391 – A Novel, First-In-Class Anti-fibrin Antibody for Treatment of Inflammation in Alzheimer's Disease: An Ongoing Phase 1b Study for the Treatment of Early Alzheimer's Disease
Presenter: Brad Navia

Brad NAVIA [1], Aaron KANTOR [1], Tanja HOFFMAN [1], June KAPLOW [1], Henk MUTSAERTS [2], Frederik BARKHOF [2], Khalid ABD-ELAZIZ [3], E. Jort VIJVERBEG [2], Catherine MUMMERY [4], Craig RITCHIE [5]
[1] Therini Bio, Sacramento, Ca, United States, [2] Amsterdam UMC, Amsterdam, Netherlands, [3] UniverUniversity Medical Center Groningen, Groningen, Netherlands, [4] University College London Hospitals, London, United Kingdom, [5] Scottish Brain Science, Edinburgh, United Kingdom

P111 PNA5 For Treatment of Vascular Dementia: Composite Serum Biomarkers for VCID Patients Enrollment Stratification.
Presenter: Meredith Hay

Meredith HAY [1, 2, 3] , Lee RYAN [1, 4], Nancy SWEITZER [5], Christina HOYER-KIMURA [1]
[1] University of Arizona, Tucson, United States, [2] ProNeurogen, Inc, Tucson, United States, [3] Evelyn F. McKnight Brain Institute, , Tucson, United States, [4] Evelyn F. McKnight Brain Institute, Tucson, United States, [5] Washington University School of Medicine, St. Louis, United States

P112 Phase 1 studies of MK-2214, a novel antibody targeting pS413 tau, for the treatment of Alzheimer's disease
Presenter: Seth Robey

Seth ROBEY [1] , Jonathan KURZ [1], Kristine CERCHIO [1], Zhiqing XU [1], Jan DE HOON [2], An BAUTMANS [3], Kristien VAN DYCK [3], Kazuki MATSUDA [4], Katsukuni FUJIMOTO [4], Arie STRUYK [1]
[1] Merck & Co., Inc., Rahway, United States, [2] University Hospital Leuven, Leuven, Belgium, [3] MSD Europe Belgium, Brussels, Belgium, [4] MSD K.K., Tokyo, Japan

P113 Incidence, Risk Factors with Cut-off Values, and Management of Lecanemab-Related Infusion-Related Reactions in Chinase Patients with Early Alzheimer's Disease: A Multicenter Retrospective Study
Presenter: Yuchen Qiao

Yuchen QIAO [1] , Hong CHEN [1], Kaiting FAN [1], Zhen WANG [2], Zhengluan LIAO [3], Mengli YANG [4], Ying GU [5], Jiehao ZHAO [6], Jin WANG [7], Lijun CHI [8], Xian LIU [9], Pingqiao YUAN [10], Hairong QIAN [11], Ai SUN [12], Kunmu ZHENG [13]
[1] Xuanwu Hospital Capital Medical University, Beijing, China, [2] The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, [3] Zhejiang Provincial People's Hospital, Hangzhou, China, [4] Henan Provincial People's Hospital, Zhengzhou, China, [5] The First Hospital of China Medical University, Shenyang, China, [6] Guangdong Provincial People's Hospital, Guangzhou, China, [7] The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China, [8] The First Affiliated Hospital of Harbin Medical University, Harbin, China, [9] Tianjin Medical University General Hospital, Tianjin, China, [10] The Affiliated Hospital of Guizhou Medical University, Guiyang, China, [11] The Third Medical Center, PLA General Hospital, Beijing, China, [12] The First Hospital of Hebei Medical University, Shijiazhuang, China, [13] The First Affiliated Hospital of Xiamen University, Xiamen, China

P114 Clinical Trials with Laughter Interventions for Alzheimer's Disease and Related Disorders (ADRD) and At-Risk Populations
Presenter: Tara Rose

Tara ROSE
Department of Neurology, Keck School of Medicine of USC, University of Southern California, Los Angeles, United States

P115 Efficacy, Safety and Plasma Biomarkers of Lecanemab Treatment in China: A Multicenter Real-World Study
Presenter: Wang Liao

Wang LIAO [1] , Qun YU [1], Bin CHEN [1], Hualin CHEN [1], Xiaoya GAO [2], Yang LI [3], Ying YANG [4], Ziyu SHE [5], Qinggan ZENG [6], Guihua LI [7], Shujun FENG [8], Han LIN [9], Jipeng OUYANG [10], Zhou LIU [11], Jun LIU [1]
[1] Department of Neurology, the Second Affiliated Hospital of Guangzhou Medical University, Institute of Neuroscience, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China,, Guangzhou, China, [2] Department of Neurology?Department of Pediatric Neurology, Zhujiang Hospital of Southern Medical University, Guangzhou Guangdong, China, Guangzhou, China, [3] Department of Neurology, Department of Pediatric Neurology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China., Guangzhou, China, [4] Department of Neurology, The First Affiliated Hospital, Jinan University Guangzhou Guangdong China, Guangzhou, China, [5] Department of Neurology, the First Affiliated Hospital of Jinan University Medical College?Guangzhou? Guangdong, China., Guangzhou, China, [6] Department of Neurology, Zhongshan People's Hospital, Guangdong, China., Zhongshan, China, [7] Department of Neurology, Heyou Hospital,Shunde District, Foshan City, Guangdong, China., Foshan, China, [8] Department of Neurology, Guangdong Provincial People's Hospital, Guangzhou Guangdong,China, Guangzhou, China, [9] Department of Neurology, Houjie Hospital of Dongguan,Dongguan Guangdong,China, Guangzhou, China, [10] Shunde Hospital, Southern Medical University The First People's Hospital of Shunde, Foshan Foshan Guangdong China, Foshan, China, [11] The Affiliated Hospital of Guangdong Medical University Zhanjiang Guangdong China, Zhanjiang, China

P116 Transcranial Direct Current Stimulation–Augmented Cognitive Training in Mild Cognitive Impairment and Alzheimer's Disease: Protocol Design and Preliminary Findings
Presenter: Choe Young Min

Lee MIN JI [1], Choi HYE JI [1], Kim JEE WOOK [1, 2], Choe YOUNG MIN [1, 2]
[1] Department of Neuropsychiatry, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Republic of Korea, [2] Department of Psychiatry, Hallym University College of Medicine, Chuncheon, Republic of Korea

P117 Region-Specific Effects of 40Hz Transcranial Current Stimulation (tACS) on EEG Activity in Patients with Mild Cognitive Impairment
Presenter: Do Hoon Kim

Do Hoon KIM
Department of Psychiatry, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Gangwon, Republic of Korea

P118   Barriers to Current Anti-Amyloid ? Infusion Therapies for Alzheimer's Disease and Preferences for Future Treatment: A Quantitative Survey
Presenter: Chad Swanson

Abigail SILBER [1], Amod ATHAVALE [1], Matthew O'HARA [1], Preeti S. BAJAJ [2], Chad SWANSON [2]
[1] *Trinity Life Sciences, Waltham, Ma, United States,* [2] *Prothena Biosciences, Inc, Brisbane, Ca, United States*

P119   Design and Rationale for a Study to Evaluate Blood and Imaging Biomarkers of Personalized Neuromodulation Therapy of the Default Mode Network in patients with Alzheimer's Disease
Presenter: Lisa Fosdick

Lisa FOSDICK [1] , Giacomo KOCH [2, 3]
[1] *Sinaptica Therapeutics, Cambridge, United States,* [2] *Santa Lucia Foundation IRCCS, Rome, Italie,* [3] *University of Ferrara, Ferrara, Italie*

P120   Evaluation of an ultra-high-frequency visual stimulation intervention on mild cognitive impairment and Alzheimer's Disease
Presenter: Julian Keil

Julian KEIL [1, 2, 3] , Maria BUTHUT [1], Ravit HADAR [3], Jana FASS [4], Liam DOHERTY [3], Jakob LITSCH [3], Nikolett GAJDA [3], Victor HERNANDEZ-URBINA [3], Fabian QUEISNER [3], Markus MÜSCHENICH [3], Surjo SOEKADAR [1]
[1] *Clinical Neurotechnology Lab, Department of Psychiatry and Neurosciences, Charité Campus Mitte CCM, Charité – Universitätsmedizin Berlin, Berlin, Germany,* [2] *Potsdam Embodied Cognition Group, Department of Cognitive Science, University of Potsdam, Potsdam, Germany,* [3] *Nuuron GmbH, Berlin, Germany,* [4] *Medical School Berlin, Berlin, Germany*

P121   Phase 1, Multiple Ascending Dose Study of a Novel Orally Administered Mitochondria-Directed Drug Candidate (SUL-238) in Healthy Volunteers
Presenter: Nadir Ulu

Nadir ULU [1] , Daniël H SWART [2, 3], Zafer SEZER [4, 5], Ahmet INAL [4, 5], Mustafa M MAZICIOGLU [6], Sedat ALTUG [7], Serhat KOZLU [1], Adrianus C VAN DER GRAAF [3], Robert H HENNING [2], Guido KRENNING [2, 3], Murat EMRE [8]
[1] *Gen ?laç ve Sa?l?k Ürünleri A.?., Ankara, Türkiye,* [2] *Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands,* [3] *Sulfateq B.V., Groningen, Netherlands,* [4] *Department of Pharmacology, Faculty of Medicine, Erciyes University, Kayseri, Türkiye,* [5] *Hakan Cetinsaya Good Clinical Practice and Research Centre IKUM, Kayseri, Türkiye,* [6] *Department of Family Medicine, Faculty of Medicine, Erciyes University, Kayseri, Türkiye,* [7] *Department of Pharmacology, Faculty of Medicine, Demiroglu Bilim University, Istanbul, Türkiye,* [8] *Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye*

P122   A First-in-Human, Single Dose-Escalation Study of CM383, a Novel Anti- Amyloid Beta antibody, in healthy volunteers
Presenter: Qing Wen

Kun HE [1], Cuigang LI [1], Yaoqi HAN [1], Yanshuang LI [1], Ning LI [1], Libo ZHANG [2], Zhichuan LI [2], Jingyue MA [2], Bo CHEN [2], Qing WEN [1]
[1] *Jinan Central Hospital, Jinan, China,* [2] *Keymed Biosciences Chengdu Co., Ltd - Chengdu China, Chengdu, China*

P123   Masupirdine (A Pure 5-HT6 Receptor Antagonist): Update on the Phase-3 Clinical Study Targeting Agitation in Patients with Dementia of Alzheimer's Type
Presenter: Pradeep Jayarajan

Pradeep JAYARAJAN, Satish JETTA, Vinod Kumar GOYAL, Vijay BENADE, Anil SHINDE, Santosh Kumar PANDEY, Ramkumar SUBRAMANIAN, Abdul Rasheed MOHAMMED, Ramakrishna NIROGI, Jasti VENKAT
Suven Life Sciences Ltd, Hyderabad, Inde

04 ● BEYOND AMYLOID AND TAU
MONDAY, DECEMBER 1 (3:00 P.M.) – TUESDAY, DECEMBER 2 (5:30 P.M.)

P124 Modeling Brain Homeostasis Failure in Alzheimer's: A Digital Twin Platform for Target Discovery, Biomarkers, and Trial Design
Presenter: Cory Funk

Cory FUNK [1], Tom PATERSON [1], Allan LEVEY [2], Laura Beth MCINTIRE [3], Rima KADDURAH-DAOUK [4], Hohman TIMOTHY [5], Mapstone MARK [6], Meikle PETER [7], Hood LEE [8]
[1] Fulcrum Neuroscience, Palo Alto, United States, [2] Emory University, Emory, United States, [3] Cornell University, Ithaca, United States, [4] Duke University, Durham, United States, [5] Vanderbilt University, Nashville, United States, [6] UC Irvine, Irvine, United States, [7] Baker Institute, Melbourne, Australia, [8] Phenome Health, Seattle, United States

P125 Alzheimer's and Lewy Body Co-Pathology: Interactive Effects on Clinical Trajectories in Preclinical Disease
Presenter: Niklas Mattsson-Carlgren

Niklas MATTSSON-CARLGREN [1], Philip INSEL [2]
[1] Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden, [2] Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, United States

P126 The DNA Damage Repair Pathway as a Potential Route for Alzheimer's Disease Treatment
Presenter: David Lynch

David LYNCH [1, 2], Madison SAMPLES [1, 2], Abbigael ADAY [1, 2], Rakez KAYED [1, 2], Mauro MONTALBANO [1, 2]
[1] Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, United States, [2] Department of Neurology and Neurobiology, University of Texas Medical Branch

P127 Bone and senescence biomarkers assessed in the plasma of MCI and AD patients from the ROSMAP cohort
Presenter: Vidyani Suryadevara

Valerie HUANG [1], Siddharth KAIPA [1], Mounica BANDELA [2], Sai Rama Krishna MEKA [3], Patricia Moran LOSADA [1], Shinya TASAKI [3], Yan LI [3], Tony Wyss CORAY [1], David BENNETT [3], Vidyani SURYADEVARA [1]
[1] Stanford University, Los Altos, United States, [2] University of Illinois at Chicago, Chicago, United States, [3] Rush University Medical Center, Chicago, United States

P128 Development of Potent, Selective cPLA2 Inhibitors for Targeting Neuroinflammation in Alzheimer's Disease
Presenter: Amy Wang

Amy WANG [1], Anastasiia SADYBEKOV [2], Marlon DURO [2], Xiaohui YU [2], Stan LOUIE [2], Shaowei WANG [2], Vsevolod KATRITCH [2], Hussein YASSINE [2]
[1] PebRx, Los Angeles, United States, [2] USC, Los Angeles, United States

P129 Misfolding of alpha-synuclein as a blood based fluid biomarker for Parkinson's disease
Presenter: Klaus Gerwert

Klaus GERWERT
Centre for Protein Diagnostics/Ruhr University Bochum, Bochum, Germany

P130 Microbiome–Brain Volume Associations in Cognitively Unimpaired Adults in a Cohort Enriched for Alzheimer's Disease Risk
Presenter: Muhaison Ibrahim

Muhaison IBRAHIM [1], Jea Woo KANG [2], Margo HESTON [3, 4], Gilda ENNIS [1], Sandra HARDING [1], Sterling JOHNSON [1, 4, 5], Sanjay ASTHANA [1, 4, 5], Federico REY [6], Barbara BENDLIN [1, 4, 5]
[1] University of Wisconsin School of Medicine and Public Health, Madison, United States, [2] Wisconsin Alzheimer's Disease Research Center, Madison, United States, [3] Wisconsin Alzheimer's Disease Center, Madison, United States, [4] Division of Geriatrics, University of Wisconsin, Madison, United States, [5] Wisconsin Alzheimer's Institute, Madison, United States, [6] Department of Bacteriology, University of Wisconsin-, Madison, United States

P131 Comparing the Effects of Disclosure of Multiple Risk Factors for Alzheimer's Disease on Mood and Distress Levels in Cognitively Healthy Individuals
Presenter: Marycia Malloy

Marycia MALLOY [1], Athene LEE, PHD [2], Hannah JOYCE, SCB [3], Philip CAFFERY, PHD [1], Louisa THOMPSON, PHD [4], Alyssa DE VITO, PHD [5], Melanie FAUST, MS, FNP-C [1], Lyndsay DEMATTEO, MSG, MSN, AGPCNP-C [1], Andrea DOLAHER, MSN, AGPCNP-C [1], Brittany DAWSON, MS, FNP-BC [1], Meghan RIDDLE, MD [6], Edward HUEY, MD [6], Preeti SUNDERARAMAN [7], [7]
[1] Memory and Aging Program, Butler Hospital, Providence, United States, [2] Memory and Aging Program, Providence, United States, [3] University of Georgia, Athens, United States, [4] Alpert Medical School at Brown University, Providence, United States, [5] Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, United States, [6] Memory and Aging Program at Butler Hospital, Department of Psychiatry Warren Alpert School of Medicine, Providence, United States, [7] Butler Hospital and Alpert Medical School of Brown University, Providence, United States

P132 Efficacy and Safety of Levetiracetam to Prevent Seizures in Down Syndrome Alzheimer's Disease: The Phase III LESS-AD Trial
Presenter: Isabel Barroeta

Isabel BARROETA [1], Diego REAL DE ASÚA [2], Lucía MAURE-BLESA[1] [1], Beatriz SÁNCHEZ MORENO [2], Gina PAOLA MEJÍA [3], Miren ALTUNA [4], Joaquín ESCOBAR [5], Eloy RODRÍGUEZ [6], Juan FORTEA [1], María CARMONA-IRAGUI [1]
[1] 1. Sant Pau Memory Unit, IR SANT PAU, Hospital de la Santa Creu i Sant Pau, Barcelona, [08025], Spain, Barcelona, Spain, [2] 2. Internal Medicine Department, Adult Down Syndrome Unit, Hospital Universitario de La Princesa, Madrid, Spain, Madrid, Spain, [3] 3. Clinical Pharmacology Department, Hospital Universitario de La Princesa, Madrid, Spain, Madrid, Spain, [4] 4. Fundación CITA-Alzheimer Fundazioa, Donostia, Spain, Donostia, Spain, [5] 5. Neurology Department, Hospital Universitario Virgen de las Nieves, Granada, Spain, Granada, Spain, [6] 6. Neurology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain

P134 Early microglial activation and astrocytosis in preclinical Alzheimer's disease
Presenter: Marta Fernández-Matarrubia

Marta FERNÁNDEZ-MATARRUBIA [1], Andrea VALERA-BARRERO [2], Mónica RENUNCIO-GARCÍA [3], Marcos AGUILELLA [4], Carmen LAGE [1], Gonzalo OCEJO-VIÑALS [3], Sara LÓPEZ-GARCÍA [1], Francisco MARTÍNEZ-DUBARBIE [1], Ana POZUETA-CANTUDO [4], María GARCÍA-MARTÍNEZ [4], María BRAVO [4], Andrea CORRALES-PARDO [4], Juan IRURE-VENTURA [3], Pascual SÁNCHEZ-JUAN [5], Eloy RODRÍGUEZ-RODRÍGUEZ [6]
[1] Neurology Service, Marqués de Valdecilla University Hospital, Santander, Spain. Institute for Research Marqués de Valdecilla IDIVAL, Santander, Spain. CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, Institute of Health Carlos III, Madrid, Spain., Santander, Spain, [2] Neurology Service, Marqués de Valdecilla University Hospital, Santander, Spain., Santander, Spain, [3] Institute for Research Marqués de Valdecilla IDIVAL, Santander, Cantabria, Spain. Immunology Department, Marqués de Valdecilla University Hospital, Santander, Spain., Santander, Spain, [4] Neurology Service, Marqués de Valdecilla University Hospital, Santander, Spain. Institute for Research Marqués de Valdecilla IDIVAL, Santander, Spain., Santander, Spain, [5] Institute for Research Marqués de Valdecilla IDIVAL, Santander, Cantabria, Spain. Alzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII, Madrid, Spain., Madrid, Spain, [6] Neurology Service, Marqués de Valdecilla University Hospital, Santander, Spain. Institute for Research Marqués de Valdecilla IDIVAL, Santander, Cantabria, Spain. Medicine and Psychiatry Department, University of Cantabria, Santander, Spain, Santander, Spain

P135 Relationships between near end-of-life plasma biomarkers and postmortem cerebral and vascular amyloid, tau, TDP-43, and alpha-synuclein measurements
Presenter: Alpana Singh

Alpana SINGH [1], Marisa DENKINGER [1], Kewei CHEN [2], Kari DIECKHOFF [1], James LIU [1], Taina MARQUES [1], Geidy E. SERRANO [1], Thomas G. BEACH [1], Antoine LEUZY [1], Alireza ATRI [1], Eric M. REIMAN [2], Nicholas J. ASHTON [2, 1]
[1] Banner Health, Sun City, United States, [2] Banner Alzheimer's Institute, Phoenix, United States

P136 Fanning the flames: Did COVID-19 accelerate progression of Alzheimer's disease in the ADNI cohort?
Presenter: Patricia Andrews

Patricia ANDREWS, Ke XU, Kiara BAKER, Kathleen MATHER, Brian BOYD, Hakmook KANG, Warren TAYLOR, Paul NEWBOUSE
Vanderbilt University Medical Center, Nashville, United States

P137 Degenerative Pathologies on Cortical Biopsy, Dopaminergic Depletion, and Shunt Efficacy in iNPH
Presenter: Byoung Seok Ye

Minsun CHOI [1, 2], Su-Hee JEON [1], Sohyeon LEE [1], Yeoju KIM [1], Byoung Seok YE [1, 2]
[1] Yonsei University College of Medicine, Seoul, Republic of Korea, [2] Metabolism-Dementia Research Institute, Seoul, Republic of Korea

P138 Perceptions of and Engagement in Brain Health Activities Among Middle-Aged and Older Adults: Associations with Level of Concern, Family History of Dementia, Subjective Memory Loss, and Demographics
Presenter: Raymond L Ownby

Raymond L OWNBY [1], Gesulla CAVANAUGH [1], Shannon WEATHERLEY [1], Shazia AKHTARULLAH [1], Joshua CABALLERO [2]
[1] Nova Southeastern University, Fort Lauderdale, United States, [2] University of Georgia, Athens, United States

05 ● ARTIFICIAL INTELLIGENCE IN AD CLINICAL TRIALS

MONDAY, DECEMBER 1 (3:00 P.M.) – TUESDAY, DECEMBER 2 (5:30 P.M.)

P140 Facilitating Patient Eligibility Matching for Recruitment with a RAG-LLM Framework
Presenter: Nansu Zong

Xiaodi LI [1], Yang XIAO [2], Munhwan LEE [1], Maria VASSILAKI [1], Nansu ZONG [1]
[1] Mayo Clinic, Rochester, United States, [2] University of Tulsa, Tulsa, United States

P141 AI-Based Hyperspectral Retinal Imaging for Alzheimer's Disease Detection: Preliminary Insights from the Bio-Hermes-002 Study
Presenter: Sophie Grapentine

Sophie GRAPENTINE, Tommaso ALTERINI, Justin DIGREGORIO, Tannis KEMP, Bar MAYO, Anthony RINALDI, Joshua WEEKS, Ryan VISEE, Mailis BIETENHADER, Rozana NAUREEN, Westreich JARED, Alon HAZAN
RetiSpec, Toronto, Canada

P142 Efficient Clinical Development and Research via an AI-Ready Multimodal Data Platform
Presenter: Janis Reinelt

Manuel KIENAST [1], Aroma DABAS [1], Eoin MOLLOY [1], Elisa PIEHLER [1], Matteo UGOLINI [1], Sarah KEPPNER-WITTER [2], Mia TICHY [2], Emanuela VILLIGER [2], Fabian BULLER [2], Christoph HOCK [2], Roger M. NITSCH [2], Augusta MODESTINO [1], Janis REINELT [1], Konstantin THIERBACH [1]
[1] AICURA medical GmbH, Berlin, Germany, [2] Neurimmune AG, Schlieren, Switzerland

P143 Expanding Patient Coverage in Alzheimer's Disease Studies through Robust Multimodal Data Integration
Presenter: Sungjoon Park

Juhyun LEE [1, 2], Sungjoon PARK [1], Kyungwook LEE [1], Soorin YIM [1], Doyeong HWANG [1], Kiwoong YOO [1], Soonyoung LEE [1], Kiyoung KIM [1]
[1] LG AI Research, Seoul, Republic of Korea, [2] University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

P144 Bridging the Biomarker–AI Divide: Redesigning Trials and Incentives for Disease-Modifying Success in Alzheimer's Disease
Presenter: Ara Khachaturian

Ara KHACHATURIAN [1], Ornit CHIBA-FALEK [2], Paulo PINHO [3], Larry ALPHS [4]
[1] PAD 20/20, Potomac, United States, [2] Duke University, Durham, United States, [3] PAD 20/20, Newark, United States, [4] Alphs Solutions, Princeton, United States

P145 Practical Implementation of a MaChina Learning Model in Alzheimer's Disease trials following the recent FDA's Guidance on the use of AI to support regulatory decision making
Presenter: Ole Graff

Ole GRAFF [1], Deli WANG [1], Hana FLORIAN [1], Yujie ZHAO [1], Shau Yu LYNCH [1], Weining Z ROBIESON [1], Coco KUSIAK [2], Alyssa VANDERBEEK [2], Jonathan R WALSH [2], Run ZHUANG [2]
[1] AbbVie, North Chicago, United States, [2] Unlearn, San Francisco, United States

P146 Brain health data pilot: a national dataset of routine brain imaging for artificial intelligence and epidemiology
Presenter: William Whiteley

Brenda BAUER [1], Maria VALDES HERNANDEZ [1], Jackie CALDWELL [2], Robert WALLACE [2], Andrew BROOKS [1], Ruairidh MACLEOD [1], Kara MORAW [1], Michael CAMILLERI [1], Dorian GOUZOU [1], Eoghan FORDE [3], Matthew CLEMENT [4], Neil POSTLETHWAITE [3], William WHITELEY [1]
[1] The University of Edinburgh, Edinburgh, United Kingdom, [2] Public Health Scotland, Edinburgh, United Kingdom, [3] Health Data Research UK, London, United Kingdom, [4] Alzheimer's Disease Data Initiative, Seattle, United States

P147 The SANDBOX Study: An NHS-Embedded Multimodal Platform for AI-Enabled Dementia Diagnostics
Presenter: Hayley Holt

Hayley HOLT [1], Javkhlan-Ochir GANBAT [1], Gubbins SAMUEL [1], O'connor SORCHA [1], Madan HANNAH [1], Wan JONATHAN [1], Solanki RAVI [2], Koychev IVAN [3]
[1] Prima Mente, London, United Kingdom, [2] Prima Mente, San Francisco, United States, [3] Imperial College London, London, United Kingdom

P148 Comparison between auditory, textual, and late-fusion Transformer models for the discrimination of prodromal Alzheimer's disease based on spontaneous speech
Presenter: Rik Vandenberghe

Bastiaan TAMM [1], Helena BALABIN [1], Laure SPRUYT [1], Kevin STATZ [1], Hugo VAN HAMME [2], Rik VANDENBERGHE [3]
[1] Laboratory for Cognitive Neurology KU Leuven, Leuven, Belgium, [2] Department of Electrical Engineering, Leuven, Belgium, [3] Neurology Service UZ Leuven, Leuven, Belgium

P149 AI+MRI imaging biomarker for clinical characterization of Alzheimer's disease biological heterogeneity
Presenter: Tae Youn Kwon

Tae Youn KWON, Yeong-Hun JEON, Yeong-Hun SONG, Wha Jin LEE, Joon-Kyung SEONG, Jeong-Yeon SONG
Neuroxt, Seoul, Republic of Korea

P150 Simulating cognitive decline using generative AI model
Presenter: Youn Kwon Tae

Yeong-Hun SONG [1, 2], Youn Kwon TAE [1, 2], Wha Jin LEE [2], Joon-Kyung SEONG [1, 3, 2]
[1] Department of Artificial Intelligence, College of Informatics, Korea University, Seoul, Republic of Korea, [2] NeuroXT, Seoul, Republic of Korea, [3] School of Biomedical Engineering, College of Health Science, Korea University, Seoul, Republic of Korea

P151 Post hoc data-driven subgroup analysis of the A4 Study: spatiotemporal atrophy predicts differential treatment response to solanezumab
Presenter: Neil Oxtoby

Cameron SHAND [1, 2, 3], An ZHAO [1, 2], Pawel MARKIEWICZ [1, 4], Gonzalo CASTRO LEAL [1, 2], David CASH [1, 5], Daniel ALEXANDER [1, 2], Michael DONOHUE [6], Frederik BARKHOF [1, 7, 8], Neil OXTOBY [1, 2]
[1] UCL Hawkes Institute, University College London, London, United Kingdom, [2] Department of Computer Science, University College London, London, United Kingdom, [3] Crick Institute, London, United Kingdom, [4] Department of Medical Physics and Biomedical Engineering, University College London, London, United Kingdom, [5] Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom, [6] Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, United States, [7] UCL Queen Square Institute Of Neurology, University College London, London, United Kingdom, [8] Amsterdam University Medical Center, Amsterdam, Netherlands

P152 Speech Biomarker for Cognition and Correlation with Clinical Outcome Measures Over Time in Preclinical Alzheimer's Disease
Presenter: Alexandra König

Alexandra KÖNIG [1], Elisa MALLICK [1], Johannes TRÖGER [1], Oriol GRAU-RIVERA [2], Andreea RADOI [2], Claudia PORTA-MAS [2]
[1] ki:elements, Saarbrücken, Germany, [2] Barcelona?eta Brain Research Center BBRC, Pasqual Maragall Foundation, Barcelona, Spain

P153 Development of a Community-Based Predictive Model for Mild Cognitive Impairment Using Digital Clock Drawing and Complex Figure Tests
Presenter: Ruochen Li

Xiaonan ZHANG [1], Ruochen LI [2], Yang LI [1], [1]
[1] First Hospital of Shanxi Medical University, Taiyuan, China, [2] University of California, Davis, United States

P154 Toward In Silico Clinical Trial Emulation for Alzheimer's Disease: The Therapeutic Simulation Agent (TSA)
Presenter: Binita Rajbanshi

Binita RAJBANSHI [1], Khalid IQBAL [2], Anuj GURUACHARYA [1]
[1] Nanil Therapeutics Inc., Calgary, Canada, [2] New York State Institute for Basic Research, Staten Island, United States,

P155 Brain-Age Prediction in One Minute from Structural MRI Using Artificial Intelligence: Toward a Scalable Biomarker
Presenter: Hyun Woo Kim

Hyun Woo KIM, Kyu Bin JEON, Sun Young HWANG, Hyun Woong ROH, Chang Hyung HONG, Sunhwa HONG, Sang Joon SON
Ajou Medical Center, Suwon-Si, Republic of Korea

P156 Regulatory Considerations on Utilizing Prognostic Models for Sample Size Reduction in Alzheimer's Disease Clinical Trials
Presenter: Elena Ryapolova-Webb

Elena RYAPOLOVA-WEBB, Cary MURRAY, Run ZHUANG, Aaron SMITH, Jonathan WALSH
Unlearn.AI, San Francisco, United States

P157 MaChina Learning-Based Differentiation of Amnestic and Non-Amnestic Mild Cognitive Impairment Using Multimodal Physiological and Neuroimaging Biomarkers
Presenter: Yeo Jin Kim

Ingyu PARK [1], Sang-Kyu LEE [2], Hui-Chul CHOI [2], Moo-Eob AHN [2], Ohk-Hyun RYU [2], Yong Soon PARK [2], Dong-Kyu KIM [3], Unjoo LEE [1], Yeo Jin KIM [4]
[1] Hallym University, Chuncheon, Republic of Korea, [2] Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon, Republic of Korea, [3] OneSleep Clinic, Seoul, Republic of Korea, [4] Kangdong Sacred Heart Hospital, Seoul, Republic of Korea

P158 Assessing variability in brain segmentation across multiple recent automated methods
Presenter: Luc Bracoud

Cheng C.J. CHU [1], Chen C.J. CHU [2], Thomas CAJGFINGER [1], Joël SCHAËRER [3], Po-Han CHEN [4], Janos SZALMA [5], Chris CONKLIN [6], Madhura INGALHALIKAR [6], David SCOTT [6], Alessandro DELMONTE [1], Luc BRACOUD [1]
[1] Clario, Lyon, France, [2] Wistron ITS, Taipei, Taïwan, République de China, [3] Clario, Geneva, Switzerland, [4] Clario, Estenfeld, Germany, [5] Clario, Budapest, Hongrie, [6] Clario, Philadelphia, United States

P159 Improving FreeSurfer robustness by integrating automated failure detection using Artificial Intelligence for consistent quantitative biomarker extraction
Presenter: Luc Bracoud

Thomas CAJGFINGER [1], Alessandro DELMONTE [1], Joël SCHAËRER [2], Po-Han CHEN [3], Joonmi OH [4], Qui CAO [4], Madhura INGALHALIKAR [4], Chris CONKLIN [4], David SCOTT [4], Luc BRACOUD [1]
[1] Clario, Lyon, France, [2] Clario, Geneva, Switzerland, [3] Clario, Estenfeld, Germany, [4] Clario, Philadelphia, United States

P160 Large Language Models for Clinical Dementia Rating Severity Assessment: Domain-Specific Performance Analysis
Presenter: Hahyun Lee

Hahyun LEE [1, 2] , Da Young OH [1, 3], Jun-Young LEE [1, 2, 3]
[1] Department of Psychiatry, Seoul Metropolitan Government-Seoul National University College Boramae Medical Center,, Seoul, Republic of Korea, [2] Interdisciplinary Program in Cognitive Science, Seoul National University, , Seoul, Republic of Korea, [3] Department of Biomedical Sciences, Seoul National University, Seoul, Republic of Korea

P161 Tracking Cognitive Change over Time Using a Remote Telephone-Based AI-Driven Digital Cognitive Assessment
Presenter: Alexandra König

Elisa MALLICK [1], Johannes TRÖGER [1], Stefanie KÖHLER [2], Alexandra KÖNIG [3] , Anika WUESTEFELD [4], Erik STOMRUD [4], Pontus TIDEMAN [4], Oskar HANSSON [4], Sebastian PALMQVIST [4], Stefan TEIPEL [2], Nicklas LINZ [1]
[1] ki elements GmbH - Saarbrücken Germany, Saarbrücken, Germany, [2] German Center for Neurodegenerative Diseases DZNE, Rostock, Germany, Rostock, Germany, [3] ki elements GmbH, Saarbrücken, Germany, [4] Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden, Lund, Sweden

06 ● CLINICAL TRIALS: IMAGING
WEDNESDAY, DECEMBER 3 (7:15 A.M. – 5:30 P.M.)

P162 Cerebral blood flow ratio of the default mode network to the central executive network as a predictor of executive function following N-acetylcysteine supplementation in vascular mild cognitive impairment participants from the MOVE-IT trial
Presenter: Melissa Wong

Melissa WONG [1, 2], Guocheng JIANG [1, 3], Bradley J. MACINTOSH [1, 3], Sandra E. BLACK [1, 4, 5, 6], Damien GALLAGHER [1, 7], Fuqiang GAO [1, 5, 6], Joel RAMIREZ [1, 3, 4, 5], Nathan HERRMANN [1, 7], Yejin KANG [1, 2], Ethan MAH [1, 2], Jennifer S. RABIN [1], Krista L. LANCTÔT [1, 2, 7], Move-It INVESTIGATORS [8]

[1] Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada, [2] Department of Pharmacology & Toxicology, University of Toronto, Toronto, Canada, [3] Department of Medical Biophysics, University of Toronto, Toronto, Canada, [4] Graduate Department of Psychological Clinical Science, University of Toronto Scarborough, Scarborough, Canada, [5] Dr. Sandra Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Sunnybrook Hospital, Toronto, Canada, [6] Neurology Division, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada, [7] Department of Psychiatry, University of Toronto, Toronto, Canada, [8] MOVE-IT Investigators, Toronto, Canada

P163 Automated Neurodegeneration Index to Enhance Alzheimer's Disease Trials
Presenter: David Vaillancourt

David VAILLANCOURT, Jesse DESIMONE, Angelos BARMPOUTIS, Robin CHEN, Freydell ESPINOZA URBINA, Wei-En WANG
University of Florida, Gainesville, United States

P166 Biodistribution of radiolabeled MAPT antisense oligonucleotide BIIB080 following intrathecal administration in healthy adults
Presenter: Jessica Collins

Jessica COLLINS [1], Brendon COOK [1], Jonathan DUBIOS [1], Lori JONES [1], Osama RASLAN [2], Phu HUYNH [2], Amanda EDWARDS [1], Melanie SHULMAN [1], Danielle GRAHAM [1], R. Matthew HUTCHISON [1], Simon CHERRY [2], Sen FATMA [2]
[1] Biogen, Cambridge, United States, [2] Department of Radiology, University of California Davis, Davis, United States

P167 Monitoring and predicting amyloid therapy response using arterial spin labelling perfusion MRI
Presenter: Thomas Kirk

Thomas KIRK [1], Gloria CHIANG [2], Logan ZHANG [1], Anna NORDVIG [2], Michael CHAPPELL [1, 3]
[1] Quantified Imaging, London, United Kingdom, [2] Weill Cornell Medicine, New York, United States, [3] University of Nottingham, Nottingham, United Kingdom

P171 Discordance Between Visual and Quantitative Amyloid PET in Nearly 500 Real-World Clinical Cases
Presenter: Maria Ponisio

Maria PONISIO, Anna HOFMANN, Suzanne SCHINDLE, Ines OH, Joy SNIDER, Tammie BENZINGER
Washington University, St. Louis, United States

P172 Comparing Tau PET Tracers for Biological Staging in Early Alzheimer's: Implications for Trial Enrichment
Presenter: Marina Scop Medeiros

Marina SCOP MEDEIROS [1, 2], Lucas SCHILLING [2], Emma RUPPERT [1], Pamela FERREIRA [1], Joseph MASDEU [3], David SOLEIMANI-MEIGOONI [4], Juan FORTEA [5], Pedro ROSA-NETO [6], Val LOWE [7], Hwamee OH [8], Belen PASCUAL [3], Brian GORDON [9], Dana TUDORASCU [1], Suzanne BAKER [10], Tharick PASCOAL [1]
[1] University of Pittsburgh, Pittsburgh, United States, [2] Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brésil, [3] Houston Methodist, Houston, United States, [4] University of California San Francisco, San Francisco, United States, [5] Sant Pau, Barcelona, Spain, [6] McGill University, Montreal, Canada, [7] Mayo Clinic, Rochester, United States, [8] Brown University, Providence, United States, [9] Washington University, St Louis, United States, [10] Lawrence Berkeley, Berkeley, United States

P173 Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
Presenter: Robin Wolz

Colm MCGINNITY, Anthony S GABAY, Katherine R GRAY, R MANBER, R JOULES, Robin WOLZ
IXICO, London, United Kingdom

P174 Extending the CenTauR Standardization Framework to the Voxel Level: Preliminary Validation Using [¹?F]flortaucipir and [¹?F]MK-6240
Presenter: Alexis Moscoso

Alexis MOSCOSO [1], Antoine LEUZY [2], Victor L. VILLEMAGNE [3], Alex DEL BENE [4], Brian LOPRESTI [4], Alexandra GOGOLA [4], Gregory KLEIN [5], Hartmuth C KOLB [6], Nadine TATTON [7], Yashmin KARTEN [7], Matteo TONIETTO [5], Emily OLAFSON [8], Ruben SMITH [9], Oskar HANSSON [9], Vincent DORÉ [10]

[1] Critical Path for Alzheimer's Disease CPAD Consortium, Critical Path Institute, Tucson, USA; Nuclear medicine department and Molecular Imaging Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Travesía da Choupana s/n, Santiago de Compostela, Spain, Santiago De Compostela, Spain, [2] Critical Path for Alzheimer's Disease CPAD Consortium, Critical Path Institute, Tucson, USA; Enigma Biomedical Group, Knoxville, USA, Knoxville, United States, [3] Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, USA; Department of Molecular Imaging & Therapy, Austin Health, Victoria, Australia, Pittsburgh, United States, [4] Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, USA, Pittsburgh, United States, [5] F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland, [6] Enigma Biomedical Group, Knoxville, USA, Knoxville, United States, [7] Critical Path for Alzheimer's Disease CPAD Consortium, Critical Path Institute, Tucson, USA, Tucson, United States, [8] Clinical Imaging Group, Genentech, Inc., South San Francisco, USA, San Francisco, United States, [9] Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden; Memory Clinic, Skåne University Hospital, Malmö, Sweden, Lund, Sweden, [10] Department of Molecular Imaging & Therapy, Austin Health, Victoria, Australia; Health and Biosecurity Flagship, The Australian eHealth Research Centre, CSIRO, Victoria, Australia, Lund, Sweden

P175 Evaluating the Effects of Non-Linear SUVR Transformations for Harmonization on Statistical Power in Longitudinal Tau-PET Studies
Presenter: Alexs Moscoso

Alexs MOSCOSO [1, 2], Antoine LEUZY [1, 3], Hartmuth KOLB [3], Victor VILLEMAGNE [4, 5], Gregory KLEIN [6], Brian LOPRESTI [7], Alexandra GOGOLA [7], Diane STEPHENSON [1], Nadine TATTON [1], Yashmin KARTEN [1], Fang XIE [8], Christopher C ROWE [9, 10], Vincent DORÉ [9, 11]

[1] Critical Path for Alzheimer's Disease CPAD Consortium, Critical Path Institute, Tucson, United States, [2] Nuclear Medicine department and Molecular Imaging Group, Instituto de Investigación Sanitaria de Santiago de Compostela, Travesía da Choupana s/n,, Santiago De Compostela,, Spain, [3] Enigma Biomedical Group, Knoxville, United States, [4] Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, United States, [5] Department of Molecular Imaging & Therapy, Austin Health, Victoria, Australia, [6] F. Hoffmann-La Roche Ltd, Basel, Switzerland, [7] Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, United States, [8] Department of Nuclear Medicine & PET Center, Huashan Hospital,University, Shanghai, China, [9] Florey Department of Neuroscience, University of Melbourne, Victoria, Australia, [10] The Australian Dementia Network ADNeT, The University of Melbourne, Victoria, Australia, [11] Health and Biosecurity Flagship, The Australian eHealth Research Centre, CSIRO, Victoria, Australia

P177 Functional Network Segregation as a Neural Correlate of Cognitive Reserve in Alzheimer's Disease Spectrum
Presenter: Na Young Yeo

Na Young YEO [1], Christian G. HABECK [2], Yaakov STERN [2], Jae-Won JANG [3], Yeshin KIM [3]
[1] Kangwon National University, Chuncheon, Republic of Korea, [2] Columbia University, New York, United States, [3] Kangwon National University Hospital, Chuncheon, Republic of Korea

P178 Lower Antemortem [18F]flortaucipir PET retention in Males and Older Individuals is Explained by Lower Postmortem Tau Tangle Density
Presenter: Emma Coomans

Emma COOMANS [1, 2], Ruben SMITH [3, 4], Sebastian PALMQVIST [3, 4], Michael PONTECORVO [5], Sergey SHCHERBININ [5], Vikas KOTARI [5], Thomas BEACH [6], Geidy SERRANO [6], Erik STOMRUD [3, 4], Niklas MATTSSON-CARLGREN [3, 7], Wiesje VAN DER FLIER [1, 2], Yolande PIJNENBURG [1, 2], Elsmarieke VAN DE GIESSEN [8, 9], Oskar HANSSON [3], Rik OSSENKOPPELE [1, 3]

[1] Department of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands, Amsterdam, Netherlands, [2] Amsterdam Neuroscience, Neurodegeneration, Amsterdam, The Netherlands, Amsterdam, Netherlands, [3] Clinical Memory Research Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden, Lund, Sweden, [4] Memory Clinic, Skåne University Hospital, Malmö, Sweden, Lund, Sweden, [5] Eli Lilly and Company, Indianapolis, USA, Indianapolis, United States, [6] Banner Sun Health Research Institute, Sun City, Arizona, USA, Sun City, United States, [7] Department of Neurology, Skåne University Hospital, Lund University, Lund, Sweden, Lund, Sweden, [8] Department of Radiology & Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, The Netherlands, Amsterdam, Netherlands, [9] Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands, Amsterdam, Netherlands

P179 Towards correcting for pseudo atrophy in monoclonal antibody clinical trials on Alzheimer's disease: a model of amyloid-removal related atrophy predicts treatment benefit
Presenter: Neil Oxtoby

Neil OXTOBY [1], Bojidar RANGELOV [1], Michael DONOHUE [2]
[1] UCL Hawkes Institute and Department of Computer Science, University College London, London, United Kingdom, [2] Alzheimer Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego, United States

P180 Recommendations for DTI harmonization in multicenter clinical trials.
Presenter: Madhura Ingalhalikar

Madhura INGALHALIKAR [1], Stefan RADONJIC [1], Luc BRACOUD [2], Chris CONKLIN [1], Meredith BURKE [1], David SCOTT [1], Adni ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE [3]
[1] Clario., Philadelphia, United States, [2] Clario., Lyon, France, [3] ADNI, Adni.loni.usc.edu, United States

P181 Associations of amyloid-beta with entorhinal cortical thickness and episodic memory among a diverse oldest-old cohort: The Life After 90 Study
Presenter: Batool Rizvi

Batool RIZVI [1] , Christina YOUNG [1], Molly LAPOINT [2], Adam BRICKMAN [3], Pauline MAILLARD [1], Charles DECARLI [1], Paola GILSANZ [2], Maria CORRADA [4], Rachel WHITMER [1]
[1] UC Davis, Davis, United States, [2] Kaiser Permanente Northern California Dvision of Research, Pleasanton, United States, [3] Columbia University, New York, United States, [4] UC Irvine, Irvine, United States

P184 Florbetaben binding to amyloid plaques is unaffected by amyloid-targeting antibodies lecanemab and donanemab
Presenter: Marianne Chapleau

Marianne CHAPLEAU [1] , Andre MUELLER [2], Aleksandar JOVALEKIC [2], Julius SEIDEL [2], Maria RITTER [2], Eva BICKEL [2], Nadine KIESSLING [2], Emer MACSWEENEY [3], Andrew STEPHENS [2], Norman KOGLIN [2]
[1] Life Molecular Imaging, San Francisco, United States, [2] Life Molecular Imaging, Berlin, Germany, [3] Re:Cognition Health, London, United Kingdom

P186 Metabolic syndrome risk factors associated with lower cerebral blood flow and MoCA scores in healthy older adults
Presenter: Mason B Pirner

Mason B PIRNER [1] , Swati RANE LEVENDOVSZKY [2], Kristen M FARRIS [1], Jessica E REHMANN [1], Angela J HANSON [1]
[1] University of Washington Medical Center, Seattle, Wa, United States, [2] University of Kansas Medical Center, Kansas City, Ks, United States

P187 Integrating visual assessments and quantification methods for tau PET staging
Presenter: Cho Soo Hyun

Cho SOO HYUN [1] , Gu YUNA [2], Moscoso ALEXIS [3], Schöll MICHAEL [3], Yun JIHWAN [2], Shin DAEUN [2], Lee EUN HYE [2], Kang HEEKYONG [2], Kim JUN PYO [2], Kim HEE JIN [2], Na DUK L. [4], Kang SUNG HOON [5], Jang HYEMIN [6], Cho HANNA [7], Seo SANG WON [2]
[1] Chonnam National University Medical School and Chonnam National University Hospital,, Gwangju, Republic of Korea, [2] Samsung Medical Center, Seoul, Republic of Korea, [3] University of Gothenburg, Gothenburg, Republic of Korea, [4] Happymind Clinic, Seoul, Republic of Korea, [5] Korea University Guro Hospital, Seoul, Republic of Korea, [6] Seoul National University Hospital, Seoul, Republic of Korea, [7] Gangnam Severance Hospital, Seoul, Republic of Korea

P188 Allopregnanolone Increases Hippocampal Volume in Early Alzheimer's Disease: Importance of Segmentation Method and Baseline Atrophy
Presenter: Roberta D. Brinton

Adam C, RAIKES [1], Dawn MATTHEWS [2], Gerson HERNANDEZ [1], Ana S. LUKIC [2], Randolph D. ANDREWS [2], Claudia LOPEZ [1], Lon SCHNEIDER [3], Roberta D. BRINTON [1]
[1] Center for Innovation in Brain Science, University of Arizona, Tucson, United States, [2] ADM Diagnostics, Chicago, United States, [3] Keck School of Medicine, University of Southern California, Los Angeles, United States

P189 Longitudinal Impact of Sarcopenia on Amyloid Deposition, Brain Atrophy, and Cognitive Decline: A Multi-modal Linear Mixed Model Analysis
Presenter: Sunghwan Kim

Sunghwan KIM [1] , Sheng-Min WANG [1], Dong Woo KANG [2], Yoo Hyun UM [3], Su-Hyeong KIM [3], Yoon HAN MIN [1], Hyun Kook LIM [1]
[1] The Catholic University of Korea, Yeouido ST. Mary's Hospital, Seoul, Republic of Korea, [2] The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul, Republic of Korea, [3] The Catholic University of Korea, St. Vincent's Hospital, Suwon, Republic of Korea

P190 Exploring Individual Variation in Tau PET and CDR-SB: A Meta-Analysis of Placebo Arm Data
Presenter: Yashmin Karten

Yashmin KARTEN [1] , Dries DE WITTE [2], Gregory KLEIN [3], Antoine LEUZY [4, 1], Alexis MOSCOSO RIAL [5, 1], Philip INSEL [6], Ariel Alonso ABAD [2, 7], Geert MOLENBERGHS [2, 7], Nadine TATTON [1], Cpad ON BEHALF OF THE CRITICAL PATH FOR ALZHEIMER'S DISEASE CONSORTIUM [1]
[1] Critical Path Institute, Tucson, United States, [2] L-BioStat, KU Leuven, Leuven, Belgium, [3] F. Hoffmann-La Roche Ltd, Basel, Switzerland, [4] Enigma Biomedical Group, Knoxville, United States, [5] Instituto de Investigación Sanitaria de Santiago de Compostela, Travesía da Choupana s/n,, Santiago De Compostela, Spain, [6] University of California, San Francisco, San Francisco, United States, [7] I-BioStat, Hasselt, Belgium

P191 Advancing Clinical Research with PET Imaging: Emerging Radiotracers and Evolving Roles in Alzheimer's Dementia Diagnosis
Presenter: Abby Fuller

Ioan Laurentiu GUTIU [1], Abby FULLER [2] , Tetyana KORCHAK [2]
[1] Fortrea GmbH, Munich, Germany, [2] Fortrea, Durham, United States

P192 The BEYONDD Study: Preliminary Plasma Biomarker Findings within a Community-Based Sample
Presenter: Eden V. Barragan

Eden V. BARRAGAN [1] , Hilary W. HEUER [1], Rachel L. NOSHENY [2, 3], Monica CAMACHO [2, 4], Krista NAVARRA [2, 4], Paul AISEN [5], Omobolanle AYO [6], Julia CULHANE [7], Vanessa GUZMAN [6], Michelle HIGUERA [6], Melissa SOTELO [1], Desiree BYRD [8], Monica RIVERA-MINDT [6, 7, 9], Gil D. RABINOVICI [1], Adam L. BOXER [1]

[1] Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, United States, [2] VA Advanced Imaging Research Center, San Francisco Veteran's Administration Medical Center, San Francisco, United States, [3] Department of Psychiatry, University of California, San Francisco, San Francisco, United States, [4] Northern California Institute for Research and Education NCIRE, San Francisco, United States, [5] Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, United States, [6] Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, United States, [7] Department of Psychology, Fordham University, New York, United States, [8] Department of Psychology, Queens Collegeepartment of Neurology, Icahn School of Medicine at Mount Sinai, Flushing, United States, [9] Departments of Latin American Latino Studies, and African and African American Studies, Fordham University, New York, United States

P193 Impact of plasma collection time of day on plasma p-tau217 measures in Au?onomy and Re?ain trials
Presenter: Stephanie Slania

Stephanie SLANIA [1] , Gallen TRIANA-BALTZER [2], David HENLEY [3], Tricia THORNTON-WELLS [4], Janice WONG [4], Lennert STEUKERS [5], Maggie FEDGCHIN [3], Ziad SAAD [2]

[1] Precision Measures, Neuroscience, Johnson & Johnson, Spring House, United States, [2] Precision Measures, Neuroscience, Johnson & Johnson, San Diego, United States, [3] Clinical Development, Neuroscience, Johnson & Johnson, Titusville, United States, [4] Clinical Development, Neuroscience, Johnson & Johnson, Cambridge, United States, [5] Clinical Development, Neuroscience, Johnson & Johnson, Beerse, Belgium

P194 Automated Plasma Immunoassay for APOE ?4 Zygosity Identification in Alzheimer's Disease Biomarker Research
Presenter: Corey Carlson

Brian ENGEL [1], Scott LEVIN [2, 3], Katharine HOFFMAN [1], Ye Eun BAE [1], Miklos SZABO [1], Corey CARLSON [1] , Mark HOLLAND [1], Kinal BHATT [1], Jeremiah HINSON [2, 3], Dan FIGDORE [4], Hyun Kook LIM [5], Laurent TIERS [6], Sylvain LEHMANN [6], Yoo Hyun UM [5], Alicia ALGECIRAS-SCHIMNICH [4]

[1] Beckman Coulter, Inc., Chaska, Mn, United States, [2] Danaher Diagnostics, Washington, Dc, United States, [3] Johns Hopkins School of Medicine, Baltimore, Md, United States, [4] Mayo Clinic, Rochester, Mn, United States, [5] The Catholic University of Korea, Seoul, Republic of Korea, [6] Montpellier University Hospital of Montpellier, Montpellier, France

P195 Association of Plasma Alzheimer's Disease and Neurodegeneration Biomarkers with Perceived Stress, Neighborhood Disadvantage, and Socioeconomic Status
Presenter: Miriam Ashford

Miriam ASHFORD [1] , Vanessa GUZMAN [2], Adam DIAZ [3, 4], Alyssa ARENTOFT [5], Melanie MILLER [3, 4], Stephen CUBBELLOTTI [2], Duygu TOSUN [4], Laurel BECKETT [6], Jacqueline PONTES MONTEIRO [7], Rachel NOSHENY [1], Susan LANDAU [8], Michael WEINER [3], Monica RIVERA MINDT [9, 2], Okonkwo OZIOMA [9], For The ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE ADNI [3]

[1] University of California San Francisco, Department of Psychiatry and Behavioral Sciences, San Francisco, United States, [2] Icahn School of Medicine at Mount Sinai Department of Neurology, New York, United States, [3] Northern California Institute for Research and Education NCIRE, San Francisco, United States, [4] University of California San Francisco, Radiology and Biomedical Imaging, San Francisco, United States, [5] California State University Northridge Department of Psychology, Northridge, United States, [6] University of California Davis, Department of Public Health Sciences, Davis, United States, [7] Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, United States, [8] University of California Berkeley, Neuroscience Departmen, Berkeley, United States, [9] Fordham University Department of Psychology, New York, United States

P196 Diagnostic Accuracy of Novel Plasma pTau-217 and p-Tau181 Assays for Alzheimer's Disease
Presenter: Jessica Colon-Franco

Jessica COLON-FRANCO, Lynn BEKRIS, Christopher BOYER, Ardeshir HASHIMI, Hiba KHAN, James LEVERENZ, Drew PAYTO, Jagan PILLAI, Jordan STENGEL, Sarah ZILKA, Saket SAXENA
Cleveland Clinic, Cleveland, United States

P197   High diagnostic performance of the random-access HISCL-5000 pTau217, Aβ42 and Aβ40 plasma assays for detecting amyloid pathology across the Alzheimer's disease clinical continuum.
Presenter: Charlotte Teunissen

Inge VERBERK [1], Daniel ANTWI-BERKO [1], Thomas CLAESSEN [2], Hans HEIJST [1], Azzam ALADDIN [1], Yuko SASAKI MORI [3], Roman BOEER [4], Argonde VAN HARTEN [2], Charlotte TEUNISSEN [1]
[1] Neurochemistry Laboratory, Laboratory Medicine, Amsterdam UMC, Amsterdam, Netherlands, [2] Alzheimer Center Amsterdam, Neurology, Amsterdam UMC, Amsterdam, Netherlands, [3] Sysmex R&D Center Europe GmbH, Hamburg, Germany, [4] Neurochemistry Laboratory, Laboratory Medicine, Amsterdam UMC, Hamburg, Germany

P198   Multiomics Blood Biomarkers Combined with Amyloid Status Improve Prediction of Alzheimer's Dementia in Cognitively Unimpaired Individuals
Presenter: Jérôme Braudeau

Benoit SOUCHET [1], Sami SAKLY [1], Maud HEUILLET [2], Aude DUPUY-GAYRAL [2], Eloi HAUDEBOURG [2], Catherine PECH [2], Antoine BERTHEMY [2], François AUTELITANO [2], Baptiste BILLOIR [1], Kimiko DOMOTO-REILLY [3], Christopher FOWLER [4], Thomas GRABOWSKI [3], Suman JAYADEV [3], Colin L. MASTERS [4], Jérôme BRAUDEAU [1]
[1] AgenT, Evry, France, [2] Evotec, Toulouse, France, [3] University of Washington, Seattle, United States, [4] Florey Institute of Neuroscience and Mental Health, Parkville, Australia

P199   VeraBIND Tau: A Novel Plasma Assay Reflecting Tau Aggregation in Alzheimer's Disease Increases Over Time in Individuals with Positive Tau-PET Signal.
Presenter: Josh Soldo

Josh SOLDO [1] , Lisa QUENON [2, 3], Kavya SHAMSUNDAR [1], Winnie PAK [1], Khalid IQBAL [4, 5], Bernard HANSEEUW [2, 3, 6]
[1] Veravas, Inc, Austin, United States, [2] Institute of Neuroscience, UCLouvain, Brussels, Belgium, [3] Department of Neurology, Saint-Luc University Hospital, Brussels, Belgium, [4] SUNY Downstate/NYSIBR Center for Developmental Neuroscience, Brooklyn, United States, [5] New York State Institute for Basic Research in Developmental Disabilities, Brooklyn, United States, [6] Massachusetts General Hospital, Gordon Center for Medical Imaging and the Athinoula A. Martinos Center for Biomedical Imaging, Boston, United States

P200   Changes of Blood Biomarker in Alzheimer's Disease During Lecanemab Treatment: A Real-World Clinical Study
Presenter: Yanjiang Wang

Shan HUANG [1], Yanjiang WANG [1] , Dian HE [2], Rongchang ZHAO [1], Yuhui LIU [1]
[1] Daping Hospital, Third Military Medical University, Chongqing, China, [2] Affiliated Hospital of Guiyang Medical College, Guiyang, China

P202 SpectrisTM Treatment may mitigate the natural progression of resting state EEG in Alzheimer's disease
Presenter: Chandran Seshagiri

Chandran SESHAGIRI [1] , Offir LAUFER [2], Brennan JACKSON [1], Julia RIDDLE [1], Evan HEMPEL [1], Zachary MALCHANO [1], Ralph KERN [1], Gil ISSACHAR [2], Mihaly HAJOS [1, 3]
[1] Cognito Therapeutics, Cambridge, United States, [2] Firefly Neuroscience, Buffalo, United States, [3] Yale University, New Haven, United States

P203   Naturally Occurring IgG Targeting Neurotoxic Aβ42 Oligomers in Healthy Elderly
Presenter: Stefan Pierrou

Anders SANDBERG, Stefan PIERROU
Alzinova AB, Mölndal, Sweden

P204   Plasma GFAP identifies a transitional pathophysiological stage from misfolded protein accumulation to neurodegeneration in Alzheimer's disease
Presenter: Jun Pyo Kim

Jun Pyo KIM [1] , Minyoung CHO [2], Hyunwoo LEE [2], Bo-Hyun KIM [1], Daeun SHIN [1], Sohyun YIM [1], Heekyung KANG [1], Hong-Hee WON [2], Sang Won SEO [1]
[1] Samsung Medical Center, Seoul, Republic of Korea, [2] Samsung Advanced Institute for Health Sciences & Technology, Seoul, Republic of Korea

P205 Association of Neighborhood-Level Disadvantage with Alzheimer's Disease Blood Based Biomarkers
Presenter: Alison Myoraku

Alison MYORAKU [1] , Isabella HAUSLE [1], Marta MILA-ALOMA [1], Pamela THROPP [1], Laura WANG [2], Murali DORAISWAMY [2], Duygu TOSUN [3]
[1] NCIRE, San Francisco, United States, [2] Duke University, Durham, United States, [3] UCSF, San Francisco, United States

P206 Diagnostic Performance of Multi-Analyte Algorithms and %p-tau217 using High Resolution LC-MS/MS in a Mixed Memory Clinic Cohort

Presenter: Kristian Steen Frederiksen

Sara RIAZI [1], Steen Gregers HASSELBALCH [1], Daniel CONNELL [2], Tim WEST [2], Philip VERGHESE [2], Joel BRAUNSTEIN [2], Kristopher KIRMESS [2], Justine COPPINGER [2], Anja Hviid SIMONSEN [1], Kristian Steen FREDERIKSEN [1]
[1] Danish Dementia Research Centre, Copenhagen, Denmark, [2] C2N Diagnostics, St. Louis, Missouri, United States

P207 Clinical evaluation of blood-based assays for rapid detection of Amyloid-? pathology in Alzheimer's disease (CLEAR-AD) —a prospective?double-blinded head-to-head comparison study of blood-based biomarker

Presenter: Jiong Shi

Xinyi LV, Kaiyuan SHEN, Jiong SHI
Department of Neurology, College of Life Science and Medicine? University of Science and Technology of China, Hefei, China

P209 CSF Proteomics Reveals SPECTRIS-Induced Neuritin-1 Upregulation and Modulation of Brain Resilience Pathways

Presenter: Ralph Kern

Ralph KERN [1], Allan LEVEY [2], James LAH [2], Saima RATHORE [3], Annabelle SINGER [4], Nicholas SEYFRIED [5], Duc DUONG [5], Eric DAMMER [5], Mihaly HAJOS [1], Robbert ZUSTERZEEL [1], Lily LEE [1], Monika SHPOKAYTE [1], Zach MALCHANO [1], Julia RIDDLE [1], Chandran SESHAGIRI [1]
[1] Cognito Therapeutics, Cambridge, United States, [2] Emory University School of Medicine, Atlanta, United States, [3] Emtherapro Inc, Atlanta, United States, [4] Georgia Institute of Technology, Atlanta, United States, [5] Emory University Department of Biochemistry, Atlanta, United States

P210 Validation of an Alzheimer's Disease conformation-specific p53 antibody in patient samples

Presenter: Shmuel Agus

Shmuel AGUS [1], David LYNCH [2], Simona PICCIRELA [3], Madisson SAMPLES [2], Michael RASCHE [4], Rakez KAYED [2]
[1] Diadem Inc, Roslindale, United States, [2] UTMB, Galveston, United States, [3] Diandem SpA, Milan, Italie, [4] Diadem SpA, Munich, Germany

P211 Concordance of ApoE proteotype vs genotype assays: a low friction method for obtaining E4 carrier status

Presenter: Gallen Triana-Baltzer

Gallen TRIANA-BALTZER [1], Thierry VERBINNEN [2], Silke MILLER [1], Ziad SAAD [1], Janice WONG [3], David HENLEY [3], Yanina FLOSSBACH [2], Gahan PADINA [3], Stanley BELKOWSKI [3]
[1] Johnson & Johnson, San Diego, United States, [2] Johnson & Johnson, Beerse, Belgium, [3] Johnson & Johnson, Springhouse, United States

P212 Targeted Plasma Proteomic Biomarker Profiling in the FINGER Multimodal Lifestyle Intervention Trial

Presenter: Anna Matton

Anna MATTON [1, 2, 3], Alina SOLOMON [3, 4], Andrea LESSA BENEDET [5], Jenni LEHTISALO [6], Esko LEVÄLAHTI [6], Anna ROSENBERG [7], Makrina DANIILIDOU [8, 2], Francesca MANGIALASCHE [8, 2, 9], Henrik ZETTERBERG [5], Tiia NGANDU [6], Miia KIVIPELTO [8]
[1] Department of Neurobiology, Care Sciences and Society, Karolinska Institutet - Stockholm Sweden, Stockholm, Sweden, [2] FINGERs Brain Health Institute, Stockholm, Sweden, [3] The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, United Kingdom, [4] Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland, [5] Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden, [6] Department of Public Health, Lifestyles and Living Environments, Finnish Institute for Health and Welfare, Helsinki, Finland, [7] Department, Helsinki, Finland, [8] Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden, [9] Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden

P213 Does Amyloid Plaque Reduction Mediate the Clinical Effect of Amyloid-targeting Antibodies?

Presenter: Lon Schneider

Lon SCHNEIDER [1], James LUO [1], Richard KENNEDY [2]
[1] Keck School of Medicine of USC, Los Angeles, United States, [2] University of Alabama Birmingham, Birmingham, United States

P214 Age-related changes in plasma p-tau217 and reference levels in cognitively unimpaired A?-negative individuals

Presenter: Anna Mammel

Anna MAMMEL [1], Ali MOUSAVI [2, 3], Kelsey HALLETT [1], Mary ENCARNACION [2], Donald BIEHL [1], Pradip GILL [1], Fernando GONZALEZ [1, 4], Hans FRYKMAN [1, 2, 3]
[1] Neurocode, Bellingham, United States, [2] BC Neuroimmunology, Vancouver, Canada, [3] University of British Columbia, Vancouver, Canada, [4] University of Gothenburg, Gothenburg, Sweden

P215 A Comparative Analysis of Creatinine- and Cystatin C-based eGFR equations for the Assessment of Chronic Kidney Disease Influence on Plasma p-tau217 Concentrations
Presenter: Joshua Bornhorst

Joshua BORNHORST [1], Stephen WEIGAND [2], Daniel FIGDORE [1], Michael GRISWOLD [3], Carly LUNDGREEN [2], Heather WISTE [2], Prashanthi VEMURI [4], Jonathan GRAFF-RADFORD [5], David KNOPMAN [5], Petrice COGSWELL [4], Clifford JACK JR. [4], Ronald PETERSEN [5], Alicia ALGECIRAS-SCHIMNICH [1]
[1] Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, United States, [2] Department of Quantitative Health Sciences, Mayo Clinic,, Rochester, United States, [3] Center of Biostatistics and Bioinformatics University of Mississippi Medical Center,, Jackson, United States, [4] Department of Radiology, Mayo Clinic,, Rochester, United States, [5] Department of Neurology, Mayo Clinic, Rochester, United States

P216 Research on Biomarkers of Early Alzheimer's Disease in China in the past decade? a scoping review
Presenter: Guoping Peng

Guoping PENG [1], Yan YANG [2], Ying WANG [2], Sagar Anil CHANDEKAR [3], Jintai YU [4]
[1] Department of Neurology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, [2] Novo Nordisk China Pharmaceuticals Co., Ltd., Beijing, China, [3] Novo Nordisk A/S, Søborg, Denmark, [4] Department of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

P217 Clinical Trial Patient Cohort Enrichment Using Cost-Effective Blood-Based Biomarker Screening
Presenter: Noah Elder

Robert LIN [1], Jason WAN [2], Noah ELDER [2], Hien NGUYEN [2], Paul HUNG [2]
[1] Taudia, San Carlos, [2] Taudia, San Carlos, United States

P218 P-tau217 testing impact on patient management in a racially/ethnically diverse population: six-month follow up in a randomized clinical utility study.
Presenter: Rose C Beck

Samantha C BURNHAM [1], Haoyan HU [1], Yifeng TANG [1], Anthony SIRECI [1], Michael J PONTECORVO [1], Paul E SCHULZ [2], Curtis P SCHREIBER [3], Rose C BECK [1]
[1] Eli Lilly & Company, Indianapolis, United States, [2] Neurocognitive Disorders Center, McGovern Medical School of UTHealth, Houston, Texas, United States, [3] Missouri Memory Center, Citizen's Memorial Hospital, Bolivar, Missouri, United States

P219 Novel biomarkers drive a distinct pattern of clinical characterization of two cohorts: a Chinase Aging and Neurodegenerative Disorder Initiative (CANDI) and a Hefei Aging Study Urban Community (HAS)
Presenter: Yong Shen

Yong SHEN
University of Science and Technology of China, Hefei, China

P220 Migrating the use of plasma p-tau217 from research setting to clinical practice: a real-world study in Subjective Cognitive Decline and Mild Cognitive Impairment
Presenter: Giulia Giacomucci

Giulia GIACOMUCCI [1], Chiara CRUCITTI [1], Assunta INGANNATO [1], Silvia BAGNOLI [1], Elisa MARCANTELLI [1], Sonia PADIGLIONI [2], Valentina MOSCHINI [2], Carmen MORINELLI [2], Salvatore MAZZEO [3], Sandro SORBI [4], Benedetta NACMIAS [1], Valentina BESSI [1]
[1] Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italie, [2] Research and Innovation Centre for Dementia-CRIDEM, AOU Careggi, Florence, Italie, [3] Vita-Salute San Raffaele University, Milan, Italie, [4] IRCCS Fondazione Don Carlo Gnocchi, Florence, Italie

P221 Impact of recruitment modality on plasma pTau217 eligibility in clinical trials of Alzheimer's Disease
Presenter: Ralph Lee

Yu-Jay HUOH [1], Ralph LEE [1], Dung TRINH [2]
[1] Irvine Clinical Research, Irvine, United States, [2] Healthy Brain Clinic, Long Beach, United States

P222 Baseline Gut Microbiome Composition Informs About Cognitive Changes in Lifestyle and Diet Interventions in Older Adults: Results from the U.S. POINTER-Microbiome Study
Presenter: Lucas Patel

Lucas PATEL [1, 2, 3], Lora KHATIB [1, 4], Siamak MAHMOUDIANDEHKORDI [5], Christopher R. BRYDGES [5], Leyla SCHIMMEL [5], Colette BLACH [6], Edgar A. DIAZ [5], Alzheimer Gut Microbiome Project - [5], Madison AMBRE [1], Gilian M. WRIGHT [1], Mark A. ESPELAND [7], Laura D. BAKER [7], Rima KADDURAH-DAOUK [5, 8, 9], Rob KNIGHT [1, 10, 11, 12]
[1] Department of Pediatrics, University of California San Diego, La Jolla, United States, [2] Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, United States, [3] Medical Scientist Training Program, University of California San Diego, La Jolla, United States, [4] Neurosciences Graduate Program, University of California San Diego, La Jolla, United States, [5] Department of Psychiatry and Behavioral Sciences, Duke University, Durham, United States, [6] Duke Molecular Physiology Institute, Duke University, Durham, United States, [7] Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, United States, [8] Duke Institute of Brain Sciences, Duke University, Durham, United States, [9] Department of Medicine, Duke University, Durham, United States, [10] Department of Bioengineering, University of California San Diego, La Jolla, United States, [11] Department of Computer Science and Engineering, University of California San Diego, La Jolla, United States, [12] Halicio?lu Data Science Institute, University of California San Diego, La Jolla, United States

P223 Multiple Plasma Biomarker Diagnostic Cascade: Performance of the Beckman Coulter p-Tau217, A?42, and NFL assays in a cohort of individuals with cognitive impairment
Presenter: Andrew Becker

Andrew BECKER [1], Mark HOLLAND [1], Paul WYNVEEN [1], Justin LENGFELD [1], Dusten UNRUH [1], Jeff TODTLEBEN [1], Hyun Kook LIM [2], Yoo Hyun UM [3], Kinal BHATT [3], Narayan VAIBHAV [4], Irene MEIER [4]
[1] Beckman Coulter, Inc., Chaska, Mn, United States, [2] Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, [3] Department of Psychiatry, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, [4] Davos Alzheimer's Collaborative, Wayne, Pa, United States

P224 Comprehensive biomarker assessment of the gamma-secretase modulator nivegacetor in presymptomatic carrier participants of the PSEN1 E280A mutation
Presenter: Rosanna Tortelli

Agnès POIRIER [1], Enrique GASPAR [1], Gwendlyn KOLLMORGEN [2], Dominik LOTT [1], Stella YILMAZ [1], Tianxu YANG [3], Agnès PORTRON [1], Kalbinder MAHIL [4], Tayo BODEDE [4], David AGUILLÓN [5], David GORDON [6], Robert ALEXANDER [6], Thomas MUEGGLER [1], Rosanna TORTELLI [1], Irene GERLACH [1]
[1] F. Hoffmann-La Roche Ltd, Basel, Switzerland, [2] Roche Diagnostics GmbH, Penzberg, Germany, [3] F. Hoffmann-La Roche Ltd, Roche China Holding, Shanghai, China, [4] Roche Products Ltd, Welwyn Garden City, Welwyn, United Kingdom, [5] Grupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombie, [6] Banner Alzheimer's Institute, Phoenix, United States

P225 Developing microRNA classifiers enriched in brain and associated with inflammation in plasma samples to classify Cognitively Unimpaired, MCI, and AD study participants.
Presenter: Alidad Mireskandari

Kenny ABLORDEPPEY [1], Jacob GOLDMAN [1], Kira SHEINERMAN [1], Samuil UMANSKY [1], Alidad MIRESKANDARI [1], Jon LINKS [2], Alok VEDVYAS [2], Chodosh JOSHUA [2], Karyn MARSH [2], Arjun MASURKAR [2], Thomas WISNIEWSKI [2], Gyanendra KUMAR [1]
[1] DiamiR BioSciences, New Haven, United States, [2] NYU Alzheimer's Disease Research Center, NYU Grossman School of Medicine, New York, United States

P226 Performance of plasma pTau217/A?42 ratio and pTau217 to predict A? pathology status defined by CSF testing in SPIN cohort
Presenter: Yuko Mori Sasaki

Yuko MORI SASAKI [1], Roman BOEER [2], Javier ARRANZ [3], Daniel ALCOLEA [3]
[1] Sysmex R&D Center Europe, Hamburg, Germany, [2] Sysmex Europe SE, Hamburg, Germany, [3] Department of Neurology, Sant Pau Memory Unit, IR SANT PAU, Hospital de la Santa Creu i Sant Pau – IIB Sant Pau, Barcelona, Spain

P227 Development of MTBR-tau Fragment Assay Using a Fully Automated Immunoassay System
Presenter: Shun Murakami

Shun MURAKAMI [1], Yuki HOSHINA [1], Shunsuke WATANABE [2], Kengo ISHIKI [1], Kazuto YAMASHITA [1], Masahiro MIURA [1], Toshiyuki SATO [1]
[1] Central Research Laboratories, Sysmex Corporation, Kobe, Japan, [2] Technology Innovation Division, Sysmex Corporation, Kobe, Japan

P228 Combination of Plasma A?42/40 and p-tau217 Measured Using Fully Automated Immunoassay System Accurately Predicts Amyloid Pathology Determined by Amyloid PET
Presenter: Masanori Kurihara

Masanori KURIHARA [1,2], Kazuto YAMASHITA [3], Shun MURAKAMI [3], Kengo ISHIKI [3], Tomomi MASUDA [4], Yoshikazu OKAMURA [4], Masahiro MIURA [3], Kenji ISHII [2,5], Toshiyuki SATO [3], Atsushi IWATA [1,2]
[1] Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, [2] Department of Biomarkers, Integrated Research Initiative for Living Well with Dementia, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, [3] Central Research Laboratories, Sysmex Corporation, Kobe, Japan, [4] Medical & Scientific Affairs, Sysmex Corporation, Kobe, Japan, [5] Research Team for Neuroimaging, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

P229 Differential Age Effects on Plasma p-tau217 by Amyloid Status, Cognitive Stage, and Sex in Alzheimer's Disease
Presenter: Seonghyeon Kim

Seonghyeon KIM [1], Daeun SHIN [1], Sohyun YIM [1], Heekyoung KANG [1], Hee Kyung PARK [1], Junah LEE [2], Junpyo KIM [1], Heejin KIM [1], Sangwon SEO [1]
[1] Department of neurology, Samsung Medical center, Seoul, Republic of Korea, [2] Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Seoul, Republic of Korea

P230 The SPRING Trial: Treatment of P. gingivalis-positive mild-to-moderate Alzheimer's disease with the second-generation gingipain inhibitor LHP588
Presenter: Michael Detke

Michael DETKE [1], Marwan SABBAGH [2], Joanna BOLGER [3], Mark RYDER [1], Craig MALLINCKRODT [4], Casey LYNCH [3], Stephen DOMINY [3]
[1] Lighthouse Pharma - San Francisco United States, San Francisco, United States, [2] Barrow Neurological Institute, Phoenix, United States, [3] Lighthouse Pharma, San Francisco, United States, [4] Pentara, Millcreek, United States

P231 Prognostic Models for Development of Elevated Plasma P-tau217 in Preclinical Alzheimer's Disease: Insights from A4/LEARN
Presenter: Roy Yaari

Roy YAARI [1], Nalin PAYAKACHAT [1], Nicolae DONE [2], Urvi DESAI [2], Yun-Fei CHEN [1], Chia-Lun LIU [2], Pete ZUCKERMAN [2], Zachary SHEFF [1], Jolanda MUENZEL [1], Karen Chilcott HOLDRIDGE [1], Dulanji KURUPPU [1], Michael S. RAFII [3], Noam KIRSON [2], Reisa SPERLING [4]
[1] Eli Lilly and Company, Indianapolis, United States, [2] Analysis Group, Boston, United States, [3] University of Southern California, Los Angeles, United States, [4] Harvard Medical School, Boston, United States

P232 Evaluation of the Clinical IMpact of Blood-Based Biomarker Assays on dementia specialists' decision-making (CIMBBBA): Preliminary report from a real-world dementia subspecialty clinic study
Presenter: Mark Eldaief

Mark ELDAIEF [1], Erin KRAHN [1], Sam MURDOCK [1], Neguine REZAII [1], Diane CHAN [1], Steven ARNOLD [2], Marina AVETISYAN [2], John DICKSON [2], Liliana RAMIREZ GOMEZ [2], Seth GALE [3], Scott MCGINNIS [3], Bradford DICKERSON [1]
[1] Frontotemporal Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, United States, [2] Memory Disorders Unit, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, United States, [3] Center for Brain Mind Medicine, Department of Neurology, Brigham & Women's Hospital and Harvard Medical School, Boston, United States

P233 Combining Cognivue Clarity and Lucent AD Complete for a Time and Cost Efficient Two Stage Screening for Alzheimer's Disease Clinical Trial Recruitment Enrichment and Treatment Protocols
Presenter: James Galvin

James GALVIN [1], Lindsey METTE [2], David WILSON [2], Heather HARRIS [3], Paul ESTES [3]
[1] University of Miami, Boca Raton, United States, [2] Lucent Diagnositics, Billerica, United States, [3] Cognivue, Inc, Victor, United States

P234 Performance testing of the novel DDC Xplorer Lumipulse G1200 Immunoassay for measuring DOPA Decarboxylase in Cerebrospinal Fluid (CSF)
Presenter: Erik Stoops

Erik STOOPS [1], Megan DE PAUW [1], Nathan BLANCKE [1], Julie GOOSSENS [1], Eugeen VANMECHELEN [1], Giovanni BELLOMO [2], Federico PAOLINI PAOLETTI [3], Lorenzo GAETANI [3], Davide CHIASSERINI [3], Yihua MA [4], Carly FARRIS [4], Luis CONCHA-MARAMBIO [4], Lucilla PARNETTI [4]
[1] ADx NeuroSciences, Gent, Belgium, [2] University of Perugia, Perugia, Italie, [3] Centro Disturbi della Memoria, Perugia, Italie, [4] Amprion, San Diego, United States

P235 Blood Biomarker Testing in Real-World Care Settings: Early Learnings from the Accurate Diagnosis Implementation Project
Presenter: Amy Deckert

Amy DECKERT, Monica ZIGMAN SUCHSLAND, Karen WEYRAUCH, Tim MACLEOD, Alissa KURZMAN, Katherine J. SELZLER
Davos Alzheimer's Collaborative, Wayne, United States

P236 ADxPLORER: filling the gap for early-stage fluid biomarker research on the fully automated LUMIPULSE® G1200 platform ???
Presenter: Nathan Blancke

Nathan BLANCKE, Elisa SCHAERLAECKEN, Cindy FRANCOIS, Charlotte LAMBRECHTS, Shreyasee DAS, Charlotte DE ROCKER, Leentje DEMEYER, Megan DE PAUW, Jeroen VANBRABANT, Erik STOOPS
ADx NeuroSciences, Gent, Belgium

P237 Novel high-throughput, fully automated immunoassay for cerebrospinal fluid tau microtubule binding region (MTBR-tau)
Presenter: Dusten Unruh

Dusten UNRUH, Miklos SZABO, Brian ENGEL, Katharine HOFFMANN, Kara JOHNSON, Mikaela NICHKOVA-DOSEVA
Beckman Coulter, Chaska, United States

P238   High Fat Feeding Effects on Peripheral and Cerebrospinal Measures of Glucose, Insulin and Appetite Hormones

Presenter: Jessica E Rehmann

Jessica E REHMANN, Mason B PIRNER, Kristen M FARRIS, Sarah SPECKMAIER, Pavan K BHATRAJU, Angela J HANSON
University of Washington Medical Center, Seattle, Wa, United States

P240   Characterization of stages of neurodegeneration using circulating brain-enriched and inflammation-associated microRNAs

Presenter: Alidad Mireskandari

Kenny ABLORDEPPEY[1] [1], Jacob GOLDMAN [1], David WOLK [2], Kira SHEINERMAN [1], Samuil UMANSKY [1], Alidad MIRESKANDARI [1] , Kumar GYANENDRA [1]
[1] DiamiR BioSciences, New Haven, United States, [2] University of Pennsylvania, Philadelphia, United States

P241   Performing multiple biomarker tests delays initiation of lecanemab treatment

Presenter: Anna Hofmann

Anna HOFMANN [1] , Madeline PACZYNSKI [1], Maria PONISIO [2], Jessica ROBERTS [3], William POWELL [4], Aditi GUPTA [4], Inez OH [4], Mackenzie HOFFORD [4], Zachary POSEY [3], Melissa ALDINGER [3], Tammie BENZINGER [2], John MORRIS [1], Joy SNIDER [1], Suzanne SCHINDLER [1]
[1] Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA , Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA, St. Louis, United States, [2] Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA, St. Louis, United States, [3] Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA, St. Louis, United States, [4] Institute for Informatics, Data Science & Biostatistics, Washington University School of Medicine, St. Louis, MO, USA, St. Louis, United States

P242   A novel approach for recruiting patients for early phase trials in Alzheimer's Disease: Faster, simpler, and with reduced patient burden

Presenter: Lydia Morris

Lydia MORRIS [1] , Lev GERTSIK [2], Svetlana SEMENOVA [3]
[1] California Clinical Trials Medical Group in affiliation with Parexel International, Glendale, Îles mineures éloignées des United States, [2] California Clinical Trials Medical Group in affiliation with Parexel International, Glendale, United States, [3] Parexel International, Glendale, United States

P243   Amplified Tau Aggregates in Cerebrospinal Fluid Track Tau PET and Cognitive Decline in Alzheimer's Disease

Presenter: Md Tohidul Islam

Md Tohidul ISLAM [1] , Thomas K KARIKARI [2], Kaj BLENNOW [1]
[1] University of Gothenburg, Gothenburg, Sweden, [2] University of Pittsburg, Pittsburg, United States

P244   A Comparison of Levels and Longitudinal Trends of p-Tau 217 with MMSE, ADAS-Cog, and CDR in a Cohort of 113 Cognitively Normal and Cognitively Impaired Individuals Over 6 Years Using ADNI Data Set

Presenter: Aishwarya Prasad

Aishwarya PRASAD, Anshu ARORA, Diya NARAYAN, Dhea PUSHPRAJ, Arun ARORA, Jeena VAID, Wisam ALJUMAILI, Arif KHAN
Northwest Clinical Research Center, Bellevue, Washington, United States

P245   Regional Amyloid Positivity Predicts Alzheimer's Disease Progression Despite Low Centiloid Values in Mild Cognitive Impairment

Presenter: Oh Minyoung

Oh MINYOUNG [1] , Ryu JEONGRYUL [1], Lim JAE-SUNG [2], Kim JAE SEUNG [1], Lee JAE-HONG [2]
[1] Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, [2] Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

P246   Head-to-head comparison of 4 capillary blood sampling devices for measuring p217 tau

Presenter: Setareh Moughadam

Setareh MOUGHADAM [1] , Hanna HUBER [2], Laia MONTOLIU-GAYA [2], Nicholas ASHTON [2, 3], Henrik ZETTERBERG [2], Annemie CHIAU [4], Katrin HAEVERANS [5], Gallen TRIANA BALTZER [1]
[1] Johnson and Johnson, San Diego, United States, [2] University of Gothenburg, Gothenburg, Sweden, [3] Banner Alzheimer's Institute , Phoenix, United States, [4] ICON, Beerse, Belgium, [5] Johnson and Johnson, Beerse, Belgium

P247 Leveraging recent advances in biomarkers to optimize early phase drug development in Alzheimer's Disease
Presenter: Garrett Duncan

Garrett DUNCAN
Pentara Corporatoin, Salt Lake City, United States

P248 Identifying Neuropsychological and Sociodemographic Predictors of a Blood-Based Biomarker of Alzheimer's Disease
Presenter: Isaiah Gamble

Isaiah GAMBLE, Stephanie RUTRICK, Sarah STARLING, Hailie HALE, Jake PETITT, Sean WOMACK
Adams Clinical, Watertown, United States

P249 MK-1167, a positive allosteric modulator of ?7 nicotinic cholinergic receptors: proof-of-biology, dose selection, and clinical trial design
Presenter: Sarah Janicki Hsieh

Sarah Janicki HSIEH [1], Corin MILLER [1], Graeme MASON [2], Douglas ROTHMAN [2], Gerard SANACORA [2], Evita C WIEGERS [3], Dennis W J KLOMP [3], Narjes AHMADIAN [3], Sarah JACOBS [3], An BAUTMANS [4], Kristien VAN DYCK [4], Yi MO [1], Michael F EGAN [1], S Aubrey STOCH [1], Mk-1167_003 MK-1167_003 CLINICAL STUDY TEAM [1,3]
[1] Merck & Co., Inc., Rahway, United States, [2] Yale School of Medicine, New Haven, United States, [3] University Medical Center, Utrecht, Netherlands, [4] MSD Europe Belgium, Brussels, Belgium

P250 Optimizing Plasma p-Tau217 Cutoffs for Amyloid Pathology According to Kidney Function, Body Weight, and Anemia
Presenter: Jihwan Yun

Jihwan YUN [1], Daeun SHIN [2], Eun Hye LEE [2], Jun Pyo KIM [2], Hongki HAM [2], Yuna GU [2], Min Young CHUN [3], Sung Hoon KANG [4], Hee Jin KIM [2], Duk L. NA [5], Henrik ZETTERBERG [6], Kaj BLENNOW [6], Fernando GONZALEZ-ORTIZ [6], Sang Won SEO [2], Hyemin JANG [7]
[1] Department of Neurology, Kyung Hee University College of Medicine, Kyung Hee University Hospital,, Seoul, Republic of Korea, [2] Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, [3] Department of Neurology, Yongin Severance Hospital, Yonsei University Health System, Yongin, Republic of Korea, [4] Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea, [5] Happymid Clinic, Neurology, Seoul, Republic of Korea, [6] Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden, [7] Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea

P251 Predicting Alzheimer's Disease Progression Using Neuroimaging and Genetics Markers
Presenter: Seok Woo Moon

Seok Woo MOON [1], Bumjun KIM [1], Ivo DINOV [2]
[1] Konkuk University Chungju Hospital, Chungju, Republic of Korea, [2] UMICH, Ann Arbor, United States

P252 Semaglutide impacts proteomic signatures related to dementia risk in the SELECT cardiovascular outcomes trial
Presenter: Martí Jiménez-Mausbach

Martí JIMÉNEZ-MAUSBACH [1], Jan Christian REFSGAARD [1], Gabriel MARTINO [1], Teresa Leon COLOMBO [1], Betty TIJMS [2], Clare PATERSON [3]
[1] Novo Nordisk A/S, Søborg, Denmark, [2] Alzheimer Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, Netherlands, [3] Clinical Research and Development, Standard BioTools, Boulder, Colorado, United States

P253 Robustness of Plasma A?42/A?40 as a Predictive Biomarker for Brain Amyloid Deposition: Independence from Renal Function and Body Mass Index in a Real-World Tertiary Care Cohort with Mild Cognitive Impairment.
Presenter: José Antonio Allué

José Antonio ALLUÉ [1], Leticia SARASA [1], Noelia FANDOS [1], Jorge LOSCOS [1], Judith ROMERO [1], Adrián SÁNCHEZ [1], Jose TERENCIO [1,2], Gerard PIÑOL-RIPOLL [3,4], María PASCUAL-LUCAS [1]
[1] Araclon Biotech-Grifols, Zaragoza, Spain, [2] Grifols S.A., Barcelona, Spain, [3] Hospital Universitari Santa Maria, Lleida, Spain, [4] Hospital Clínic, Barcelona, Spain

P254 Modeling Age-Related Amyloid-? Trajectories in Cognitively Unimpaired Individuals using GAMLSS: A Ethnic Comparison between Korean and Non-Hispanic White Cohorts
Presenter: Chun Min Young

Chun MIN YOUNG [1], Sungjoo LEE [2], Kim KYUNGA [3], Kim HEE JIN [4], Na DUK L. [4], Weiner MICHAEL [5], Schindler SUZANNE E. [6], Kim JUN PYO [4], Seo SANG WON [4]
[1] Department of Neurology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea, [2] Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine - Seoul Korea, Republic of, Seoul, Republic of Korea, [3] Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea, [4] Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, [5] University of California, San Francisco, San Francisco, United States, [6] Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States

P255 Age-related blood CD8 T cells binding a non-self peptide/HLA epitope track with Alzheimer's and related MCI status in HLA-A2+ and HLA-A2- cohorts: expanding the reach of a T cell biomarker assay to all patients.
Presenter: Christopher Wheeler

Christopher WHEELER [1,2], Debby VAN DAM [3,4], Yannick VERMEIREN [3,4], Hans DE REU [3], Peter Paul DE DEYN [3,4]
[1] T-Neuro Pharma, Aptos, United States, [2] Soc. for Brain Mapping & Therapeutics, Pacific Palisades, United States, [3] University of Antwerp, Antwerp, Belgium, [4] University of Groningen, Groningen, Netherlands

P256 C2N Eligibility, APOE genotype Identification, Amyloid Confirmation. Results from the AHEAD 3-45 programme at Neuroclin Glasgow
Presenter: Jennifer Linch

Kanwal AADIL, Cowan LEWIS, Jennifer LYNCH, Inglis FRASER
NeuoClin Ltd, Motherwell, United Kingdom

P257 The role of lipids on changes of plasma pTau181, pTau217 and the 217/181 ratio in Alzheimer's disease over time: a pilot study in a memory clinic population.
Presenter: Michaela Defrancesco

Michaela DEFRANCESCO, Alex HOFER, Christian HUMPEL
Medical University, Innsbruck, Autriche

P258 Development and Evaluation of an MTBR Tau Fragment Immunoassay for the Assessment of Alzheimer's Disease Tau Pathology
Presenter: Shannon Leslie

Shannon LESLIE [1], Setareh MOUGHADAM [1], Kristof VAN KOLEN [2], Gallen TRIANA-BALTZER [1]
[1] Johnson and Johnson Innovative Medicine, San Diego, United States, [2] Johnson and Johnson Innovative Medicine, Beerse, Belgium

P259 Tau-Dependent Divergent Associations of Soluble and Plaque Amyloid with Glucose Dysregulation
Presenter: Dong Woo Kang

Dong Woo KANG [1], Hyun Kook LIM [2]
[1] Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, [2] Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

P260 A Correlation Between Plasma P-Tau181 Levels and Clinical Diagnosis of Alzheimer's Disease
Presenter: Anshu Arora

Aishwarya PRASAD [1], Anshu ARORA [1,2], Arun ARORA [1], Mahima PATIL [1], Arif KHAN [1,3]
[1] Northwest Clinical Research Center, Bellevue, United States, [2] Washington State University Elson S. Floyd College of Medicine, Spokane, United States, [3] Pacific Northwest University of Health Sciences College of Osteopathic Medicine, Yakima, United States

08 ● PROOF OF CONCEPT FOR ALZHEIMER DRUG DEVELOPMENT INTERVENTIONS
WEDNESDAY, DECEMBER 3 (7:15 A.M. – 5:30 P.M.)

P261 Clinical and PET outcomes following A?-targeting therapies in sporadic Early Onset Alzheimer's disease: Trial Emulation using the LEADS cohort
Presenter: Renaud La Joie

Konstantinos CHIOTIS [1], Ani ELOYAN [2], Kala KIRBY [3], Ganna BLAZHENETS [4], Piyush MAITI [4], Zoe LIN [4], Maryanne THANGARAJAH [2], Alexandra TOUROUTOGLOU [5], Dustin HAMMERS [3], Maria CARRILLO [6], Bradford DICKERSON [5], Liana APOSTOLOVA [3], Gil RABINOVICI [4], Renaud LA JOIE [4]
[1] Karolinska Institutet, Solna, Sweden, [2] Brown University, Providence, United States, [3] Indiana University School of Medicine, Indianapolis, United States, [4] University of California, San Francisco, San Francisco, United States, [5] Massachusetts General Hospital, Boston, United States, [6] Alzheimer's Association, Chicago, United States

P262 Advancing AKV9 (NU9) Towards Phase I Clinical Evaluation: A Small-Molecule Autophagy-Enhancing Therapeutic for Proteinopathies in Alzheimer's Disease and ALS
Presenter: Raghad Nowar

Raghad NOWAR, Elizabeth JOHNSON, Pedro SOARES, Elizabeth SMITH, William KLEIN, Richard SILVERMAN
Northwestern University, Evanston, United States

P263 Thiethylperazine Reduces Phosphorylated Tau in Alzheimer's Disease: Confirming iN-based Results with Clinical Trial Data
Presenter: Markus Krohn

Markus KROHN [1, 2], Camilla ORBJÖRN [3, 4], Janelidze SHORENA [3], Stomrud ERIK [3], Mattsson NIKLAS [3], Hansson OSKAR [3], Toresson HÅKAN [3, 4]
[1] Immungenetics AG, Hamburg, Germany, [2] Caladrix Inc., Dover, United States, [3] Lund University, Lund, Sweden, [4] Cell Invent Sweden AB, Lund, Sweden

P264 Intradermal BCG Immunotherapy Induces Durable Trained Immunity Signatures in CNS Monocytes and Reprograms Neuroimmune Pathways in Aging and Alzheimer's Disease
Presenter: Steven Arnold

Steven ARNOLD [1], Mahesh KODALI [1], Zhaozhi LI [1], Kelli DEVITTE-MCKEE [1], Pia KIVISAKK [1], Allison MCMANUS [1], Jessica GERBER [1], Rudolph TANZI [1], Sudeshna DAS [1], Denise FAUSTMAN [1], Marc WEINBERG [2]
[1] Massachusetts General Hospital, Boston, United States, [2] AbbVie, North Chicago, United States

P265 Perivascular Macrophages: A Potential Novel Pathway for Lecanemab to Ameliorate Blood-Brain Barrier Integrity and Cognitive Function in the APP/PS1 mouse model of Alzheimer's Disease
Presenter: Wen Chen

Wen CHEN, Wang JUNYI, Niu QIONGQIONG, Liu SHUAI, Wu HAO, Wang PAN, Ji YONG
Tianjin Huanhu Hospital, Tianjian, China

P268 Optimized Delivery of Anti-Amyloid Therapeutics using Brain Shuttles against Novel Blood-Brain-Barrier Receptors
Presenter: Naveen Mehta

Naveen MEHTA, Alvaro GARCIA, Isabel ALBUJA, John AVERA, Alex REIS, Kimberly SCEARCE-LEVIE, Gleb KUZNETSOV, Pierce OGDEN
Manifold Bio, Boston, United States

P269 Targeting of A? toxic oligomers via a designed peptide reduces plaque formation in an AD mouse model
Presenter: Carolyn Tallon

Carolyn TALLON, Sebastien PRADEL, Koya YAKABI, Emma BREYAK, Catalina PASCUALY, Chandresh GAJERA, Jeff POSAKONY, Gil BLOCK, Valerie DAGGETT
AltPep Corporation, Seattle, United States

P270 A treatment management platform to enable safe, scalable deployment of disease-modifying therapies in Alzheimer's disease
Presenter: Adrián Noriega De La Colina

Adrián NORIEGA DE LA COLINA [1, 2, 3] , Jorge J. LLIBRE-GUERRA [4], Mario MASELLIS [5, 6], Eric E. SMITH [7, 8], Zahinoor ISMAIL [7, 8], Nikolaos SCARMEAS [9], [10], Sinjan GHOSH [11], Nilton CUSTODIO [12], Gerard PIÑOL-RIPOLL [13], Paolo VITALI [1], [14], Pedro ROSA-NETO [1], [15], [2], [16], Mercè BOADA [17], [18], Serge GAUTHIER [1], [19], [20], Christian DANSEREAU [3], Andrew FRANK [21], [22]
[1] Department of Neurology and Neurosurgery, McGill University, Montreal, Canada, [2] Montreal Neurological Institute-Hospital, Montreal, Canada, [3] Perceiv Research Inc., Montreal, Canada, [4] Department of Neurology, Washington University in Saint Louis School of Medicine, Saint Louis, United States, [5] Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada, [6] Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Canada, [7] Hotchkiss Brain Institute Cumming School of Medicine University of Calgary, Calgary, Canada, [8] Department of Clinical Neurosciences Cumming School of Medicine, University of Calgary, Calgary, Canada, [9] 1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University, Athens, Grèce, [10] Department of Neurology, The Gertrude H. Sergievsky Center, Taub Institute for Research in Alzheimer's Disease and the Aging Brain, New York, United States, [11] Narayana Health, Rabindranath Tagore International Institute of Cardiac Sciences, Kolkata, Inde, [12] Instituto Peruano de Neurociencias, Lima, Pérou, [13] Unitat Trastorns Cognitius, Hospital Universitari Santa Maria, IRBLleida, Lleida, Spain, [14] McGill University Research Centre for Studies in Aging, Douglas Research Institute - Montreal Canada, Montreal, Canada, [15] McGill University Research Centre for Studies in Aging, Douglas Research Institute, Montreal, Canada, [16] The Peter O'Donnell Jr. Brain Institute OBI, University of Texas Southwestern Medical Centre UTSW., Dallas, United States, [17] Ace Alzheimer Center Barcelona - Universitat Internacional de Catalunya, Barcelona, Spain, [18] Networking Research Center On Neurodegenerative Diseases CIBERNED, Instituto de Salud Carlos III, Madrid, Spain, [19] Department of Psychiatry, McGill University, Montreal, Canada, [20] McGill Dementia Education Program, Montreal, Canada, [21] Bruyère Health Research Institute, Ottawa, Canada, [22] University of Ottawa, Ottawa, Canada

P271 The brain permeable immunoproteasome-selective inhibitor AR-01 is a promising drug candidate for Alzheimer's disease
Presenter: Ji Eun Park

Ji Eun PARK [1] , Til Bahadur THAPA MAGAR [1], Kyung Bo KIM [1, 2]
[1] Center for Translational Science, Florida International University, Port St Lucie, United States, [2] Cellular and Molecular Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, United States

P272 Valiltramiprosate/ALZ-801 Inhibits Amyloid Oligomer Formation: Quantitative Systems Pharmacology Analysis of A? Aggregation Dynamics and Impact on AD Progression
Presenter: John Hey

John HEY [1] , Hugo GEERTS [2], Shaina SHORT [2], Jeremy YU [1], Jean SCHAEFER [1], Susan ABUSHAKRA [1], Aidan POWER [1], Martin TOLAR [1]
[1] Alzheon, Inc., Framingham, United States, [2] Certara, Radnor, United States

P273 Proof-of-concept phase 2a clinical trial of a novel septin modulator reveals early EEG pharmacodynamic effects in Alzheimer's disease.
Presenter: Velislava Zoteva

Velislava ZOTEVA [1] , Julie CLAROT [1], Mieke NUYTTEN [2], Emiel VEREYCKEN [1], Gert VANHOLLEBEKE [1], Nigel COLENBIER [1], Pieter VAN MIERLO [1], Gerard GRIFFIOEN [2]
[1] 1Clouds of Care NV, Ghent, Belgium, [2] 2Remynd NV, Leuven, Belgium

P274 Efferocytosis-Driven Reduction of Neuroinflammation by Novel GAS6 Fusion Protein (GAIA) in Anti-A? Immunotherapies
Presenter: Jinkyung Lee

Soomin JI, Jinkyung LEE, Juho LEE, Sanghoon PARK
Illimis Therapeutics., Inc., Seoul, Republic of Korea

P275 Clinical Utility of Plasma Biomarkers in Anti-Amyloid Treatment Clinic to Evaluate Treatment Response and Predict of Side Effects
Presenter: Nicholas Schwartz

Nicholas SCHWARTZ, Tara ELLINGSON, Hong NGUYEN, Connor DIETZ, Gautam TAMMEWAR, Nhat Minh BUI, Rowan SALONER, Adam STAFFARONI, Melanie STEPHENS, Peter LJUBENKOV, Julio ROJAS, Gil RABINOVICI, Bruce MILLER, Adam BOXER, Lawren VANDEVREDE
University of California, San Francisco, San Francisco, United States

P276 Cross-Platform CSF Proteomics Reveals Reproducible Biomarkers and Novel Mechanisms Beyond Amyloid and Tau in Alzheimer's Disease
Presenter: Pallavi Sachdev

Pallavi SACHDEV [1], Yuanqing YE [1], Satya SAXENA [1], Takeo KAMAKURA [2], Kazunari SASAKI [2], Kazuhiro TAHARA [2], Hongmei NIU [1], Kristin WILDSMITH [1], Larisa REYDERMAN [1], Michael IRIZARRY [1], Viswanath DEVANARAYAN [1], Kanta HORIE [1, 2, 3]
[1] Eisai Inc., Nutley, United States, [2] Eisai Co., Ltd, Tsukuba, Japan, [3] Washington University School of Medicine, St. Louis, United States

P277 Valiltramiprosate Prevents Hippocampal Atrophy and Clinical Decline in An Early Symptomatic APOE4/4 AD Subpopulation in Phase 3 Study via Potential Neurogenesis/Neuroplasticity Action
Presenter: John Hey

Jeremy YU [1], Hugo GEERTS [2], Shaina SHORT [2], Jean SCHAEFER [1], Susan ABUSHAKRA [1], Aidan POWER [1], Pat KESSLAK [1], Martin TOLAR [1], John HEY [1]
[1] Alzheon, Framingham, United States, [2] Certara, Radnor, United States

P278 A Simulation of Long-Term Lecanemab Treatment Effect on the Alzheimer's Disease Progression in ApoE4 Non-Carriers and Heterozygous Carriers
Presenter: Se Ryeong Jang

Troy WILLIAMS [1], Se Ryeong JANG [2], Krista LANCTOT [3], Ashley KANG [1], Lisa BLOUDEK [1], Guoqiao WANG [4]
[1] Curta Inc., Seattle, United States, [2] Eisai Inc., Nutley, United States, [3] Sunnybrook Health Sciences Centre, Toronto, Canada, [4] Washington University in Saint Louis, St. Louis, United States

P279 Neuro-Dynamic Quantitative Systems Pharmacology (QSP) Model Predicts Increasing Benefits of Continued Lecanemab Treatment with Clarity AD 48-Month Data
Presenter: Youfang Cao

Youfang CAO, Pallavi SACHDEV, Natasha PENNER, Kristin WILDSMITH, Kanta HORIE, Arnaud CHARIL, Akihiko KOYAMA, Michael IRIZARRY, Larisa REYDERMAN
Eisai Inc., Nutley, United States

P280 ACE-2223, a novel oral small molecule for TDP-43 proteinopathies, treats both gain- and loss-of-function TDP-43 pathology, extends survival and decreases NfL in vivo and has a favorable preclinical safety profile
Presenter: Katie Planey

Katie PLANEY [1], Vidhu MATHUR [1], Marcela KOKES [1], Arya SHRUTI [1], Devi KORUMILLI [1], Vanessa SEAWRIGHT [1], Haque MD ANZARUL [2], Naomi MORENO [2], Rakez KAYED [2]
[1] Acelot, South San Francisco, United States, [2] UTMB, Galveston, United States

P281 Neonatal CSF and plasma p-tau exceed Alzheimer's disease levels: insights into antagonistic pleiotropy and potential tau therapies
Presenter: Fernando Gonzalez-Ortiz

Fernando GONZALEZ-ORTIZ [1], Henrik ZETTERBERG [1], Tormod FLADBY [2], Bjørn-Eivind KIRSEBOM [2], Peter HARRISON [3], Michael TURTON [3], Kaj BLENNOW [1]
[1] Gothenburg University, Göteborg, Sweden, [2] Oslo University, Oslo, Norway, [3] Bioventix, United Kingdom, United Kingdom

P282 Higher P-tau217 Levels in Type 2 Diabetes Mellitus: Sex Differences in Neuropathological Resilience
Presenter: Bernadette Fausto

Bernadette FAUSTO [1], Darian NAPOLEON [2], Salma ABEDULLAH [2], Mc Derby CENEUS [2], Victoria PARUZEL [1], Ashley POWELL [1], Maureen GICHURA [1], Robert PERNA [1], Stanley ROMAIN [1], Bisma IQBAL [1], Andrea DICKANTONE [1], Miray BUDAK [1], Mark GLUCK [1]
[1] Rutgers University–Newark, Newark, United States; [2] Rutgers New Jersey Medical School, Newark, United States

P283 An Optimized Polygenic Risk Score Predicts Amyloid-? Positivity, Longitudinal Cognitive Decline, and Brain Organoid Pathology
Presenter: Min Young Chun

Min Young CHUN [1], Jung SANG-HYUK [2], Choe JURAN [3], Lee SEUNG-YEON [4], Seo SANG WON [5], Won HONG-HEE [6], Seo JINSOO [7], Kim HEE JIN [5]
[1] Department of Neurology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea; [2] Department of Medical Informatics, Kangwon National University College of Medicine, Chuncheon, Republic of Korea; [3] Department of Brain Sciences, Daegu Gyeongbuk Institute of Science & Technology, Daegu, Republic of Korea; [4] Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea; [5] Departments of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; [6] Department of Digital Health, SAIHST, Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea; [7] Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea

P284 The Global Neurodegeneration Proteomics Consortium (GNPC) V2: Expanding Real-World Proteomics to include lifestyle and drug interventions, additional geographies, and multiple proteomic platforms
Presenter: Farhad Imam

Farhad IMAM [1], Simon LOVESTONE [2], Krish VARSHA [1], Martin BRINGMANN [2]
[1] Gates Ventures, Seattle, United States; [2] Johnson & Johnson, London, United Kingdom

P285 Translational Progress of NA-831, NA-911, and NA-931: Clinical Evidence Supporting a Unified Theory for Alzheimer's Disease, Stroke, and Obesity
Presenter: Lloyd Tran

Lloyd TRAN, Fern VU, Zung TRAN
Biomed Industries, Inc., San Jose, United States

P286 Biallelic Human Genetic Background: Foundation for Divergent Pathomechanisms
Presenter: Kinga Szigeti

Kinga SZIGETI, Ivanna IHNATOVYCH, Nicolas ROSAS, Michael DWYER, Niels BERGSLAND, Ralph BENEDICT, Robert ZIVADINOV
University at Buffalo, Buffalo, United States

P288 Exploration of Longitudinal Changes in Gut Microbiome Composition Stratified by Amyloid Status
Presenter: Jea Woo Kang

Jea Woo KANG [1], Rob KNIGHT [2], Rima KADDURAH-DAOUK [3], Sterling C. JOHNSON [1], Sanjay ASTHANA [1], Cynthia M. CARLSSON [1], Nathaniel A. CHIN [1], Sandra HARDING [1], Kaj BLENNOW [4], Henrik ZETTERBERG [4], Tobey BETTHAUSER [1], Bradley CHRISTIAN [1], Tyler K. ULLAND [5], Federico E. REY [6], Barbara B. BENDLIN [1]
[1] Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, United States; [2] Department of Pediatrics, University of California, San Diego, La Jolla, United States; [3] Department of Psychiatry and Behavioral Sciences, Duke University, Durham, United States; [4] Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; [5] Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, United States; [6] Department of Bacteriology, University of Wisconsin-Madison, Madison, United States

P289 Associations Between Alzheimer's Disease and Stroke: Clinical Studies of NA-831 for AD and NA-911 for Stroke
Presenter: Lloyd Tran

Lloyd TRAN, Fern VU, Zung TRAN
BioMed Industries, Inc., San Jose, United States

P290 Associations Between Alzheimer's Disease and Obesity: Clinical Trials of NA-831 for AD and NA-931 for the Treatment of Obesity
Presenter: Lloyd Tran

Lloyd TRAN, Fern VU, Zung TRAN
Biomed Industries, Inc., San Jose, United States

P291 TfR1-binding peptides to transport antibodies across blood brain barrier in cynomolgus monkeys
Presenter: Hao Wu

Hao WU, Xuefeng ZHANG, Yibo QIU, Fei SHENG, Yue WU
ChainGen Bio, Shanghai, China

P292 Binding profiles of lecanemab and other amyloid-beta antibodies to amyloid-beta species isolated from Alzheimers's disease brain
Presenter: Linda Söderberg

Lars LANNFELT [1], Linda SÖDERBERG [2], Malin JOHANNESSON [2], Eleni GKANATSIOU [2], Nicolas FRITZ [2], Charlotte SAHLIN [2], Patrik NYGREN [2], Olof ZACHRISSON [2], Christer MÖLLER [2]
[1] Uppsala University, Uppsala, Sweden, [2] BioArctic AB, Stockholm, Sweden

P293 A diagnostic and prognostic plasma omics-biomarkers panel for Alzheimer's Disease based on microglial single-cell transcriptomics
Presenter: Ornit Chiba-Falek

Michael LUTZ, Ornit CHIBA-FALEK
Duke University, Durham, United States

P294 RNA Transcripts in Salivary Extracellular Vesicle Cargo isolated from Aged Populations
Presenter: Chuang-Kuo Wu

Chuang-Kuo WU [1], Sicheng WEN [2], Chang YU [3], Maxfield KELSEY [4], Mandy PEREIRA [2], Hannah ALAIMO [1], Em TEIXEIRA [1], Jenna PRACHT [1], Lori DAIELLO [1], Jonathan DRAKE [1], John SEDIVY [4], Zhijin WU [3], Peter QUESENBERRY [2], Jill KREILING [4]
[1] Department of Neurology, Warren Alpert Medical School of Brown University, Providence, United States, [2] Department of Medicine, Division of Hematology/Oncology, Brown University, Providence, United States, [3] Department of Biostatistics, Brown University School of Public Health, Providence, United States, [4] Brown Center on the Biology of Aging, Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, United States

P295 AI-Driven Proteomics Analysis Reveals Distinct Molecular Subtypes in Neurodegeneration
Presenter: Jermaine Ross

Yoonjeong CHA, Aleksandra LESZCZYNSKA, Jermaine ROSS, Mohamedi KAGALWALA
Alleo Labs, San Francisco, United States

P296 Quantitative System Pharmacology Analysis of Oral Valiltramiprosate Natural Trajectory of Alzheimer's Disease Progression by APOE4 Genotype: Contribution of Anti-Amyloid Oligomer and APOE4 Corrector Modes of Action
Presenter: Jean Schaefer

Jean SCHAEFER [1], Hugo GEERTS [2], Shaina SHORT [2], Jeremy YU [1], Susan ABUSHAKRA [1], Aidan POWER [1], Martin TOLAR [1], John HEY [1]
[1] Alzheon, Framingham, United States, [2] Certara, Radnor, United States

P297 Analytical characterization of a highly sensitive and automated immunoassay for Brain-Derived pTau-217 in human biofluids
Presenter: Xiao-Jun Ma

Xiao-Jun MA, Li WANG, Adheesha DANTHANARAYANA, Sean KIM, Hayeun JI, Niyati JHAVERI, Bingqing ZHANG, Xiaolei QIU, Sasi MUDUMBA, Yuling LUO
Alamar Biosciences, Fremont, United States

P298 GLP-1 Agonists and Cognitive Decline in Alzheimer's Disease: Real-World Evidence from the SiteRx Alzheimer's Real World Data Network
Presenter: Daniel Gautieri

Daniel GAUTIERI, Ashish GAGNEJA, Jackson DOOLEY
SiteRx, New York, United States

P299 Utilization of Alzheimer's Disease Diagnostics by Patient Type: Real-World Evidence from the SiteRx Alzheimer's Real World Data Network
Presenter: Daniel Gautieri

Daniel GAUTIERI, Alex LI
SiteRx, New York, United States

P301 Assessing The Roles of Estrogen, Inflammation and Nutrition on Brain and Cognitive Decline in Aging Women: Factors Reducing Alzheimer's Disease
Presenter: Lephart Edwin

Klayton JOESEL [1], Hedges DAWSON [2], Lephart EDWIN [2]
[1] University of Texas at Austin, Austin, United States, [2] Brigham Young University, Provo, United States

P302 Plasm p-tau217 predictive ability of Cognitive and Functional Decline in Non-demented Amyloid PET positive Older Individual: Three-year follow up data from Japanese Trial Ready cohort for preclinical and prodromal AD.
Presenter: Yoshiki Niimi

Yoshiki NIIMI [1], Saki NAKASHIMA [1], Kenichiro SATO [1], Kensaku KASUGA [2], Takeshi IKEUCHI [3], Takeshi IWATSUBO [4]
[1] The University of Tokyo Hospital, Tokyo, Japan, [2] National Center for Geriatrics and Gerontology, Aichi, Japan, [3] Niigata University, Niigata, Japan, [4] National Center of Neurology and Psychiatry, Tokyo, Japan

P303 Amyloid aggregation inhibition by physiological levels of dopamine: towards levodopa drug reformulation for correcting mild dopamine deficits and delaying Alzheimer's disease progression
Presenter: Joana Saavedra

Joana SAAVEDRA, Zsuzsa SÁRKÁNY, Isabel CARDOSO, Sandra MACEDO-RIBEIRO, Pedro M MARTINS
i³S, Porto, Portugal

P304 Functional decline associated with all-cause mortality in patients with mild cognitive impairment and Alzheimer's dementia in real-world clinical practice
Presenter: Ying Wang

Peter MORIN [1], Ying WANG [2], Joel REISMAN [3], Dan BERLOWITZ [3], Donald MILLER [3], Wen HU [3], Shou-En LU [4], Raymond ZHANG [5], Amir Abbas TAHAMI MONFARED [5], Quanwu ZHANG [5], Weiming XIA [1], [1]
[1] Boston University, Boston, United States, [2] Wentworth Institute of Technology, Boston, United States, [3] University of Massachussetts, Lowell, United States, [4] Rutgers University, Piscataway, United States, [5] Eisai, Inc, Nutley, United States

P305 Integrating Cognitive and Biological Signals in Early Alzheimer's: Predicting p217tau and MCI using the multi-modal Altoida NeuroMarker Platform
Presenter: Nicholas Griffin

Nicholas GRIFFIN [1], Srinivasan VAIRAVAN [2], Gallen TRIANA-BALTZER [3], Anahita KYANI [2], Ziad SAAD [3], Meenakshi KHARE [4], Kara BARTONE [3], Silvia FALLONE [1], Victoria BRUGADA-RAMENTOL [1], M. Florencia IULITA [1], Marc JONES [1], Gayle WITTENBERG [2], Emmanuel STREEL [1]
[1] Altoida, Washington, Dc, United States, [2] JNJ Innovative Medicine, Titusville, New Jersey, United States, [3] JNJ Innovative Medicine, San Diego, California, United States, [4] Quanterix, Billerica, Massachusetts, United States

P306 Worse cognitive performance and poorer quality of life are associated with lower self-reported confidence in accomplishing personal priorities: the utility of the electronic Person Specific Outcome Measure (ePSOM) tool
Presenter: Ali Jannati

Stina SAUNDERS [1, 2], Claudio TORO-SEREY [1], Ali JANNATI [1, 3] , Sean TOBYNE [1], Craig RITCHIE [4], Sarah GREGORY [4], Miles WELSTEAD [4], Álvaro PASCUAL-LEONE [1, 3, 5]
[1] Linus Health, Boston, United States, [2] University of Edinburgh, Edinburgh, United Kingdom, [3] Department of Neurology, Harvard Medical School, Boston, United States, [4] Scottish Brain Sciences, Edinburgh, United Kingdom, [5] Marcus Institute for Aging Research and Wolk Center for Memory Health, Hebrew SeniorLife, Boston, United States

P307 Four-Year Follow-Up of a Multimodal Intervention for Dementia Prevention: Extended Results from the J-MINT PRIME Tamba Randomized Controlled Trial
Presenter: Hisatomo Kowa

Hisatomo KOWA [1] , Tohmi OSAKI [2], Ryoko KUMAGAI [1], Yutaro OKI [1]
[1] Kobe University Graduate School of Health Sciences, Kobe, Japan, [2] Kobe Gaukuin University, Faculty of Rehabilitation, Kobe, Japan

P308 Comparing longitudinal trajectories of Storyteller and CDR-SB: Initial data from ADNI4
Presenter: Emil Fristed

Emil FRISTED [1] , Jack WESTON [1], Adni FOR THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE [2]
[1] Novoic Ltd, London, United Kingdom, [2] ADNI, San Francisco, United Kingdom

P309 Speed-Based Cognitive Training Improves Cholinergic Network Health: Implications for Cognitive Aging and Dementia Prevention from the INHANCE Randomized Clinical Trial
Presenter: Thomas Van Vleet

Thomas VAN VLEET [1] , Mouna ATTARHA [1], Ana De Figueiredo PELEGRINO [2], Paule-Joanne TOUSSAINT [2], Sarah-Jane GRANT [1], Lydia OUELLET [2], Etienne DE VILLERS-SIDANI [2]
[1] Posit Science, San Francisco, United States, [2] McGill University, Montreal, Canada

P310 Evidence Supporting the Use of the Clinical Dementia Rating® as an Outcome Measure in Dementia with Lewy Bodies Clinical Trials
Presenter: James Galvin

James GALVIN, Andreas SALCEDO
University of Miami Miller School of Medicine, Boca Raton, United States

P311 Synergistic effects of Pozibio and Cerbella supplementation on brain function and wellbeing in older adults
Presenter: Hariom Yadav

Courtney DAVIES [1], Alina WARREN-WALKER [1], Nigel HOLT [1], Denis KAY [2], Kevin STEPHENS [3], Hariom YADAV [4, 5] , Alexander TAYLOR [1], Amanda LLOYD [1]
[1] Aberystwyth University, Wales, United Kingdom, [2] Neurodyn Life Sciences Inc, Prince Edward Island, Canada, [3] Agroceutical Products Ltd, England, United Kingdom, [4] University of South Florida, Tampa, United States, [5] Postbiotics Inc, Winston-Salem, United States

P312 Toward clinical trial readiness for the posterior cortical atrophy phenotype: Baseline characteristics in a longitudinal, prospective cohort
Presenter: Victoria Pelak

Victoria PELAK [1] , Asher MAHMOOD [1], Lily NOTEBOOM [1], Bernard CROISILE [2], Allison MCKENDRICK [3], Brianne BETTCHER [1], Sebastian CRUTCH [4], Keir YONG [4]
[1] University of Colorado School of Medicine, Aurora, United States, [2] Neurological Hospital of Lyon, France Hôpital Neurologique Pierre Wertheimer, Lyon, France, [3] The University of Western Australia, Perth, Australia, [4] University of College London, London, United Kingdom

P313 Meaningful benefits in global AD trials: feasibility, applicability, and user acceptability of the ePSOM tool in Japanese memory clinics
Presenter: Atsushi Iwata

Atsushi IWATA [1] , Hisatomo KOWA [2], Yuki TAKEDA [2], Stina SAUNDERS [3, 4], Himanshi MALIK [3], Claudio TORO-SEREY [3], Ali JANNATI [3, 5], Sean TOBYNE [3], Álvaro PASCUAL-LEONE [3, 5]
[1] Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, [2] Kobe University, Kobe, Japan, [3] Linus Health, Boston, United States, [4] University of Edinburgh, Edinburgh, United Kingdom, [5] Harvard Medical School, Boston, United States

P314 Baseline Study-Partner Reported ECog-12 score is associated with subsequent progression on CDR-SB over 78 weeks of follow-up
Presenter: Cai Gillis

Cai GILLIS, Jin WANG, Jing XIE, Melanie SHULMAN, Shuang WU, Shardae SHOWELL, Jennifer MURPHY
Biogen, Cambridge, United States

P315 Identifying individually-defined treatment priorities sensitive to change in cognition
Presenter: Ali Jannati

Stina SAUNDERS [1, 2], Claudio TORO-SEREY [1], Ali JANNATI [1, 3] , Sean TOBYNE [1], Craig RITCHIE [4, 5], Sarah GREGORY [4], Miles WELSTEAD [4], Álvaro PASCUAL-LEONE [1, 3, 6]
[1] Linus Health, Boston, United States, [2] University of Edinburgh, Edinburgh, United Kingdom, [3] Department of Neurology, Harvard Medical School,, Boston, United States, [4] Scottish Brain Sciences, Edinburgh, United Kingdom, [5] School of Medicine, University of St Andrews, St Andrews, United Kingdom, [6] Marcus Institute for Aging Research and Wolk Center for Memory Health, Hebrew SeniorLife, Boston, United States

P316 Validation of the Early Mild Alzheimer's Cognitive Composite (EMACC) Through Associations with Blood-Based Biomarkers of Alzheimer's Disease
Presenter: Sarah Barnum

Sarah BARNUM [1] , Kim STAATS [2], Judith JAEGER [1]
[1] CognitionMetrics, LLC, Hixson, United States, [2] CognitionMetrics, LLC, Boca Raton, United States

P317 Best-Fit Clinical Outcomes Assessment Measures to Evaluate What Matters Most in Alzheimer's Disease: Identifying a Core Outcomes Set from Existing Measures
Presenter: Russ Paulsen

Carla ROMANO [1], Jacqueline MOGLE [1], Audra GOLD [1], Ann HARTRY [2], Jim TAYLOR [3], Leigh F. CALLAHAN [4], Doreen MONKS [5], Ian KREMER [6], Debra LAPPIN [7], Terry FRANGIOSA [8], Jae LEE [9], Elaheh SHIRNESHAN [9], Diana SLOWIEJKO [10], Russ PAULSEN [11]
[1] RTI Health Solutions, Durham, United States, [2] Eli Lilly & Co, Indianapolis, United States, [3] Memory Advocate Peers MAP, New York, United States, [4] University of North Carolina at Chapel Hill, Chapel Hill, United States, [5] Advocate and person living with Alzheimer's disease, Livingston, United States, [6] LEAD Coalition Leaders Engaged on Alzheimer's Disease, Washington, Dc, United States, [7] Lappin Kramer LLC, Denver, United States, [8] Faegre Drinker Consulting, Washington, Dc, United States, [9] AbbVie Inc., Chicago, United States, [10] Genentech, San Francisco, United States, [11] UsAgainstAlzheimer's, Washington, Dc, United States

P318 Early Infusion-Related Reactions with CSF Inflammatory Changes in two Lecanemab-Treated Autosomal Dominant Alzheimer's Disease Cases
Presenter: Patricio Chrem Mendez

Patricio CHREM MENDEZ [1] , Emiliana SEMINARA [1], Sofia ELGANI [1], Juan Pablo TARAVONE [1], Hernan CHAVES [1], Florencia YORIO [1], Yanina BERGAMO [1], Pablo BAGNATI [1], Ricardo ALLEGRI [1], David CLIFFORD [2], Lon SCHNEIDER [2], Eric MCDADE [2], Randall BATEMAN [2], Jorge LLIBRE [2]
[1] Dr., Buenos Aires, Argentine, [2] Dr., Saint Louis, United States

P320 Validation of a novel cognitive-functional outcome measure optimized for early AD: Evidence from the VIVA-MIND trial
Presenter: Steven Edland

Jasmin DUEHRING [1] , Diane JACOBS [1], Carolyn REVTA [1], Jody-Lynn LUPO [1], Andrew MACKELFRESH [1], Antje MEYER [2], Torsten HOFFMANN [2], Michael SCHAEFFER [2], Sylvia SCHELL-MADER [2], Tanja WASSMANN [2], Frank WEBER [2], Christine WENXKOWSKI [2], Howard FELDMAN [1], Steven EDLAND [1]
[1] UCSD, La Jolla, United States, [2] Vivoryon Therapeutics N.V., Halle, Germany

P321 Evaluating a Personalized Endpoint in Down Syndrome–Associated Alzheimer's Disease: Feasibility and Stakeholder Perspectives
Presenter: Chere Chapman

Gunes SEVINC [1], Michelle GEORGE [2], Katherina CRESPO [2], Lois KELLY [3], Hampus HILLERSTORM [3], James A. HENDRIX [4, 3], Chere CHAPMAN [2] , Kenneth ROCKWOOD [5, 6, 2]
[1] Ardea Outcomes, Vancouver, Bc, Canada, [2] Ardea Outcomes, Halifax, Ns, Canada, [3] LuMind IDSC Foundation, Woburn, Ma, United States, [4] Eli Lilly and Company, Indianapolis, In, United States, [5] Dalhousie University, Halifax, Ns, Canada, [6] Nova Scotia Health Authority, Halifax, Ns, Canada

P322 Development of Prognostic Models for Five-Year Risk of Clinical Progression from Preclinical Alzheimer's Disease (Stage 1 and 2) to Cognitive Impairment: Findings from the A4 Study
Presenter: Nalin Payakachat

Nalin PAYAKACHAT [1] , Nicolae DONE [2], Urvi DESAI [2], Yun-Fei CHEN [1], Pete ZUCKERMAN [2], Chia-Lun LIU [2], E. Jolanda MUENZEL [1], Katie Ann VANDERGRIFF [1], Karen Chilcott HOLDRIDGE [1], Dulanji KURUPPU [1], Michael S. RAFII [3], Roy YAARI [1], Noam KIRSON [2], Reisa SPERLING [4]
[1] Eli Lilly and Company, Indianapolis, United States, [2] Analysis Group, Boston, United States, [3] University of Southern California, Los Angeles, United States, [4] Harvard Medical School, Boston, United States

P323 Regional Differences in the Presence of Data Quality Concerns in Dementia Clinical Trials
Presenter: David Miller

David MILLER [1] , Xingmei WANG [2], Alan KOTT [3]
[1] Signant Health, Philadelphia, United States, [2] Signant Health, Blue Bell, United States, [3] Signant Health, Prague, Czech Republic

P324 Comparative Sensitivity of MMSE, Resting-State EEG, and Event-Related Potentials in Longitudinal Cognitive Decline Detection
Presenter: Caroline Ma

Caroline MA [1] , Amir MEGHDADI [1], Grant FOSTER [1], Corinne FISCHER [2], David SALAT [3], Chris BERKA [1]
[1] Advanced Brain Monitoring, Inc., Carlsbad, United States, [2] St. Michael's Hospital - Toronto Canada, Toronto, Canada, [3] Massachusetts General Hospital, Boston, United States

P325 Memory support training and lifestyle modifications to promote healthy aging in persons at risk for Alzheimer's disease: Brain Boosters randomized controlled trial initial results
Presenter: Sarah Tomaszewski Farias

Sarah TOMASZEWSKI FARIAS [1] , Jaclyn FOX [1], Hilary ARALIS [1], Danielle HARVEY [1], Michelle CHAN [1], Michael RYAN [1], Alyssa WEAKLEY [1], Samina RAHMAN [2], Catherine LUNA [2], Maureen SCHMITTER-EDGECOMBE [2]
[1] University of California, Davis, Sacramento, United States, [2] Washington State University, Pullman, United States

P326 Mediterranean Diet in Subjective Cognitive Decline: Cognitive, Mobility, and Neuroimaging Outcomes from a Randomized Cross-Over Trial
Presenter: Yu-Ruei Lin

Yu-Ruei LIN [1] , Li-Ning PENG [2, 3], Liang-Kung CHEN [2, 3, 4], Chih-Ping CHUNG [1, 5]
[1] Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei City, Taïwan, République de China, [2] Center for Geriatric and Gerontology, Taipei Veterans General Hospital, Taipei City, Taïwan, République de China, [3] Center for Healthy Longevity and Aging Sciences, National Yang Ming Chiao Tung University, Taipei City, Taïwan, République de China, [4] Taipei Municipal Gan-Dau Hospital Managed by Taipei Veterans General Hospital, Taipei City, Taïwan, République de China, [5] School of Medicine, National Yang Ming Chiao Tung University, Taipei City, Taïwan, République de China

P327 The Efficacy and Safety of Mobile-App-Based Metamemory Cognitive Training for Mild Cognitive Impairment: A Multicenter, Randomized Clinical Trial
Presenter: Sunyoung Kang

Sunyoung KANG [1, 2] , Jung-In LIM [3], Lukas STENZEL [4], Keun You KIM [1], Eosu KIM [1, 5, 6], Hong Jun JEON [7], Doo-Heum PARK [7], Hyun Kook LIM [8, 9], Yongsoo SHIM [10], Jae-Won JANG [11], Yeshin KIM [11], Kee Hyung PARK [12]
[1] Department of Psychiatry & Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, [2] Emocog Inc., Seoul, Republic of Korea, [3] Interdisciplinary Program in Cognitive Science, Seoul, Republic of Korea, [4] Cogthera GmbH, Munich, Germany, [5] Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea, [6] Metabolism-Dementia Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea, [7] Department of Psychiatry, Konkuk University Medical Center, Seoul, Republic of Korea, [8] Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, [9] CMC Institute for Basic Medical Science, the Catholic Medical Center of The Catholic University of Korea, Seoul, Republic of Korea, [10] Department of Neurology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, [11] Department of Neurology, Kangwon National University Hospital, Kangwon National University College of Medicine, Chuncheon, Republic of Korea, [12] Department of Neurology, College of Medicine, Gachon University, Gil Medical Center, Incheon, Republic of Korea

P328 SGMA: Computational Phenotyping for the Rapid, Repeatable, and Reliable Longitudinal Assessments of Long-Term Memory Function in Clinical Trials
Presenter: Andrea Stocco

Andrea STOCCO [1] , Holly HAKE [2], Anais CAPIK [3], Thomas WILSCHUT [3], Maarten VAN DER VELDE [4], Michael ROSENBLOOM [1], Thomas GRABOWSKI [1], Hedderik VAN RIJN [5]
[1] University of Washington, Seattle, United States, [2] MemoryLab Health, Seattle, United States, [3] MemoryLab Health, Groningen, Netherlands, [4] MemoryLab, Groningen, Netherlands, [5] University of Groningen, Seattle, Netherlands

P329 Refer-MCI: Enriching referrals of patients to memory clinics for mild cognitive impairment (MCI)
Presenter: Emrah Duzel

Emrah DUZEL [1, 2, 3] , Jochen René THYRIAN [4], Vanessa KURTH [5], Nadine DIERSCH [3], Anne BOEHLEN [6], Hannes VOSSFELDT [3], David BERRON [1, 3], Frank JESSEN [6, 7], Annika SPOTTKE [6], Stefan TEIPEL [8]
[1] German Center for Neurodegenerative Diseases DZNE, Magdeburg, Germany, [2] Otto-von-Guericke University, Institute of Cognitive Neurology and Dementia Research IKND, Magdeburg, Germany, [3] neotiv GmbH, Magdeburg, Germany, [4] German Center for Neurodegenerative Diseases DZNE, Greifswald, Germany, [5] Lilly Germany, Bad Homburg, Germany, [6] German Center for Neurodegenerative Diseases DZNE, Bonn, Germany, [7] University of Cologne, Medical Faculty, Department of Psychiatry, Cologne, Germany, [8] German Center for Neurodegenerative Diseases DZNE, Rostock, Germany

P330 An integrated model of diagnosis, treatment, prevention and research: patient journeys at the Geneva Memory Center
Presenter: Federica Ribaldi

Federica RIBALDI, Augusto MENDES, Aurelien LATHUILIERE, Giovanni FRISONI
Geneva Memory Center, Geneva, Switzerland

P331 Preventing Cognitive Decline in Aging: A Network Meta-Analysis of Nutritional Supplement Trials in Cognitively Unimpaired Older Adults
Presenter: Federica Ribaldi

Augusto J. MENDES [1] , Sophie MUTEL [1], Federica RIBALDI [1], Ozge SAYIN [1], Giorgi KHACHVANI [1], Roberta MULARGIA [2], Gabriele VOLPARA [3], Giulia REMOLI [4], Umberto NENCHA [5], Stefano GIANONNI-LUZA [6], Stefano CAPPA [7], Giovanni FRISONI [1]
[1] Laboratory of Neuroimaging of Aging LANVIE, University of Geneva, Geneva, Switzerland, Geneve, Switzerland, [2] Institute of Neurology, University of Cagliari, Cagliari, Italy, Cagliari, Italie, [3] Institute of Neurology, University of Cagliari, Cagliari, Italy, Pavia, Italie, [4] Institute of Neurology, University of Cagliari, Cagliari, Italy, Milano, Italie, [5] Geneva Memory Centre, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland, Geneve, Switzerland, [6] Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, Bari, Italy, Bari, Italie, [7] ICoN Cognitive Neuroscience Centre, Institute for Advanced Studies, IUSS, Pavia, Italy, Pavia, Italie

P332 Speech measures enhance the prediction of Alzheimer's disease biomarkers
Presenter: Jessica Robin

Jessica ROBIN [1] , Mengdan XU [2], Michael SPILKA [2], Francesca CORMACK [3]
[1] Cambridge Cognition, Vancouver, Canada, [2] Cambridge Cognition, Toronto, Canada, [3] Cambridge Cognition, Cambridge, United Kingdom

P333 ERP biomarkers of cognitive dysfunction in Alzheimer's disease: Real-world evidence for translation into clinical trial endpoints
Presenter: Amir Meghdadi

Amir MEGHDADI [1] , Natasha KOVACEVIC [1], Chris BERKA [1], Katy TARRIT MIRAKHORLI [2], Shay NAKAHIRA [2], Kirra BORRELLO [2], Janette BOW-KEOLA [2], Kylie YAMAUCHI [2], Enrique CARRAZANA [2], Janette ABRAMOWITZ [2], Qi ZHI [3], Kore LIOW [2]
[1] Advanced Brain Monitoring, Carlsbad, United States, [2] University of Hawaii, Honolulu, United States, [3] Hawaii Pacific Neuroscience, Honolulu, United States

P334 Integrating Plasma pTau-217 and Digital Cognitive Assessments for Early Detection in Alzheimer's Disease
Presenter: Casey Vanderlip

Casey VANDERLIP, Craig STARK
UC Irvine, Irvine, United States

P335 Combining plasma pTau217 and a remote digital cognitive assessment to predict cognitive decline in cognitively unimpaired older adults
Presenter: Hairin Kim

Hairin KIM [1] , Daniel SOBERANES [1], Roos JUTTEN [2], Mark DUBBELMAN [1], Gad MARSHALL [1], Hyun-Sik YANG [1], Dorene RENTZ [1], Keith JOHNSON [3], Reisa SPERLING [3], Rebecca AMARIGLIO [1], Kathryn PAPP [1]
[1] Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Boston, United States, [2] Department of Neurology, Amsterdam UMC location VUmc, Amsterdam, The Netherlands, Amsterdam, Netherlands, [3] Department of Radiology, Massachusetts General Hospital, Harvard Medical School. Boston, MA, USA, Boston, United States

P336 Speech-based digital cognitive assessments for scalable and cost-effective pre-screening of preclinical Alzheimer's Disease: Insights from the RETAIN study
Presenter: Anahita Kyani

Anahita KYANI [1] , Srinivasan VAIRAVAN [2], Federico PARISI [3], Dzmitry KALIUKHOVICH [4], Macarena GARCIA VALDECASAS COLELL [5], Sara GALE [2], Bahador MARZBAN [3], Nicklas LINZ [6], Johannes TRÖGER [6], Janna HERRMANN [6], David HENLEY [2], Fiona ELWOOD [3], Tricia THORNTON-WELLS [3], Bryan HANSEN [7], Lennert STEUKERS [4]
[1] Johnson & Johnson, La Jolla, United States, [2] Johnson & Johnson, Titusville, United States, [3] Johnson & Johnson, Cambridge, United States, [4] Johnson & Johnson, Beerse, Belgium, [5] Johnson & Johnson, Basel, Switzerland, [6] ki elements GmbH, Saarbrücken, Germany, [7] Johnson & Johnson, Spring House, United States

P337 Electric Field of the Default Mode Network is Correlated with Effects of Transcranial Alternating Current Stimulation in Mild Alzheimer's Disease
Presenter: Yi Tang

Aonan LI, Yi XING, Yi TANG
Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, National Center for Neurological Disorders, Beijing, China

P338 The validation of the new Chinase Short Cognitive Performance Test (SKT)
Presenter: Mark Stemmler

Mark STEMMLER [1] , Melina ARNOLD [1], Liang CUI [2], Qi-Hao GUO [2]
[1] University of Erlangen-Nuremberg, Erlangen, Germany, [2] Shanghai Jiao Tong University School of Medicine, Shanghai, China

P339 Subjective Cognitive Complaints and Stages of Objective Memory Impairment (SOMI) Predict Clinical Progression
Presenter: Priyanka Kumari

Priyanka KUMARI [1] , Richard LIPTON, B. [1, 2], Ellen GROBER [1]
[1] Albert Einstein College of Medicine, New York, United States, [2] Montefiore Medical Center, Bronx, NY, USA

P340 The Digital Clock and Recall identifies eligible candidates for Alzheimer's disease-modifying treatment
Presenter: Ali Jannati

Ali JANNATI, Karl THOMPSON, Claudio TORO-SEREY, Connor HIGGINS, John SHOWALTER, David BATES, Alvaro PASCUAL-LEONE, Sean TOBYNE
Linus Health, Boston, United States

P342 Clinical Outcomes and Patient Experience of Subcutaneous Lecanemab Administration from an Alzheimer's Disease Treatment Center
Presenter: David Watson

David WATSON, Michael NEAM, Mark STAFFORD, Cynthia BOUCHARD, Venessa RANNEY, Sydney WERNER
Alzheimer's Research and Treatment Center, Wellington, United States

P343 Prediction of plasma p-tau217 status and Alzheimer's risk with the remote-ready digital assessment of cognition
Presenter: Ali Jannati

Ali JANNATI, Karl THOMPSON, Daniel SCHULMAN, David LIBON, Rod SWENSON, John SHOWALTER, David BATES, Alvaro PASCUAL-LEONE, Sean TOBYNE
Linus Health, Boston, United States

P344 Advancing Precision in Cognitive Impairment Research: The Role of the Institute for Cognitive Intervention
Presenter: Bon D. Ku

Bon D. KU [1] , Hong Mo KU [2]
[1] *Director of Neuroscience Center & Institute for Cognitive Intervention Department of Neurology, International St. Mary's Hospital Catholic Kwandong University College of Medicine, Incheon, Republic of Korea, [2] Institute for Cognitive Intervention International St. Mary's Hospital, Incheon, Republic of Korea*

P345 Interview Quality Matters: A Cross-Trial Analysis of CDR Administration Errors in Alzheimer's Disease Clinical Research
Presenter: Amanda Aedo

Amanda AEDO [1] , Gila BARBATI [1], Sayaka MACHIZAWA [1], Andrei IACOB [2], Jessica STENCLIK [1], Erica APPLEMAN [1]
[1] *Signant Health, Blue Bell, United States, [2] Signant Health, Iasi, Roumanie*

P346 Linking the Mini-Mental State Examination and the 13-Item Version of Alzheimer's Disease Assessment Scale-Cognitive Subscale
Presenter: David Miller

David MILLER [1] , Alan KOTT [2], Xingmei WANG [3]
[1] *Signant Health, Philadelphia, United States, [2] Signant Health, Prague, Czech Republic, [3] Signant Health, Blue Bell, United States*

P347 Development and preliminary findings of the MoCA-Cognitive Health Questionnaire
Presenter: Ziad Nasreddine

Laura KLAMING, Murray GILLIES, Ziad NASREDDINE
MoCA Cognition, Montreal, Canada

P348 Cognitive Trajectories in Alzheimer's Disease: Findings from the Multinational CICERO-AD Chart Review Study
Presenter: Diego Novick

Diego NOVICK [1] , Giuseppe BRUNO [2], Grazie DELL'AGNELLO [3], Anthony ZAGAR [4], Agota SZENDE [5], Victor KIRI [6], Mercè BOADA [7], Mercè BOADA [8]
[1] *Eli Lilly and Company Ltd., Bracknell, United Kingdom, [2] Department of Neurology and Psychiatry, University of Rome "Sapienza", Rome, Italie, [3] Eli Lilly Italia Spa, Sesto Fiorentino, Italie, [4] Eli Lilly and Company Ltd., Indianapolis, United States, [5] Fortrea, York, United Kingdom, [6] Fortrea, Maidenhead, United Kingdom, [7] Ace Alzheimer Center Barcelona. Universitat Internacional de Catalunya, Barcelona, Spain, [8] Networking Research Center on Neurodegenerative Diseases CIBERNED, Instituto de Salud Carlos III, Madrid, Spain*

P349 Automated linguistic and acoustic metrics of a smartphone-captured cued narration and recall assessment for detecting early memory and biomarker changes in early Alzheimer's disease
Presenter: Thanneer Perumal

Raphael ULLMANN [1], Arnaud WOLFER [1], Kami KOSEK [2], Monika ZBYTNIEWSKA-MÉGRET [3], Thanneer PERUMAL [1] , Irma KURNIAWAN [1], Kirsten TAYLOR [1]
[1] *F. Hoffmann-La Roche Ltd., Basel, Switzerland, [2] Roche Global IT Solution Center, Warsaw, Pologne, [3] CTC Resourcing Solutions AG, Basel, Switzerland*

12 ● BEHAVIORAL DISORDERS AND CLINICAL TRIALS

THURSDAY, DECEMBER 4 (7:15 A.M. – 5:00 P.M.)

P350 Pain Severity Moderates Efficacy of Nabilone for Agitation in Alzheimer's Disease
Presenter: Oriel Feldman

Oriel FELDMAN [1, 2] , Myuri RUTHIRAKUHAN [3], Nathan HERRMANN [2, 4, 3], Damien GALLAGHER [2, 4, 3], Giovanni MAROTTA [2, 5], Alex KISS [3], Sandra BLACK [3, 6], Krista LANCTOT [1], [2], [4], [3]
[1] Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada, [2] Geriatric Psychopharmacology Research Group, Sunnybrook Research Institute, Toronto, Canada, [3] Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada, [4] Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Canada, [5] Division of Geriatric Medicine, Sunnybrook Health Sciences Centre, Canada, [6] Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Canada

P351 Pharmacological Class and Dose Effects on Neuropsychiatric Symptoms and Disease Severity in Dementia: A Defined Daily Dose-Based Cohort Study
Presenter: Jong-Ling Fuh

Yu-Ruei LIN, Jong-Ling FUH
Taipei Veterans General Hospital, Taipei, Taïwan, République de China

P352 Evaluation of the Benefits of Benzgalantamine (ZUNVEYL®) Therapy on Sleep Quality and Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease Patients, and on Reduction of Care-Partner Burden: A Proposed Study Design.
Presenter: Denis Kay

Denis KAY [1] , Andrew WAHLERT [2], Pavel SVINTOZELSKIY [2], Michael MCFADDEN [2], Kurt GRADY [2]
[1] Alpha Cognition Inc, Vancouver, Bc, Canada, [2] Alpha Cognition Inc, Grapevine, Tx, United States

13 ● HEALTH ECONOMICS AND CLINICAL TRIALS
THURSDAY, DECEMBER 4 (7:15 A.M. – 5:00 P.M.)

P355 Cost saving by plasma p-tau217 versus p-tau217/A?42 ratio using two-step approach in the Japanese health care system
Presenter: Masanori Kurihara

Masanori KURIHARA [1] , Ryoko IHARA [1], Kenichiro SATO [2], Atsushi IWATA [1]
[1] Tokyo Metropolitan Institure for Geriatrics and Gerontology, Tokyo, Japan, [2] The University of Tokyo Hospital, Tokyo, Japan

P356 A Low-cost, Scalable Blood Biomarker Assay for Alzheimer's Disease Testing in Resource- Limited Settings
Presenter: Noah Elder

Robert LIN, Jason WAN, Noah ELDER, Hien NGUYEN, Paul HUNG
Taudia, San Carlos, United States

P357 Economic value of a blood test for Alzheimer's disease pathology in primary and specialty care in the U.S.
Presenter: Soeren Mattke

Soeren MATTKE [1] , Jiahe CHEN [1], Mark HANSON [1], Kim JOHNSON [2], Cara LEAHY [3], David MERRILL [4], Victoria SHADA [5], Jorge RUIZ [6]
[1] University of Southern California, Los Angeles, Ca, United States, [2] Duke University, Durham, Nc, United States, [3] Memorial Healthcare Institute, Owosso, Mi, United States, [4] Pacific Brain Health Center,, Santa Monica, Ca, United States, [5] Wake Forest School of Medicine, Winston-Salem, Nc, United States, [6] Memorial Healthcare System, Hollywood, Fl, United States

P358 Cost-Effectiveness Analysis of Initiating Novel Monoclonal Antibodies at Early Alzheimer's Disease Stages
Presenter: Minseon Chung

Minseon CHUNG [1] , Sean D. SULLIVAN [1, 2]
[1] The CHOICE Institute, School of Pharmacy, University of Washington, Seattle, Wa, United States, [2] Department of Health Policy, London School of Economics and Political Science, London, United Kingdom

P359 Neurologists' perceptions and experiences with Amyloid-targeting therapies in Alzheimer's disease in the United States: Baseline data
Presenter: Oralee Varnado

Oralee VARNADO [1] , Ann HARTRY [1], Bridget GAGLIO [2], Viviana NGUYEN [2], Traci SCHILLING [1]
[1] Eli Lilly and Company, Indianapolis, In, United States, [2] PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, Wilmington, Nc, United States

P360 Enhancing Alzheimer's Disease Diagnostic Efficiency and Accuracy with Plasma-Based pTau217 Testing: A Comparative Analysis in Primary and Secondary Care
Presenter: Martin Guess

Sophie ROTH [1], Martin GUESS [1] , Gustaf ORTSÄTER [2]
[1] Roche Diagnostics International, Rotkreuz Zg, Switzerland, [2] Quantify Research AB, Stockholm, Sweden

P361 Societal Cost and Efficiency Comparison of Subcutaneous vs Intravenous Lecanemab for Early Alzheimer's Disease in the United States
Presenter: Amir A. Tahami Monfared

Amir A. TAHAMI MONFARED [1, 2] , Stephanie BARROWS [3], Lindsey FOX [3], Brittney HERBEL [3], William L. HERRING [3, 4], Alisha KRUMBACH [3], Quanwu ZHANG [1]
[1] Eisai Inc., Nutley, United States, [2] McGill University, Montreal, Canada, [3] RTI Health Solutions, Durham, United States, [4] Karolinska Institutet, Stockholm, Sweden

P362 Medication Adherence and Cost of Care for Comorbid Conditions in Patients with Early Alzheimer's Disease: A Retrospective Cohort Study Using the Axon Registry and Claims Data

Presenter: Abdalla Aly

Lei LV [1], Abdalla ALY [1], Caroline MCKAY [1], Paul MYSTKOWSKI [1], Shannon GALLAGHER [2], Kristian GARCIA [2], Heather E. MOSS [3], Soeren MATTKE [4]

[1] Novo Nordisk Inc., Plainsboro, United States, [2] Verana Health, New York, United States, [3] Department of Ophthalmology, Stanford University & Department of Neurology & Neurological Sciences, Stanford University, Stanford, United States, [4] University of Southern California, Los Angeles, United States

14 ● EPIDEMIOLOGY AND CLINICAL TRIALS
THURSDAY, DECEMBER 4 (7:15 A.M. – 5:00 P.M.)

P363 Higher DNA methylation-based intrinsic capacity reflects resilience against neurodegeneration in midlife: insights from the INSPIRE-T lifespan cohort
Presenter: Laure Rouch

Laure ROUCH [1], Sophie GUYONNET [1], Christelle CANTET [1], Matias FUENTEALBA [2], David FURMAN [2], Bruno VELLAS [1], Sandrine ANDRIEU [1]
[1] IHU HealthAge CERPOP, Toulouse, France, [2] Buck Institute for Research on Aging, Novato, United States

P364 Population-based reference values for Alzheimer blood biomarkers in France
Presenter: Sylvain Lehmann

Sylvain LEHMANN [1], Tahiana ANDRIAMBELOSOA [1], Mehdi MORCHIKH [1], Marion MORTAMAIS [1], Marie DUCHIRON [1], Audrey GABELLE [1], Constance DELABY [1], Karim BENNYS [1], Catherine HELMER [2], Marie ZINS [3], Thibault MURA [1]
[1] Montpellier University, Montpellier, France, [2] Bordeaux University, Montpellier, France, [3] Paris-Saclay University, Montpellier, France

P365 MCI Detection in Primary Care in the U.S.: Who is Finding the Cases?
Presenter: Ying Liu

Ying LIU, Wei YE, Andrew BECKER, Soeren MATTKE
University of Southern California, Los Angeles, United States

P366 Odor Identification and Tau Burden in Persons without Dementia: Insights from the Mayo Clinic Study of Aging
Presenter: Mohamed Y Elminawy

Mohamed Y ELMINAWY [1], Jeremiah A AAKRE [2], Jonathan GRAFF-RADFORD [1], Prashanthi VEMURI [3], Christopher G. SCHWARZ [3], Walter K. KREMERS [2], David S. KNOPMAN [1], Val J. LOWE [3], Clifford R. JACK JR [3], Ronald C. PETERSEN [1, 2], Maria VASSILAKI [2]
[1] Department of Neurology, Mayo Clinic, Rochester, MN, Rochester, United States, [2] Quantitative Health Sciences, Mayo Clinic, Rochester, MN, Rochester, United States, [3] Department of Radiology, Mayo Clinic, Rochester, MN, Rochester, United States

P367 Cross-Cohort Validation of Metabolomic Predictors of Global Cognition Using Elastic Net Regression
Presenter: Brandi Vollmer

Brandi VOLLMER [1], Amaryllis SKYFA [2], Christopher PAPANDREOU [2], Christian HABECK [1], Michal BEERI [3], Yaakov STERN [1], Nikolaos SCARMEAS [1], Yian GU [1]
[1] Columbia University, New York, United States, [2] Hellenic Mediterranean University, Chania, United States, [3] Rutgers University, New Brunswick, United States

P368 Sex/gender differences in the associations between parental education and hippocampal volume in the oldest-old: The Life After 90 Study
Presenter: Batool Rizvi

Batool RIZVI [1], Paola GILSANZ [2], Pauline MAILLARD [1], Maria CORRADA [3], Rachel WHITMER [1]
[1] UC Davis, Davis, United States, [2] Kaiser Permanente Northern California Division of Research, Pleasanton, United States, [3] UC Irvine, Irvine, United States

P369 Associations between epigenetic and inflammatory aging, cognitive function, and blood-based biomarkers of Alzheimer's disease: cross-sectional and longitudinal findings from the INSPIRE-T cohort
Presenter: Laure Rouch

Samuel THURIOT, Jason SHOURICK, David FURMAN, Jean Marc LEMAITRE, Sophie GUYONNET, Bruno VELLAS, Sandrine ANDRIEU, Laure ROUCH
IHU HealthAge, Toulouse, France

P370 Cardiorespiratory fitness and brain atrophy: Sex differences and potential vascular mechanisms.
Presenter: Adam J. Paulsen

Adam J. PAULSEN [1, 2] , Ira DRISCOLL [1, 2], Brianne M. BREIDENBACH [1, 2], Matthew P. GLITTENBERG [1, 2], Sarah R. LOSE [1, 2], Yue MA [1], Mark A. SAGER [1], Catherine L. GALLAGHER [3, 4], Sanjay ASTHANA [1, 2], Sterling C. JOHNSON [1, 2], Bradley T. CHRISTIAN [5], Leonardo A. RIVERA-RIVERA [5], Oliver WIEBEN [5, 6], Dane B. COOK [7, 8], Ozioma C. OKONKWO [1, 2]
[1] Wisconsin Alzheimer's Disease Research Center, Department of Medicine, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, United States, [2] Wisconsin Alzheimer's Institute, Madison, United States, [3] Department of Neurology, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, United States, [4] Geriatric Research Education and Clinical Center, William S. Middleton VA Hospital, Madison, United States, [5] Department of Medical Physics, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, United States, [6] Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, United States, [7] William S. Middleton Memorial Veterans Hospital, Madison, United States, [8] Department of Kinesiology, University of Wisconsin School of Education, Madison, United States

P371 ABIDEing with automated cerebrospinal fluid assays; update of an MCI to dementia prediction model
Presenter: Pieter Van Der Veere

Pieter VAN DER VEERE [1] , Argonde VAN HARTEN [1], Stefanie VOS [2], Pieter Jelle VISSER [2], Sterling JOHNSON [3], Erik STORMRUD [4], Oskar HANSSON [4], Sebastian PALMQVIST [4], Gerard PIÑOL-RIPOLL [5], Hans BERKHOF [1], Wiesje VAN DER FLIER [1]
[1] Amsterdam UMC, Amsterdam, Netherlands, [2] Maastricht University, Maastricht, Netherlands, [3] University of Wisconsin-Madison, Madison, United States, [4] Lund University, Malmo, Sweden, [5] Hospital Universitari Santa Maria, Lleida, Spain

P372 Real-world eligibility for lecanemab and donanemab based on Appropriate Use Recommendations in Korea
Presenter: So Yeon Jeon

So Yeon JEON [1] , Min Soo BYUN [2], Hye Ji CHOI [3], Yoon Hee KIM [4], Chung Hee GWAG [5], Gijung JUNG [5], Dong Young LEE [5]
[1] SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, [2] Seoul National University College of Medicine, Seoul, Republic of Korea, [3] Hallym University Dongtan Sacred Heart Hospital, Gyeonggi, Republic of Korea, [4] Seoul National University Hospital, Seoul, Republic of Korea, [5] Seoul National University Hospital - Seoul Korea, Republic of, Seoul, Republic of Korea

P373 The Alzheimer's Disease Sequnecing Project Phenotype Harmonization Consortium
Presenter: Timothy Hohman

Timothy HOHMAN
Vanderbilt University Medical Center, Nashville, United States

P374 Equol-Producing Status is Associated with Greater Frontal Cortex Volume in Community-Dwelling Older Adults: Baseline findings from the ACE Trial
Presenter: Jiatong Li

Jiatong LI [1] , Mengyi LI [1], Yueyang CHI [2], Beth SNITZ [3], Yuefang CHANG [4], Cristina MURRAY-KREZAN [5], Howard AIZENSTEIN [2, 6], Shaolin YANG [2, 6], Minjie WU [2, 6], Whitney WHARTON [7], Timothy HUGHES [8], Akira SEKIKAWA [1]
[1] Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, United States, [2] Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, United States, [3] Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, United States, [4] Department of Neurological Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, United States, [5] Department of Medicine, Center for Research on Health Care, University of Pittsburgh, Pittsburgh, United States, [6] Department of Engineering, Swanson School of Engineering, University of Pittsburgh,, Pittsburgh, United States, [7] Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, United States, [8] Department of Internal Medicine, Section on Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, United States

P375 A MaChina Learning Approach to Predict Cognitive Decline Using Physical, Behavioral, and Blood Markers: Interpreting XGBoost with SHAP
Presenter: Jieun Yoon

Jieun YOON [1] , Kyohei SHIBUYA [1], Namhoon LIM [1], Kenji TSUNODA [1], Tetsuaki ARAI [1], Keisuke FUJII [2], Jaehoon SEOL [1], Tomohiro OKURA [1]
[1] University of Tsukuba, Tsukuba, Japan, [2] Suzuka University of Medical Science, Suzuka, Japan

P376 Therapeutic Time Window of Disease-Modifying Therapy for Early Alzheimer's Disease in Japan
Presenter: Saki Nakashima

Saki NAKASHIMA [1] , Kenichiro SATO [2], Yoshiki NIMI [2], Wataru SATAKE [1], Takeshi IWATSUBO [2]
[1] Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, [2] Unit for Early and Exploratory Development, The University of Tokyo Hospital, Tokyo, Japan

P377 Caregiving and Economic Burden of Alzheimer's Disease in Japan
Presenter: Kavita Nair

Ran GAO [1], Kavita NAIR [2], Brien SMITH [3], Babak HAJI [1], Raymond ZHANG [1], Noemi HUMMEL [4], Dave MORTON [5], Marta MARTINEZ [6], Stephanie READ [7], Quanwu ZHANG [1], Amir Abbas TAHAMI MONFARED [1]
[1] Eisai, Nutley, United States, [2] University of Colorado Anschutz Medical Campus, Aurora, United States, [3] Henry Ford Hospital, Detroit, United States, [4] Certara GmbH, Loerrach, Germany, [5] Certara, Princeton, United States, [6] Certara, Madrid, Spain, [7] Certara, Sheffield, United Kingdom

P378 High Eligibility of Frail Older Adults with Early AD for Lecanemab Treatment in Real-World Practice: Is There a Need for New Clinical Trials?
Presenter: Federico Bellelli

Federico BELLELLI, Sandrine SOURDET, Gaelle SORIANO, Bruno VELLAS, Davide ANGIONI
Centre Hospitalo-Universitaire de Toulouse, Toulouse, France

P379 Physician perception of treatment landscape and readiness in care delivery with anti-amyloid therapy for Alzheimer's disease in China
Presenter: Raymond Zhang

Amir Abbas TAHAMI MONFARED [1], Brien SMITH [2], Kavita NAIR [3], Ran GAO [1], Raymond ZHANG [1], Babak HAJI [1], Noemi HUMMEL [4], Agnieszka KOPIEC [5], Marta MARTINEZ [6], Stephanie READ [7], Quanwu ZHANG [1]
[1] Eisai, Nutley, United States, [2] Henry Ford Hospital, Detroit, United States, [3] University of Colorado Anschutz Medical Campus, Aurora, United States, [4] Certara, Loerrach, Germany, [5] Certara, Krakow, Pologne, [6] Certara, Madrid, Spain, [7] Certara, Sheffield, United Kingdom

P380 TRIM21 mediated clearance of intracellular protein pathologies
Presenter: Rakez Kayed

Rakez KAYED
University of Texas Medical Branch, Galveston, United States

P381 Fusing Transferrin Receptor Binders to the A?O-targeting Antibody Sabirnetug Achieves Increased Brain Penetration in Mice While Preserving Target Binding
Presenter: Elizabeth Johnson

Erika CLINE [1], Shunsuke IIZUKA [2], Mahiro KURODA [2], Elizabeth JOHNSON [1] , Alex DAVIS [1], Martin KLEINSCHMIDT [3], Oladayo OLADIRAN [4], Jennifer GILLIES [4], Jacob WOHLSTADTER [4], Thomas LAVOIE [1], Liean SCHENCK [1], Mathias SCHMIDT [2], Hiroyuki SONODA [2], Jasna JERECIC [1], Paul SHUGHRUE [1]
[1] Acumen Pharmaceuticals, Inc, Newton, Massachusetts, United States, [2] JCR Pharmaceuticals Co., Ltd, Ashiya, Hyogo, Japan, [3] Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany, [4] Meso Scale Diagnostics, LLC, Rockville, Maryland, United States

P382 APOE-Targeted Microglia-Specific Epigenome Therapy for Alzheimer's Disease
Presenter: Ornit Chiba-Falek

Boris KANTOR, Bernadette O'DONOVAN, Joseph RITTINER, Ornit CHIBA-FALEK
Duke University, Durham, United States

P383 Passive Immunotherapy Targeting tau oligomeric strains reverses tauopathy phenotypes in aged in a mouse model sepecific manner
Presenter: Nemil Bhatt

Nemil BHATT, Alice BITTAR, Jia Yi LIEW, Twisha CHATTERJEE, Dhvani PANSURIYA, Nopparat SUTHPRASERTPORN, Ahmet BALCI, Rakez KAYED
University of Texas Medical Branch, Galveston, United States

P385 Lecanemab Ameliorates Alzheimer's Disease-Related Sleep Disorders via Modulating the Orexinergic System and Microglial Function: Evidence from Translational Models
Presenter: Hu Hao

Hu HAO [1], Yi QU [2] , Lan TAN [1]
[1] Qingdao Hospital Qingdao Municipal Hospital, Qingdao, China, [2] University of Health and Rehabilitation Sciences, Qingdao, China

P386 Administration of benzgalantamine, a galantamine prodrug, reduces multiple forms of hyperphosphorylated Tau and mitigates neuropathology in two animal models of traumatic brain injury: potential implication for reduced dementia risk.
Presenter: Denis Kay

Denis KAY [1] , Michael CHOPP [2], Haiyan PANG [2], Zheng Gang ZHANG [2], Ye XIONG [2], Abigail SCHINDLER [3], David COOK [3], James MEABON [4]
[1] Alpha Cognition Inc, Grapevine ,tx, United States, [2] Henry Ford Health, Detroit, Mi, United States, [3] VA Puget Sound, Seattle,wa, United States, [4] SIBCR, Seattle,wa, United States

P387 The APOE4 knock-in APPswe/PSEN1dE9/Tau-P301S triple transgenic (E4-3Tg) mouse model exhibited Tak1–NF-?B-mediated astrocytic C3 overproduction, neurodegeneration and a severely reduced lifespan.
Presenter: Tatsuhiro Hisatsune

Chenxu LEI, Tatsuhiro HISATSUNE
The University of Tokyo, Kashiwa, Japan

P388 A conditionally activated siRNA (CASi) targeting APOE for the treatment of Alzheimer's Disease
Presenter: Anindya Bhattacharya

Maxine NELSON, Akila RAM, Priya PULYA, Anna BADNER, Marina KOVALIOV, Clara TOURINO, Priyanka SINGH, Shilpi MAHAJAN, Lisa SCHERER, Don BUTTON, Robert DUFF, Dee DATTA, Charles ALLERSON, Anindya BHATTACHARYA
Switch Therapeutics, San Francisco, United States

P389 A conditionally-activated siRNA targeting MAPT for the treatment of tauopathies
Presenter: Anindya Bhattacharya

Clara TOURINO, Marina KOVALIOV, Maxine NELSON, Priya PULYA, Shilpi MAHAJAN, Lisa SCHERER, Abhinav KUMAR, Don BUTTON, Robert DUFF, Dee DATTA, Charles Allerson CHARLES ALLERSON, Craig BLANCHETTE, Anindya BHATTACHARYA
Switch Therapeutics, San Francisco, United States

P390 Antibody effector function of the murine analogue of Etalanetug drives efficacy in an animal model of pathological tau seeding and spreading
Presenter: Malcolm Roberts

Jane GARTLON, Sonia TALMA, Kavita MISTRY, Malcolm ROBERTS
Eisai Ltd., Hatfield, United Kingdom

P391 SUVN-I6107, a True Positive Allosteric Modulator at Muscarinic M1 Receptor for Treatment of Cognitive Disorders, Update on the Development
Presenter: Vijay Benade

Vijay BENADE, Veera Raghava Chowdary PALACHARLA, Vinod Kumar GOYAL, Satish JETTA, Renny ABRAHAM, Rajeshbabu MEDAPATI, Ramkumar SUBRAMANIAN, Surendra PETLU, Anil SHINDE, Ilayaraja KALAIKADHIBAN, Ramakrishna NIROGI, Jasti VENKAT
Suven Life Sciences, Hyderabad, Inde

16 ● DIGITAL HEALTH/ E-TRIALS

THURSDAY, DECEMBER 4 (7:15 A.M. – 5:00 P.M.)

P392 Dementia Trials Accelerator: UK services for clinical trials in dementia and related disorders
Presenter: William Whiteley

William WHITELEY [1], Cornelia VAN DUIJN [1], Neil POSTLETHWAITE [1], Rhoswyn WALKER [1], Monika ZIMINSKA [1], Katie SMITH [2], Ivan KOYCHEV [2], Paresh MALHOTRA [2], Jonathan SCHOTT [2], Henrik ZETTERBERG [2], Amanda HESLEGRAVE [2], Graham BLAKOE [3], Kimberley BENNET [3], Andrew MORRIS [1], Siddharthan CHANDRAN [2]

[1] Health Data Research UK, London, United Kingdom, [2] UK Dementia Research Institute, London, United Kingdom, [3] Imperial College London, London, United Kingdom

P393 QSP model for next-generation brainshuttle antibodies
Presenter: Lara Herriott

Lara HERRIOTT [1], Mark COLES [1], Eamonn GAFFNEY [1], Nicolas FOURNIER [2], Nicolas SANCHEZ [3], Olivier SOL [2], Gunther STAFFLER [2], Andrea PFEIFER [2], Jonathan WAGG [2]

[1] University of Oxford, Oxford, United Kingdom, [2] AC Immune SA, Lausanne, Switzerland, [3] Previously AC Immune SA, Lausanne, Switzerland

P394 Validating a Multi-Domain Digital Endpoint Platform (NeuLogiq) for Decentralized Alzheimer's Trials: Results from the CNS-101 Study
Presenter: Brian Murphy

Brian MURPHY [1], Alison BUICK [2], Shannon DIGGIN [2], Ruth MCKERNAN [3], James B. ROWE [4], Laura RUEDA-DELGADO [1]

[1] Cumulus Neuroscience, Dublin, Irlande, [2] Cumulus Neuroscience, Belfast, United Kingdom, [3] Dementia Discovery Fund, London, United Kingdom, [4] Cambridge University, Cambridge, United Kingdom

P395 Double XpressO: repeated online prescreening of cognitive impairment
Presenter: Willem Huijbers

Willem HUIJBERS [1], Hans-Aloys WISCHMANN [2], Kacylia PISTOIA [3], Joana KRIEGER [3], Johanna GRUBER [3], Murray GILLIES [1], Ziad NASREDDINE [3]

[1] MoCA Cognition, Eindhoven, Netherlands, [2] Charite, Berlin, Germany, [3] MoCA Cognition, Montreal, Canada

P396 Adherence to a multi-domain, person-centered, dementia risk factor management intervention to prevent cognitive decline (The BetterBrains Trial)
Presenter: Yen Ying Lim

Emily ROSENICH [1], Darshini AYTON [1], Stephanie PIROTTA [1], Hannah CUMMINS [1], Samantha DE ARAUGO [1], Amelia BEVINS [1], Catherine ROBB [1], Paul MARUFF [2], Yen Ying LIM [1]

[1] Monash University, Melbourne, Australia, [2] Cogstate Ltd., Melbourne, Australia

P397 A Holistic Approach for Understanding Alzheimer's Disease via Wearables, Speech, and eCOA
Presenter: Marissa Ballesteros

Kevin MACHADO GAMBOA [1], Brett MEYER [2], Paul O'DONOHOE [1], Marissa BALLESTEROs[1]

[1] Medidata, London, United Kingdom, [2] Medidata, Vermont, United Kingdom

P398 Impact of Telemedicine on Time and Process Measures Associated with Detection and Diagnosis of Alzheimer's Disease
Presenter: Eric Klein

Eric KLEIN [1], Eric ANDERSON [2], Chad PANNUCCI [1], Jiaying GUO [1], Aadrika AADRIKA [1], Bert VARGAS [1], Julie BEYRER [1]

[1] Eli Lilly and Company, Indianapolis, United States, [2] Syanpticure, Chicago, United States

P399　A Digital Olfactory Biomarker Platform for Prognostic Enrichment of Neurodegeneration
Presenter: Subhanjan Mondal

Subhanjan MONDAL [1], Sara MOUSTAFA [2], Levi MUYELA [3], Anne GITERE [3], Anne NYAMBURA [3], Karen BLACKMON [3], Farooq WAHEED [1], Mie RIZIG [4], Mohamed SALAMA [2], Irene MEIER [5], Vaibhav NARAYAN [5]
[1] Sensify Inc, New York, United States, [2] Institute of Global health and Human Ecology, American University at Cairo, Egypt, Cairo, Égypte, [3] Brain and Mind Institute, Aga Khan University Nairobi, Kenya, Nairobi, Kenya, [4] UCL Queen Square Institute of Neurology, London, UK, London, United Kingdom, [5] Davos Alzheimer's Collaborative, Geneva, Switzerland, Geneva, Switzerland

P400　Technology and human support: a combined approach to improving quality of life in older adults living at home with cognitive impairments
Presenter: Achille Tchalla

Achille TCHALLA [1, 2], Abdoul SAWADOGO [1], Clément RIMLAWI [1], Caroline GAYOT [1, 2]
[1] VieSanté laboratory UR [24134], Limoges University, Limoges, France, [2] Clinical Research and Innovation in Gerontology, Limoges Hospital Center, Limoges, France

P401　Assessing the validity of the MIND GamePack: A novel digital health technology (DHT) for the collection of supplementary cognitive data using games
Presenter: Steven Arnold

Jake GALLER [1], Liuqing YANG [2], Chao-Yi WU [1, 3], Cathrine YOUNG [1], Edmarie GUZMÁN-VÉLEZ [4, 3], Anthony BANNON [2], Hiroko DODGE [1, 3], Jessica GERBER [1], Steven ARNOLD [1, 3]
[1] Department of Neurology, Massachusetts General Hospital, Boston, United States, [2] AbbVie Inc., Chicago, United States, [3] Harvard Medical School, Boston, United States, [4] Department of Psychiatry, Massachusetts General Hospital, Boston, United States

P402　Association of Linguistic and Acoustic Digital Language Markers with CSF Biomarkers of Alzheimer's Disease
Presenter: S Ahmad Sajjadi

Pooyan MOBTAHEJ [1], Rojan JAVAHERI [2], Sam T. GOURON [3], David SULTZER [1, 4], Elizabeth HEAD [1, 5], S Ahmad SAJJADI [1, 4]
[1] University of California , Irvine, Irvine, United States, [2] Tufts University, School of Medicine, Boston, United States, [3] University of Colorado, School of Medicine, Aurora, United States, [4] The UC Irvine Institute for Memory Impairments and Neurological Disorders UCI MIND, Irvine, United States, [5] The UC Irvine Institute for Memory Impairments and Neurological Disorders UCI MIND , Irvine, United States

P403　Federated Data pilots for international collaboration in Alzheimer's disease and dementia research
Presenter: Eoghan Forde

Eoghan FORDE [1], Brenda BAUER [2], William WHITELEY [2], Jackie CALDWELL [3], Robert WALLACE [3], Ariel ONG [4], Siegfried WAGNER [4], Pearse KEANE [4], Manjit BENNING [4], Matthew CLEMENT [5], Neil POSTLETHWAITE [1]
[1] Health Data Research UK, London, United Kingdom, [2] The University of Edinburgh, Edinburgh, United Kingdom, [3] Public Health Scotland, Edinburgh, United Kingdom, [4] INSIGHT Health Data Research Hub at Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom, [5] Alzheimer's Disease Data Initiative, Seattle, United States

P404　Protocol for SUPERBRAIN-BOOM Trial: A multicenter, randomized controlled feasibility study on SoUth Korean study to PrEvent cognitive impaiRment and protect BRAIN heath via Behavioral, Optimized, Organized Movement therapy in mild cognitive impairment
Presenter: Sun Min Lee

Sun Min LEE [1], Da Ae KIM [1], Kyunghwa SUN [1], Jung Yun SEO [1], Eun-Joo KIM [2], Hyun Sook KIM [3], Soo Hyun CHO [4], Yeshin KIM [5], Sung Min KANG [6], Jiwoo JEONG [6], Sugyeong KIM [6], Hang Rai KIM [6], So Young MOON [1]
[1] Department of Neurology, Ajou University School of Medicine, Suwon, Republic of Korea, [2] Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Medical Research Institute, Busan, Republic of Korea, [3] Department of Neurology, CHA Bundang Medical Center, Seongnam, Republic of Korea, [4] Department of Neurology, Chonnam National University Hospital, Gwangju, Republic of Korea, [5] Department of Neurology, Kangwon National University Hospital, Chuncheon, Republic of Korea, [6] Rowan Inc., Seoul, Republic of Korea

P405　In-Air-Time during Drawing Tests as a Potential Predictor of Amyloid Positivity in Mild Cognitive Impairment Patients
Presenter: Ko Woon Kim

Ko Woon KIM [1, 2], Byoung-Soo SHIN [3]
[1] Beth Israel Hospital, Harvard Medial School, Boston, United States, [2] Jeonbuk National University Medical School and Hospital , Jeonju, Republic of Korea, [3] Jeonbuk National University Medical School and Hospital, Jeonju, Republic of Korea

P406 Real-World Care of Alzheimer's Disease Patients (n=2,358) in Germany: Insights from Registry of the Neurologists Network NeuroTransData (NTD) using the Physician/Patient Platform (DESTINY)
Presenter: Arnfin Bergmann

Arnfin BERGMANN, Stefan BRAUNE, Oliver FASOLD, Niloofar TAVAKOLI, Ntd STUDY GROUP
NeuroTransData GmbH, NTD Study Group, Neuburg an der Donau, Neuburg, Germany

P407 Leveraging the FTD Disorders Registry to Enhance Clinical Trial Recruitment in Frontotemporal Degeneration
Presenter: Shana Dodge

Mary KRAUSE [1], Carrie MILLIARD [2], Reinecker ROBERT [3], Sweatha REDDY [4], Shana DODGE [5], Penny DACKS [6]
[1] FTD Disorders Registry, Norristown, United States, [2] FTD Disorders Registry, Scarborough, United States, [3] FTD Disorders Registry, Myrtle Beach, United States, [4] FTD Disorders Registry, Jessup, United States, [5] Association for Frontotemporal Degeneration, Philadelphia, United States, [6] Association for Frontotemporal Degeneration, Brecksville, United States

P408 Exploring Persona-Based Large Language Model Simulation for Social Surveys on Dementia Treatment
Presenter: Kenichiro Sato

Kenichiro SATO [1], Yoshiki NIIMI [1], Saki NAKASHIMA [1], Ryoko IHARA [2], Kazushi SUZUKI [3], Atsushi IWATA [2], Takeshi IWATSUBO [1]
[1] The University of Tokyo Hospital, Tokyo, Japan, [2] Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, [3] National Defense Medical College, Saitama, Japan

P409 Preliminary Efficacy of the Healthy Actions and Lifestyles to Avoid Dementia (HALT-AD) Program for Enhancing Dementia-Risk Knowledge, Self-Efficacy, and Diet Quality in Primary-Care Patients
Presenter: Sarah Banks

Sarah BANKS, Sara MOUKARZEL, Ashley ROBLES, Ammar MANDVI, Breanna HOLLOWAY, Jordan STIVER
UC San Diego, San Diego, United States

17 ● CLINICAL TRIALS EARLY CAREER INVESTIGATOR SHOWCASE

PEC001 Plasma p-tau181 levels are associated with cognitive and physical decline in a population of older adults meeting frailty criteria: longitudinal data from the CogFrail Study
Presenter: Davide Angioni

Davide ANGIONI, Julien DELRIEU, Christelle CANTET, Gaelle SORIANO, Federico BELLELLI, Bruno VELLAS, Sandrine ANDRIEU, Sandrine SOUDET
IHU HealthAge, Toulouse, France

PEC002 Effects of escitalopram on Neuropsychiatric Symptoms in Alzheimer's Disease: a secondary analysis from the S-CitAD Study
Presenter: Emily Clark

Emily CLARK [1] , Jamie PERIN [2], D.P. DEVANAND [3], Prasad PADALA [4], David SHADE [5], Constantine LYKETSOS [6], Anton PORSTEINSSON [1]
[1] Department of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, United States, [2] Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, United States, [3] Department of Psychiatry, New York State Psychiatric Institute and Columbia University Irving Medical Center, New York, United States, [4] Central Arkansas Veterans Healthcare System, Baptist Health-University of Arkansas for Medical Sciences, Little Rock, United States, [5] Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, United States, [6] Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine and Johns Hopkins Bayview Medical Center, Baltimore, United States

PEC003 Plasma and CSF proteomic signatures of lifestyle activities: a search for biomarkers of cognitive reserve in the Stanford Aging and Memory Study (SAMS)
Presenter: Irina Skylar-Scott

Olivia LU [1], Patricia MORAN LOSADA [1], Amelia FARINAS [1], Veronica BOT [1], Daisy DING [1], Zihuai HE [1], Valerie CARR [2], Hillary VOSSLER [1], Jennifer PARK [3], Sharon SHA [3], Tony WYSS-CORAY [3], Elizabeth MORMINO [3], Anthony WAGNER [3], Irina SKYLAR-SCOTT [3]
[1] Stanford University, Palo Alto, United States, [2] San Jose State University, San Jose, United States, [3] Stanford Univeresity, Palo Alto, United States

PEC004 Testing and Tailoring Group Cognitive Behavioral Therapy for Insomnia (CBTi) with Persons with Early-Stage Alzheimer's disease and their Care Partners.
Presenter: Inga Antonsdottir

Inga ANTONSDOTTIR, Molly ATWOOD, Constantine LYKETSOS
Johns Hopkins School of Medicine, Baltimore, United States

PEC005 MRI utilization for ARIA response in patients receiving lecanemab
Presenter: Giovanna Pilonieta

Giovanna PILONIETA [1, 2] , Karen FAHNESTOCK [1], Christina MAMAEVA [1], Laurie MORRISON [1], Danielle WILLS [1], Maria PISU [3, 4], David GELDMACHER [1, 5]
[1] Division of Cognitive and Behavioral Neurology, Birmingham, United States, [2] Alzheimer's Disease Center - Birmingham United States, Birmingham, United States, [3] Division of General Internal Medicine & Population Science, Birmingham, United States, [4] Alzheimer's Disease Center, Birmingham, United States, [5] Alzheimer's Disease Center, Birmingham, United States

PEC006 Feasibility and accuracy of the LILA app: Pilot study of a fully remote, self-administered, verbal list learning task for community cognitive screening
Presenter: Karra D Harrington

Karra D HARRINGTON [1] , Jess SEGURA [1], Shannon ARCHER [1], Laura MILLER [1], Ruth RAY [1], Najeeba FAROUK [1], Anders NORDBLOM [2], Sophia LERDAHL [2], Kaycee M SINK [1], Pam VENTOLA [1]
[1] Cogstate Ltd, New Haven, United States, [2] Asteroidea Ventures LLC, DBA Formative, Seattle, United States

PEC007 A preliminary study on the effectiveness of therapeutic agricultural programs for healthy individuals and patients with dementia

Presenter: Bon D. Ku

Bon D. KU [1] , Boram KIM [2], Nayeon LEE [2], Hong Mo KU [3], Jeon YESEO [4]
[1] Department of Neurology, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Republic of Korea, [2] GyeYang Mubicipal Dementia Daycare Center, Incheon, Republic of Korea, [3] Institute for Cognitive Intervention, International St. Mary's Hospital, Incheon, Republic of Korea, [4] Incheon Metropolitan City Agricultural Technology Center, Incheon, Republic of Korea

PEC008 Broad Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus in Alzheimer's Disease: A Rationale, Study Design, and Preliminary Open-Label Data

Presenter: Michael Leuchter

Michael LEUCHTER [1] , Hanadi OUGHLI [1], Kelly DURBIN [1], Nicholas JACKSON [1], David ELASHOFF [1], Timothy CHANG [1], Juliana CORLIER [1], Cole MATTHEWS [1], Julia SUN [1], Darice WONG [1], Brent FOGEL [1], Andrew LEUCHTER [1], Keith VOSSEL [1], Nanthia SUTHANA [2]
[1] UCLA, Los Angeles, United States, [2] Duke, Durham, United States

● BIOTECH
SHOWCASE SESSIONS
FLASH PRESENTATIONS DURING COFFEE BREAKS

As part of a new initiative at CTAD 2025, we are hosting dedicated Biotech Showcase Sessions — dynamic flash presentation slots where selected biotech companies will:
- Present their work in 3-minute / 3-slides lightning talks
- Engage in 3 minutes of live Q&A with moderators and attendees
- Gain expert feedback and investor attention
- Build high-value connections with leaders in AD clinical trials

Tuesday, December 2nd – 10:30 a.m. to 11:00 a.m.

Session 1 – Artificial Intelligence and Digital Innovation
Focus: AI platforms, digital biomarkers, virtual and mobile cognitive assessment.
Moderators: Sandrine Andrieu, *IHU HealthAge, Toulouse (France)* and Lefkos Middleton, *Imperial College London – London (United Kingdom)*

1. Prima Mente – AI neuroscience integrating data generation and clinical translation
   Ravi Solanki, *Prima Mente - San Francisco, CA (United States)*

2. Tolion Health – AI-driven brain health and longevity guidance app
   Ondřej Lerch, *Tolion Health - Prague (Czech Republic)*

3. Unlearn.AI – Digital twin platform for modern Alzheimer's trials
   Kwame Marfo, *Unlearn AI - San Francisco, CA (United States)*

4. Indivi AG – Adaptive cognitive assessments with dynamic difficulty adjustment
   Shibeshih Belachew, *Indivi AG - Basel (Switzerland)*

Tuesday, December 2nd – 3:50 p.m. to 4:20 p.m.

Session 2 – Digital and Neurotechnology–Based Biomarkers and Therapeutics
Focus: novel neurotech and at-home stimulation tools.
Moderator: Michael Weiner, *UCSF – San Francisco (United States)*

1. Nuuron GmbH – Ultra-high-frequency visual stimulation for memory enhancement
   Fabian Queisner, *Nuuron GmbH - Berlin (Germany)*

2. Clarity Health Technologies – VR-integrated 40Hz sensory stimulation
   Carolina Reis, *Clarity Health Technologies - Delaware (United States)*

3. REGEnLIFE – Photomedical neurotechnology for brain–gut stimulation
   Guillaume Blivet, *REGEnLIFE - Paris (France)*

4. Cumulus Neuroscience – Remote digital biomarkers for trial efficiency
   Brian Murphy, *Cumulus Neuroscience - Dublin (Ireland)*

SHOWCASE SESSIONS
FLASH PRESENTATIONS DURING COFFEE BREAKS

Wednesday, December 3rd – 10:55 a.m. to 11:25 a.m.

Session 3 – Blood-Based Diagnostics and Biomarkers
Focus: plasma and proteomic biomarker innovation.
Moderators: Robert Rissman, *ATRI –USC – San Diego, CA (United States)*

1. Diadem Inc. – AlzoSure® Predict plasma test (unfolded p53)
   Shmuel Agus, *Diadem Inc - Palo Alto (United States)*

2. Veravas – VeraBIND Tau plasma assay for active tau pathology
   Josh Soldo, *Veravas Inc - Austin (United States)*

3. betaSENSE GmbH – Immuno-infrared sensor detecting misfolded proteins
   Klaus Gerwert, *betaSENSE GmbH - Bochum (Germany)*

4. Taudia – Detection of low-abundance biomarkers for patient screening
   Noah Elder, *Taudia - San Carlos (United States)*

Wednesday, December 3rd – 3:50 p.m. to 4:20 p.m.

Session 4 – Multiomics and Precision Diagnostics
Focus: Omics-based platforms and biomarker qualification.
Moderators: Mirranda Orr, *Washington University in St. Louis – St Louis, MO (United States)* and Howard Feldman, *UCSD – San Diego, CA (United States)*

1. AgenT – Multiomics blood biomarkers for Alzheimer's drug development
   Jérôme Braudeau, *AgenT - Evry (France)*

2. Washington University in St. Louis – Proteomic classifier for precision diagnosis
   Carlos Cruchaga, *Department of Psychiatry, NeuroGenomics and Informatics Center, Washington University School of Medicine - St Louis (United States)*

3. Fujirebio/ADx NeuroSciences – ADxPLORER qualified assays for early biomarker access
   Charlotte Lambrechts, *ADx NeuroSciences - Ghent (Belgium)*

4. Ricoh Biosciences – iPSC neuron panel for biomarker discovery
   Marama Diaz-Asper, *Ricoh Biosciences - Baltimore (United States)*

BIOTECH
SHOWCASE SESSIONS
FLASH PRESENTATIONS DURING COFFEE BREAKS

Thursday, December 4th– 10:30 a.m. to 11:00 a.m.

Session 5 – Next-Generation Therapeutics
Focus: novel small molecules, peptides, and new treatment modalities.
Moderators: Jeffrey Cummings, *UNLV – Las Vegas, NV (United States)* and Bruno Vellas, *IHU HealthAge – Toulouse (France)*

1. ProNeurogen Inc. – PNA5 first-in-class therapy for vascular dementia
   Meredith Hay, *ProNeurogen, Inc - Tucson (United States)*

2. Galimedix Therapeutics – GAL-101 Phase 1 oral small molecule
   Alexander Gebauer, *Galimedix Therapeutics Inc. - Kensington (United States)*

3. ChainGen Bio – BrainPortal peptides for blood–brain barrier transport
   Hao Wu, *ChainGen Bio - Shanghai (China)*

4. Anavex Life Sciences – Oral Blarcamesine Phase IIb/III trial results
   David Gould, *Anavex Life Sciences - New York (United States)*

Thursday, December 4th – 3:55 p.m. to 4:30 p.m.

Session 6 – Late-Stage Biotech and Industry Innovations
Focus: advanced clinical programs and scalable biomarker platforms.
Moderator: Jacques Touchon, *University of Montpellier – Montpellier (France)*

1. AriBio Co. Ltd. – AR1001 Phase 3 neurodegeneration program (POLARIS-AD)
   Fred Kim, *AriBio Co., Ltd. - San Diego (United States)*

2. Beckman Coulter Inc. – Blood-based biomarker solutions for AD diagnostics
   Kinal Bhatt, *Beckman Coulter, Inc. - Chaska, Mn (United States)*

3. Advanced Brain Monitoring – BEAM™ mobile EEG/ERP platform for cognitive assessment
   Chris Berka, *Advanced Brain Monitoring - Carlsbad (United States)*

4. Sunbird Bio – EV-based plasma assay platform for non-invasive detection of modified αSyn species
   Vijay Parthasarathy, *Sunbird Bio - Cambridge (United States)*

● EARLY CAREER
INVESTIGATOR SHOWCASE
FLASH PRESENTATIONS DURING COFFEE BREAKS

Tuesday, December 2nd – 10:25 a.m. to 11:00 a.m.

Category 1 – Translational Therapeutics and Clinical Innovation
Moderators: Sandrine Andrieu, *IHU HealthAge – Inserm – Toulouse (France)* and Michael Rafii, *ATRI – USC, San Diego (United States)*

1. **Michael Leuchter (UCLA)** – Broad Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus in Alzheimer's Disease – Poster PEC008

   Exploring large-coil rTMS targeting the precuneus to improve brain network function and memory in Alzheimer's disease through a two-stage feasibility trial.

2. **Emily Clark (University of Rochester)** – Effects of Escitalopram on Neuropsychiatric Symptoms in Alzheimer's Disease: S-CitAD Secondary Analysis – Poster PEC002

   Analyzing escitalopram's effect on mood and caregiver distress, suggesting potential antidepressant and behavioral benefits in Alzheimer's care.

3. **Melissa Wong (University of Toronto / Sunnybrook Research Institute)** – Cerebral Blood Flow Ratio of the Default Mode Network to the Central Executive Network as a Predictor of Executive Function Following N-acetylcysteine Supplementation in Vascular Mild Cognitive Impairment – Poster P162

   Examining whether cerebral blood flow ratios can predict treatment response to N-acetylcysteine in vascular MCI, highlighting personalized neurovascular biomarkers for intervention response.

Tuesday, December 2nd – 3:50 p.m. to 4:20 p.m.

Category 2 – Biomarkers and Mechanisms of Frailty and Cognitive Decline
Moderators: Robert Rissman, *ATRI – USC – San Diego, CA (United States)* and Mark Espeland, *Wake Forest University – Winston Salem, NC (United States)*

1. **Davide Angioni (IHU HealthAge, Toulouse)** – Plasma p-tau181 Levels and Cognitive & Physical Decline in Frail Older Adults (CogFrail Study) – Poster PEC001

   Linking elevated plasma p-tau181 to both cognitive and physical decline, identifying a shared biological pathway for frailty and neurodegeneration.

2. **Irina Skylar-Scott (Stanford University)** – Proteomic Signatures of Lifestyle Activities and Cognitive Reserve – Poster PEC 003

   Identifying plasma and CSF proteins associated with physical and cognitive activity, suggesting molecular pathways underlying resilience and cognitive reserve.

3. Lara Herriott (University of Oxford / AC Immune SA) – Modeling Brain Exposure and Efficacy of Next-Generation Brainshuttle Antibodies – Poster P393

Developing a quantitative systems pharmacology model to predict brain exposure and efficacy of receptor-mediated transcytosis antibodies such as trontinemab, offering insights into amyloid clearance mechanisms.

Wednesday December 3rd – 10:55 a.m. to 11:25 a.m.

Category 3: Digital Health and New Tools for Early Detection
Moderators: Charlotte Teunissen, *VUMC – Amesterdam (The Netherlands)* and Anton Porsteinsson, *University of Rochester Medical Center, New York, NY (United States)*

1. Karra D. Harrington (Cogstate Ltd) – Feasibility and Accuracy of the LILA App for Community Cognitive Screening – Poster PEC006

Demonstrating the feasibility of a fully remote, AI-based verbal learning test for large-scale cognitive screening via smartphone.

2. Giovanna Pilonieta (University of Alabama at Birmingham) – MRI Utilization for ARIA Response in Lecanemab-treated Patients – Poster PEC005

Investigating MRI monitoring practices in amyloid therapy, highlighting the clinical and economic implications of ARIA management.

3. Marina Ritchie (ATRI, University of Southern California – San Diego) – Characterizing Enrollment Patterns in a Preclinical Alzheimer's Disease Trial – Poster P006

Analyzing enrollment dynamics and demographic factors influencing participation in a preclinical Alzheimer's disease trial, providing insights to optimize recruitment strategies and improve trial diversity.

Wednesday December 3rd – 3:50 p.m. to 4:20 p.m.

Category 4: Non–Pharmacological and Lifestyle Interventions
Moderators: Laura Baker, *Wake Forest Alzheimer's Disease Research Center, Winston-Salem, NC (United States)* and Joshua Grill, *University of California, Irvine – Irvine, CA (United States)*

1. Bon D. Ku (Catholic Kwandong University – South Korea) – Therapeutic Agriculture for Cognitive and Emotional Well-being – Poster P344

Evaluating gardening-based interventions as a novel, low-cost therapy to improve mood and executive function in older adults and dementia patients

2. Inga Antonsdottir (Johns Hopkins University – United States) – Group Cognitive Behavioral Therapy for Insomnia (CBTi) in Dementia Dyads – Poster PEC004

Testing the feasibility of group CBTi tailored for persons with early Alzheimer's and their care partners, aiming to enhance sleep and reduce frailty.

CTAD would like to thank its 2025 privileged partners for their continued support.

ULTIMATE SPONSOR

Alzheimer's
Drug Discovery
Foundation

PLATINUM SPONSORS

Biogen.

Eisai

Lilly

GOLD SPONSORS

ALZHEIMER'S® ASSOCIATION

Alzheimer's Disease **Data Initiative**

Bristol Myers Squibb®

Johnson&Johnson Innovative Medicine

LANTHEUS

novo nordisk®

Roche

PRACTICAL DETAILS

CONFERENCE VENUE
Hilton San Diego Bayfront
1 Park Boulevard, San Diego, CA 92101

✈ *The Hilton is located just 3 miles (5km) from San Diego International Airport, easily accessible by taxi or Uber.*

REGISTRATION & BADGES

📍 **Sapphire Foyer - Level 4**

Opening Hours
- Mon, Dec 1: **9:00 a.m. - 6:00 p.m.**
- Tue-Thu, Dec 2-4: **7:30 a.m. - 6:00 p.m.**

Badge required for all sessions and breaks.
No reprints available.

HIGHLIGHTS

Early Career Investigators Showcase
Short Flash talks during Coffee Breaks
(see details p.91)

NEW **Biotech Showcase Sessions**
3-min talks by emerging biotech companies, Q&A, and netwoking (see details p.88)

Wi-Fi

Network & Password: CTAD2025

LUNCH OPTIONS

Lunch not included. Nearby restaurants listed in the app and at the registration desk.

CTAD WELCOME RECEPTION WITH THE SUPPORT OF THE ALZHEIMER'S ASSOCIATION

Monday, December 1 from 6:45 p.m. to 7:45 p.m. in the Sapphire Ballroom (Level 4).

ALZHEIMER'S ASSOCIATION

PARKING

Both valet adn self-parking are available on-site at the Hilton.

- Self-Parking: $50.00 per day
- Valet Parking: $65.00 per day

ROOM LOCATOR

📍 **LEVEL 5 - COBALT**
Sponsors Meeting Rooms

📍 **LEVEL 4 - SAPPHIRE**
Registration Desk
Conference Room (Main Sessions)

📍 **LEVEL 3 - AQUA**
Sponsors Meeting Rooms

📍 **LEVEL 2 - INDIGO**
Coffee Breaks
Posters
Showcases
Business Suites
Sponsors Meeting Rooms

📍 **LEVEL 1 - PROMENADE**
Meeting Room: The Pointe

● NOTES

SAVE THE DATE

CTAD 2025

Clinical Trials on Alzheimer's Disease

November 16-19, 2026
Boston, MA (USA)

www.ctad-alzheimer.com
Email: ctad@ant-congres.com

JPAD
THE JOURNAL OF PREVENTION OF ALZHEIMER'S DISEASE